<?xml version='1.0' encoding='UTF-8'?>
<!-- Created by Xince -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:genelux.com="http://genelux.com/20250630" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025">
  <link:schemaRef xlink:href="./GNLX_taxonomy_Q2_2023_2025.zip/GNLX_taxonomy_Q2_2023_2025/GNLX-20251231.xsd" xlink:type="simple"/>
  <xbrli:context id="c">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c5">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c6">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c7">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c8">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c9">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">genelux.com:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c10">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c11">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">genelux.com:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c12">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c16">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c17">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c18">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c19">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">genelux.com:ExercisePriceRangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c21">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c22">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c23">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c24">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c25">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-04-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c26">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-30</xbrli:startDate>
      <xbrli:endDate>2023-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c27">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-02-01</xbrli:startDate>
      <xbrli:endDate>2023-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c29">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesJPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c32">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesIPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c33">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c34">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c35">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c36">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">genelux.com:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c37">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-02-01</xbrli:startDate>
      <xbrli:endDate>2023-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c38">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c39">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c40">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c41">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c42">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c43">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">genelux.com:TwoOptionHoldersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-08-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c44">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c45">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">genelux.com:NotePayableAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c46">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c47">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c48">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c49">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">genelux.com:TwoOptionHoldersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c50">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">genelux.com:NoteHoldersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c51">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c52">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c53">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c54">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c55">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">genelux.com:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c56">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c57">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c58">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c59">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesKPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c60">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-09-01</xbrli:startDate>
      <xbrli:endDate>2022-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c61">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesKPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c62">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">genelux.com:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c63">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-04-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c64">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-04-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c65">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c66">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c67">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-04-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c68">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-04-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c69">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c70">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c71">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">genelux.com:WarrantHolderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-08-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c72">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-04-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c73">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c74">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">genelux.com:ExercisePriceRangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c75">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-04-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c76">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c77">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c78">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">genelux.com:WarrantHolderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c79">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c80">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">genelux.com:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c81">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c82">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">genelux.com:ExercisePriceRangeOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">genelux.com:ExecutiveOfficersAndDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c83">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-07-01</xbrli:startDate>
      <xbrli:endDate>2021-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c84">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c85">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c86">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c87">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">genelux.com:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c88">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c89">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c90">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c91">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c92">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c93">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-08-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c94">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-05-12</xbrli:startDate>
      <xbrli:endDate>2023-05-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c95">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c96">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">genelux.com:MayTwelveTwoThousandTwentyThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-05-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c97">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-08-01</xbrli:startDate>
      <xbrli:endDate>2022-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c98">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c99">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">genelux.com:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c100">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">genelux.com:MayTwelveTwoThousandTwentyThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-05-11</xbrli:startDate>
      <xbrli:endDate>2023-05-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c102">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c103">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c104">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c105">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">genelux.com:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c107">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c108">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">genelux.com:MayTwelveTwoThousandTwentyThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c110">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c111">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c112">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c113">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">genelux.com:MayTwelveTwoThousandTwentyThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c114">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c115">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c116">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">genelux.com:MayTwelveTwoThousandTwentyThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-07-01</xbrli:startDate>
      <xbrli:endDate>2023-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c117">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c118">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c119">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">genelux.com:MayTwelveTwoThousandTwentyThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-08-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c120">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">genelux.com:LenderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c121">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c122">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c123">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c124">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-02-16</xbrli:startDate>
      <xbrli:endDate>2023-02-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c125">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">genelux.com:CommonStockEquivalentOfSeriesAThroughKConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c126">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c127">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c128">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">genelux.com:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c132">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c133">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">genelux.com:LenderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c134">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c135">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c136">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-30</xbrli:startDate>
      <xbrli:endDate>2023-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c137">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c138">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">genelux.com:JuneNineTwoThousandTwentyThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-06-09</xbrli:startDate>
      <xbrli:endDate>2023-06-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c139">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c140">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">genelux.com:JuneNineTwoThousandTwentyThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c141">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">genelux.com:CommonStockEquivalentOfSeriesAThroughKConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c142">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c143">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c144">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">genelux.com:JuneNineTwoThousandTwentyThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-06-08</xbrli:startDate>
      <xbrli:endDate>2023-06-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c145">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-08-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c146">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c147">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c148">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c149">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">genelux.com:JuneNineTwoThousandTwentyThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c150">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c151">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c152">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c153">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c154">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c155">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c156">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">genelux.com:WarrantHolderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c157">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c158">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c159">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c160">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c161">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">genelux.com:WarrantHolderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c162">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c163">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c164">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c165">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-30</xbrli:startDate>
      <xbrli:endDate>2023-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c166">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c167">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c168">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c169">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c170">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">genelux.com:TwoThousandNineEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c171">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c172">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c173">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-30</xbrli:startDate>
      <xbrli:endDate>2023-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c174">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c175">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c176">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-04-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c177">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c178">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c179">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c180">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c181">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-30</xbrli:startDate>
      <xbrli:endDate>2023-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c182">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c183">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">genelux.com:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c184">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c185">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-30</xbrli:startDate>
      <xbrli:endDate>2023-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c186">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">genelux.com:TwoThousandNineEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-30</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c187">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c188">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">genelux.com:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c189">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c190">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c191">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">genelux.com:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c192">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-30</xbrli:startDate>
      <xbrli:endDate>2023-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c193">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-04-01</xbrli:startDate>
      <xbrli:endDate>2022-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c194">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c195">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">genelux.com:TwoThousandTwentyTwoPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c196">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c197">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">genelux.com:ConvertibleNotePayableAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c198">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c199">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c200">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c201">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-30</xbrli:startDate>
      <xbrli:endDate>2023-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c202">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c203">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">genelux.com:SeriesAThroughKPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c204">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c205">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c206">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c207">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">genelux.com:ConvertibleNotesPayableShareholderThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c208">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c209">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-08-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c210">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c211">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c212">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">genelux.com:StockWarrantsIssuableUponConversionOfNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c213">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c214">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c215">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c216">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-08-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c217">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c218">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">genelux.com:StockWarrantsIssuableUponConversionOfNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c219">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001231457</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="usd1">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <us-gaap:OperatingExpenses id="f" decimals="-3" contextRef="c" unitRef="usd">12027000.0</us-gaap:OperatingExpenses>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="f1" decimals="-3" contextRef="c1" unitRef="usd">758000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f2" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="f3" xsi:nil="true" contextRef="c3" unitRef="shares"/>
  <genelux.com:CostOfStockOptionRepricing id="f4" decimals="-3" contextRef="c" unitRef="usd">-2642000.0</genelux.com:CostOfStockOptionRepricing>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="f5" decimals="-3" contextRef="c" unitRef="usd">14503000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:OperatingLeaseLiability id="f6" decimals="-3" contextRef="c4" unitRef="usd">12000.0</us-gaap:OperatingLeaseLiability>
  <us-gaap:DebtInstrumentPeriodicPaymentInterest id="f7" decimals="-3" contextRef="c" unitRef="usd">63000.0</us-gaap:DebtInstrumentPeriodicPaymentInterest>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f8" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedInPeriodTotalFairValueBeginning id="f9" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees id="f10" decimals="-3" contextRef="c5" unitRef="usd">4000.0</genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees>
  <us-gaap:TreasuryStockCommonShares id="f11" decimals="INF" contextRef="c3" unitRef="shares">433333.0</us-gaap:TreasuryStockCommonShares>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f12" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="f13" xsi:nil="true" contextRef="c3" unitRef="usd1"/>
  <genelux.com:AmortizationOfDebtDiscount id="f14" decimals="-3" contextRef="c7" unitRef="usd">61000.0</genelux.com:AmortizationOfDebtDiscount>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest id="f15" decimals="-3" contextRef="c8" unitRef="usd">22000.0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f16" decimals="INF" contextRef="c9" unitRef="shares">4092887.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f17" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="f18" xsi:nil="true" contextRef="c" unitRef="shares"/>
  <us-gaap:Depreciation id="f19" decimals="-3" contextRef="c" unitRef="usd">271000.0</us-gaap:Depreciation>
  <us-gaap:OperatingLeaseLiabilityCurrent id="f20" decimals="-3" contextRef="c3" unitRef="usd">266000.0</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="f21" decimals="INF" contextRef="c" unitRef="shares">73134.0</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="f22" decimals="INF" contextRef="c11" unitRef="shares">108132.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice id="f23" decimals="INF" contextRef="c" unitRef="usd1">9.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f24" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="f25" xsi:nil="true" contextRef="c" unitRef="shares"/>
  <us-gaap:Assets id="f26" decimals="-3" contextRef="c13" unitRef="usd">31363000.0</us-gaap:Assets>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f27" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodTotalFairValue id="f28" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <us-gaap:DebtInstrumentUnamortizedDiscount id="f29" decimals="-3" contextRef="c3" unitRef="usd">108000.0</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:OperatingLeaseRightOfUseAsset id="f30" decimals="-3" contextRef="c14" unitRef="usd">649000.0</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:ConvertibleNotesPayable id="f31" decimals="-3" contextRef="c15" unitRef="usd">5369000.0</us-gaap:ConvertibleNotesPayable>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f32" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="f33" xsi:nil="true" contextRef="c" unitRef="usd1"/>
  <us-gaap:StockholdersEquity id="f34" decimals="-3" contextRef="c16" unitRef="usd">2691000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f35" decimals="-3" contextRef="c" unitRef="usd">1174000.0</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:AccruedBonusesCurrent id="f36" decimals="-3" contextRef="c13" unitRef="usd">2684000.0</us-gaap:AccruedBonusesCurrent>
  <us-gaap:SharesOutstanding id="f37" decimals="INF" contextRef="c17" unitRef="shares">-433333.0</us-gaap:SharesOutstanding>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="f38" decimals="-3" contextRef="c" unitRef="usd">1865000.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:ConvertibleNotesPayable id="f39" decimals="-3" contextRef="c18" unitRef="usd">700000.0</us-gaap:ConvertibleNotesPayable>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f40" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="f41" xsi:nil="true" contextRef="c" unitRef="shares"/>
  <us-gaap:TreasuryStockCommonShares id="f42" decimals="INF" contextRef="c13" unitRef="shares">433333.0</us-gaap:TreasuryStockCommonShares>
  <us-gaap:OperatingLeaseLiability id="f43" decimals="-3" contextRef="c14" unitRef="usd">649000.0</us-gaap:OperatingLeaseLiability>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f44" decimals="INF" contextRef="c13" unitRef="shares">4005267.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:OperatingIncomeLoss id="f45" decimals="-3" contextRef="c19" unitRef="usd">-5395000.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingExpense id="f46" decimals="-3" contextRef="c" unitRef="usd">3110000.0</us-gaap:OtherNonoperatingExpense>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f47" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="f48" xsi:nil="true" contextRef="c" unitRef="usd1"/>
  <genelux.com:AmortizationOfDebtDiscount id="f49" decimals="-3" contextRef="c" unitRef="usd">108000.0</genelux.com:AmortizationOfDebtDiscount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f50" decimals="INF" contextRef="c20" unitRef="shares">932854.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="f51" decimals="-3" contextRef="c15" unitRef="usd">780000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f52" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="f53" xsi:nil="true" contextRef="c" unitRef="shares"/>
  <us-gaap:LesseeOperatingLeaseDiscountRate id="f54" decimals="INF" contextRef="c14" unitRef="pure">0.055</us-gaap:LesseeOperatingLeaseDiscountRate>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest id="f55" decimals="-3" contextRef="c" unitRef="usd">69000.0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f56" decimals="INF" contextRef="c3" unitRef="shares">725174.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued id="f57" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="f58" xsi:nil="true" contextRef="c" unitRef="usd1"/>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees id="f59" decimals="-3" contextRef="c" unitRef="usd">29896000.0</genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="f60" decimals="-3" contextRef="c21" unitRef="usd">5460000.0</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:LeaseAndRentalExpense id="f61" decimals="-3" contextRef="c" unitRef="usd">18000.0</us-gaap:LeaseAndRentalExpense>
  <dei:DocumentPeriodEndDate id="f62" contextRef="c">2023-06-30</dei:DocumentPeriodEndDate>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f63" decimals="-3" contextRef="c22" unitRef="usd">1865000.0</genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest>
  <us-gaap:PropertyPlantAndEquipmentGross id="f64" decimals="-3" contextRef="c23" unitRef="usd">127000.0</us-gaap:PropertyPlantAndEquipmentGross>
  <genelux.com:NonconvertibleAccruedAndUnpaidInterest id="f65" decimals="-3" contextRef="c24" unitRef="usd">58000.0</genelux.com:NonconvertibleAccruedAndUnpaidInterest>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued id="f66" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="f67" xsi:nil="true" contextRef="c" unitRef="shares"/>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f68" decimals="INF" contextRef="c25" unitRef="shares">9111694.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="f69" decimals="INF" contextRef="c26" unitRef="shares">2500000.0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued id="f70" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="f71" xsi:nil="true" contextRef="c" unitRef="usd1"/>
  <us-gaap:LiabilitiesNoncurrent id="f72" decimals="-3" contextRef="c13" unitRef="usd">1229000.0</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:DebtInstrumentFaceAmount id="f73" decimals="-3" contextRef="c3" unitRef="usd">1100000.0</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f74" decimals="INF" contextRef="c25" unitRef="shares">9111694.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:IncreaseDecreaseInOperatingLeaseLiability id="f75" decimals="-3" contextRef="c27" unitRef="usd">637000.0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
  <us-gaap:PaymentsForProceedsFromInvestments id="f76" decimals="0" contextRef="c28" unitRef="usd">2500.0</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued id="f77" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod id="f78" xsi:nil="true" contextRef="c" unitRef="shares"/>
  <dei:EntityAddressPostalZipCode id="f79" contextRef="c">91361</dei:EntityAddressPostalZipCode>
  <genelux.com:ConvertibleNotesPayableShareholdersTextBlock id="f80" contextRef="c">&lt;p id="xdx_80C_ecustom--ConvertibleNotesPayableShareholdersTextBlock_zh9z9dhqx3d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTE
7  &lt;span id="xdx_820_zXTBPd96Upv9"&gt;CONVERTIBLE NOTES PAYABLE  SHAREHOLDERS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--ScheduleOfConvertibleNotesPayableToShareholdersTableTextBlock_zo0TQ9uG9fC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
notes payable to shareholders consisted of the following as of June 30, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_z7CnBoYmzlOa" style="display: none"&gt;SCHEDULE
OF CONVERTIBLE NOTES PAYABLE TO SHAREHOLDERS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230630_zubLt0ixcyBb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;June
    30,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zuv3m9yk67Z6" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
    31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zADCMmlY5Kx9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    notes payable - shareholders (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span id="xdx_F40_zp6jjVMA9Qqf" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;65&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;7,838&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zioXQAMyd8Rf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    note payable - shareholder (b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F4E_z5pySqSr3ufj" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1059"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zLuww6w1CMk5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    notes payable  shareholders (c)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F4F_z2ksBmH5VM9l" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;700&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_z5JZRhlEcYyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    notes payable - shareholders (d)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_F49_z7CyFZ1xnhSa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(d)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;5,369&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ConvertibleNotesPayable_iI_zH1muCF9Qno6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible notes payable - shareholders&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;65&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;15,407&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ConvertibleNotesPayableCurrent_iNI_pn3n3_di_zB5Ogawor7gd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Less:
    current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(65&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(15,407&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ConvertibleLongTermNotesPayable_iI_pn3n3_ziGxbUdoC7zc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    notes payable  shareholders  long - term portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1074"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F08_zcptrqkktFUa" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F13_zHJ2cNXcivM8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;During
    the years ended December 31, 2011 through 2016, the Company entered into convertible note payable agreements with individuals aggregating
    to a total amount of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20161231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_z6CYmUZyMQSg" title="Convertible notes payable"&gt;7,988&lt;/span&gt;. The notes initially accrued interest at &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20161231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zpEjixCeRAf1" title="Accrued interest percentage"&gt;8&lt;/span&gt;% per annum, are unsecured and are convertible into the Companys
    Series K preferred stock at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20161231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zc4xPjdvzuC" title="Conversion price per share"&gt;25.73&lt;/span&gt; per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    of December 31, 2022, the principal amount due on the notes aggregated to $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zeDAxY3fL9ok"&gt;7,838&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_z9pgPwLcLj53" title="Accrued and unpaid interest"&gt;2,890&lt;/span&gt;
    was owed on the notes. During the six months ended June 30, 2023, $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--RepaymentsOfDebt_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zjiRGy6AWW9g" title="Repayment of debt"&gt;60&lt;/span&gt; of principal and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--InterestExpenseDebt_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zITGMEv6uE9f" title="Payment on accrued and unpaid interest"&gt;36&lt;/span&gt; of accrued and unpaid interest were paid
    on the notes, and the notes accrued interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zwHRCaSUxSKk" title="Accrued interest"&gt;15&lt;/span&gt;. On January 30, 2023, the date of the closing of the IPO, total principal of
    $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zuArDuKlI5T9" title="Convertible notes payable"&gt;7,778&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zCLJHcNaVJu8" title="Accrued and unpaid interest"&gt;2,867&lt;/span&gt; was owed on the notes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Upon
    the closing of the IPO, all of the principal plus accrued and unpaid interest, except for $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--NotesPayable_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zh3zCrL0RDej" title="Notes payable"&gt;65&lt;/span&gt; of principal and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--NonconvertibleAccruedAndUnpaidInterest_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zkFD3kJubYfh" title="Nonconvertible accrued and unpaid interest"&gt;58&lt;/span&gt; of accrued and
    unpaid interest, automatically converted into &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230130__20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zIr0hHsZorf7" title="Debt conversion shares issued"&gt;1,554,814&lt;/span&gt; shares of the Companys common stock based on the conversion price
    of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zyl2mqqOgKN8" title="Conversion price"&gt;6.78&lt;/span&gt; per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    of June 30, 2023, total principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zYB7zKdgHlE5" title="Convertible notes payable"&gt;65&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zhYPWdFsOFRk" title="Accrued and unpaid interest"&gt;60&lt;/span&gt; was owed on the notes. The notes accrue interest
    at &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zs6bixIB5xPf" title="Accrued interest percentage"&gt;8&lt;/span&gt;% per annum, are unsecured and are past due and payable on demand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F01_z4Gum6JTe71k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zU5Go73PBnT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
    April 2016, the Company entered into a convertible note payable agreement with a shareholder in the amount of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20160430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zcFaEXPxTlM4" title="Convertible notes payable"&gt;2,661&lt;/span&gt;. The note accrued
    interest at &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20160430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zN9TQOnwxd17" title="Accrued interest percentage"&gt;11.51&lt;/span&gt;% per annum, was unsecured, had an initial maturity date of May 2018 and was convertible into the Companys
    common stock at the price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20160430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_z3LCRFqiKMZ3" title="Conversion price"&gt;6.78&lt;/span&gt; per share. Interest payments are due monthly. In May 2018, the note was amended to include a provision
    under which the loan will accrue $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--LoanProcessingFee_pn3n3_c20180501__20180531__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zzP1DpC3X0c9" title="Loan fees"&gt;10&lt;/span&gt; per month of loan fees through the date the loan is repaid or is converted into the Companys
    common stock. The loan fees can be converted into shares of the Companys common stock at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20180531__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zXvs67LlZ3Xl" title="Conversion price"&gt;6.78&lt;/span&gt; per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    of December 31, 2022, total principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zBnt9Vl9u9ti"&gt;1,500&lt;/span&gt; and total accrued and unpaid loan fees of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--DebtInstrumentFeeAmount_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zf1XKJE8wwca" title="Accrued and unpaid loan fees owed on notes"&gt;560&lt;/span&gt; was owed on the note. During the six
    months ended June 30, 2023, the note accrued loan fees of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--LoanProcessingFee_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zaItfU4rV2Sh" title="Accrued loan fees"&gt;10&lt;/span&gt;, and on January 30, 2023, the date of the closing of the IPO, total
    principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zItRqxS5Czzg"&gt;1,500&lt;/span&gt; and total accrued and unpaid loan fees of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentFeeAmount_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_z29H5eonEQLg" title="Accrued and unpaid loan fees owed on notes"&gt;570&lt;/span&gt; was owed on the notes. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Upon
    the closing of the IPO, all of the principal plus accrued and unpaid loan fees automatically converted into &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230130__20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zuOatzeccjsf" title="Debt conversion shares issued"&gt;303,835&lt;/span&gt; shares of the
    Companys common stock based on the conversion price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_z7asHZqCWx3i" title="Conversion price"&gt;6.78&lt;/span&gt;. As of June 30, 2023, no principal, interest or loan fees was
    due on the notes. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F0A_zyECcDj7h2Wb" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_ziHjfgpDvJZi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
    April 2018, the Company entered into two convertible note payable agreements with a shareholder under which the Company borrowed
    an aggregate total of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20180430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zdWHrbBzFX8h" title="Convertible notes payable"&gt;700&lt;/span&gt;. The notes accrue interest at&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20180430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zrfV0TbCQy4" title="Accrued interest percentage"&gt; 5.0&lt;/span&gt;% per annum, are unsecured, and are convertible into the Companys
    common stock at the lesser of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20180430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zy2Z1HKX7kN7" title="Conversion price"&gt;12.00&lt;/span&gt; per share, or &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--InitialPublicOfferingClosingPricePercentage_iI_pid_dp_c20180430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zJxLefVAXA15" title="Initial public offering closing price"&gt;90&lt;/span&gt;% of the Companys IPO price, if it were to occur. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    of December 31, 2022, total principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_z9ovmBKxizL5" title="Principal amount owed on notes"&gt;700&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zqppqRcRuEId"&gt;164&lt;/span&gt; was owed on the notes. During the six
    months ended June 30, 2023, the notes accrued interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zhAmUOwlmcs9" title="Accrued interest"&gt;3&lt;/span&gt;, and on January 30, 2023, the date of the closing of the IPO, total
    principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_z6DC2RtTimZh"&gt;700&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zNmWduK5k354"&gt;167&lt;/span&gt; was owed on the notes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Upon
    the closing of the IPO, all of the principal plus accrued and unpaid interest automatically converted into &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230130__20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zCY8CmIXhQob" title="Debt conversion shares issued"&gt;160,563&lt;/span&gt; shares of the
    Companys common stock based on the conversion price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zoTT5lHg1h9e" title="Conversion price"&gt;5.40&lt;/span&gt;, which was &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--InitialPublicOfferingClosingPricePercentage_iI_pid_dp_c20180430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zUwnf10ISvp4" title="Initial public offering closing price"&gt;90&lt;/span&gt;% of the IPO closing price. As of June 30, 2023,
    no principal or interest was due on the notes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0D_z6LRLcKGnnNi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(d)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zpXhdBJRpVC" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
    the years ended December 31, 2019 through 2021, the Company entered into convertible note payable agreements with several shareholders under which the Company borrowed an aggregate amount of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zEdWuOv6Bqr" title="Convertible notes payable"&gt;5,369&lt;/span&gt;. The notes accrue
interest at&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zKGyoNthY867" title="Accrued interest percentage"&gt; 5.0&lt;/span&gt;% per annum, are unsecured, and are convertible into the Companys common stock at the price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zlwkfbhURW72" title="Conversion price"&gt;12.00&lt;/span&gt; per share,
    or &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_ecustom--InitialPublicOfferingClosingPricePercentage_iI_pid_dp_c20191231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_z1rbAwSAMqak"&gt;90&lt;/span&gt;% of the Companys IPO price, if it were to occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    of December 31, 2022, total principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zneBwt09seYa"&gt;5,369&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zoblmnSqgsq7" title="Accrued and unpaid interest"&gt;758&lt;/span&gt; was owed on the notes. During the six
    months ended June 30, 2023, the notes accrued interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zdCKFFJz8x0k" title="Accrued interest"&gt;22&lt;/span&gt;, and on January 30, 2023, the date of the closing of the IPO, total
    principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zyTxPomkYF7h" title="Principal amount owed on notes"&gt;5,369&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zEdlkDffphy7"&gt;780&lt;/span&gt; was owed on the notes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Upon
    the closing of the IPO, all of the principal plus accrued and unpaid interest automatically converted into &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230130__20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zRAh7bifUp66" title="Conversion of common stock"&gt;1,134,063&lt;/span&gt; shares of the
    Companys common stock based on the conversion price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_z0DIpY0Otpx9" title="Conversion price"&gt;5.40&lt;/span&gt;, which was &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_ecustom--InitialPublicOfferingClosingPricePercentage_iI_pid_dp_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_z7XIic4G7ina" title="Initial public offering closing price"&gt;90&lt;/span&gt;% of the IPO closing price. As of June 30, 2023,
    no principal or interest was due on the notes. During the six months ended June 30, 2023, the Company issued the shareholders stock
    warrants to purchase up to &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zfGZ0vrGn6re" title="Warrants to purchase shares"&gt;111,828&lt;/span&gt; shares of the Companys common stock at an exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_z3zKuhbBnBI7" title="Warrants exercise price"&gt;10.50&lt;/span&gt;. All of the warrant
    shares were exercised during the six months ended June 30, 2023 (see Note 9).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A7_zzUJI6eFRL6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</genelux.com:ConvertibleNotesPayableShareholdersTextBlock>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f81" decimals="INF" contextRef="c29" unitRef="usd1">1282.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <dei:DocumentFiscalYearFocus id="f82" contextRef="c">2023</dei:DocumentFiscalYearFocus>
  <us-gaap:Assets id="f83" decimals="-3" contextRef="c3" unitRef="usd">5531000.0</us-gaap:Assets>
  <us-gaap:StockholdersEquity id="f84" decimals="-3" contextRef="c30" unitRef="usd">2000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f85" decimals="-3" contextRef="c31" unitRef="usd">-36540000.0</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued id="f86" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice id="f87" xsi:nil="true" contextRef="c" unitRef="usd1"/>
  <genelux.com:ReclassificationOfWarrantLiabilitiesToShareholdersEquity id="f88" decimals="-3" contextRef="c" unitRef="usd">169000.0</genelux.com:ReclassificationOfWarrantLiabilitiesToShareholdersEquity>
  <us-gaap:PreferredStockSharesAuthorized id="f89" decimals="INF" contextRef="c32" unitRef="shares">2775000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:SaleOfStockPricePerShare id="f90" decimals="INF" contextRef="c33" unitRef="usd1">6.0</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="f91" decimals="INF" contextRef="c34" unitRef="pure">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="f92" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f93" decimals="-3" contextRef="c35" unitRef="usd">669000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AccruedBonusesCurrent id="f94" decimals="-3" contextRef="c3" unitRef="usd">2852000.0</us-gaap:AccruedBonusesCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross id="f95" decimals="-3" contextRef="c36" unitRef="usd">148000.0</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="f96" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <us-gaap:OperatingExpenses id="f97" decimals="-3" contextRef="c21" unitRef="usd">6263000.0</us-gaap:OperatingExpenses>
  <us-gaap:AmortizationOfDebtDiscountPremium id="f98" decimals="-3" contextRef="c25" unitRef="usd">50000.0</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="f99" decimals="-3" contextRef="c24" unitRef="usd">2867000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised id="f100" decimals="INF" contextRef="c" unitRef="shares">128494.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="f101" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="f102" decimals="INF" contextRef="c37" unitRef="shares">153000.0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <genelux.com:ConversionOfPreferredStockToCommonStock id="f103" decimals="-3" contextRef="c" unitRef="usd">22000.0</genelux.com:ConversionOfPreferredStockToCommonStock>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExercisePriceRange id="f104" decimals="INF" contextRef="c38" unitRef="usd1">10.5</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExercisePriceRange>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="f105" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <us-gaap:PreferredStockSharesIssued id="f106" decimals="INF" contextRef="c39" unitRef="shares">5000000.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="f107" contextRef="c">&lt;p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zPytCGMLiLAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the Companys warrants activities for the six months ended June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zbONsK35yyej" style="display: none"&gt;SCHEDULE
OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Price Range&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrant Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230630_zjGDIUlEHMxd" style="width: 14%; text-align: right" title="Number of warrant shares, beginning"&gt;725,174&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange_iS_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zm3amvkQTmvi" title="Exercise price range range per share, beginning"&gt;3.00&lt;/span&gt;
- &lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange_iS_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zGyQr17D1iC4" title="Exercise price range range per share, beginning"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630_zdLfrDgxu4m2" style="width: 14%; text-align: right" title="Weighted average exercise price, beginning"&gt;8.24&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230630_zCgZhlWhm1lc" style="text-align: right" title="Number of warrant shares, granted"&gt;340,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisePriceRange_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zY8qZn09C4J" title="Exercise price range range per share, granted"&gt;5.40&lt;/span&gt; - &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisePriceRange_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zwe4JC6Z3zub" title="Exercise price range range per share, granted"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_pid_c20230101__20230630_zz3aXMgehR97" style="text-align: right" title="Weighted average exercise price, granted"&gt;7.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20230101__20230630_zYrd8Eeb8tzh" style="text-align: right" title="Number of warrant shares, cancelled"&gt;(36&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedExercisePriceRange_pid_c20230101__20230630_zdW8RgPK6ZP" title="Exercise price range range per share, cancelled"&gt;9.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice_pid_c20230101__20230630_zzFzMbSZqek4" style="text-align: right" title="Weighted average exercise price, cancelled"&gt;9.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20230630_zSidSuTdSLg4" style="text-align: right" title="Number of warrant shares, exercised"&gt;(128,494&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedExercisePriceRange_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zmZoAjyWU0N6" title="Exercise price range range per share, exercised"&gt;9.00&lt;/span&gt;  &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedExercisePriceRange_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zqQhT7xxQXze" title="Exercise price range range per share, exercised"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_pid_c20230101__20230630_zAf2cpDMnjc3" style="text-align: right" title="Weighted average exercise price, exercised"&gt;10.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20230630_zKVATZOoYsUb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrant shares, expired"&gt;(4,762&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredExercisePriceRange_pid_c20230101__20230630_zrbfnzm763h2" title="Exercise price range range per share, expired"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice_pid_c20230101__20230630_zGRjqmeMnCK7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;10.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230630_zqxR8PP6pPSf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrant shares, ending"&gt;932,854&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zWqFfB0Tg5Sc" title="Exercise price range range per share, ending"&gt;3.00&lt;/span&gt; - &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zNc1heACnARf" title="Exercise price range range per share, ending"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630_zVnYYK4cqjVb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, ending"&gt;7.64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested and exercisable, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20230101__20230630_zEXsfSrK7ik6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrant shares, exercisable"&gt;932,854&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExercisePriceRange_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zMpG9Gisejdd" title="Exercise price range range per share, exercisable"&gt;3.00&lt;/span&gt; - &lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExercisePriceRange_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zsxj90JfAx4a" title="Exercise price range range per share, exercisable"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20230630_ztTj4ud69AAl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercisable"&gt;7.64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="f108" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="f109" contextRef="c">&lt;p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zy2Bbd9YIJXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_86F_zSkbarTNl9Qk"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company measures all stock options and other stock-based awards granted based on the fair value of the award on the date of the grant
and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the
respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized
for an award that is forfeited because of a failure to satisfy a service or performance condition is recognized in the period of the
forfeiture. Generally, the Company issues stock options with only service-based vesting conditions and records the expense for these
awards using the straight-line method over the requisite service period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipients
payroll costs are classified or in which the award recipients service payments are classified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company was a private company until the completion of its IPO on January 30, 2023. In 2022 and prior, the Company estimated the fair
value of common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified
Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. Each
valuation methodology includes estimates and assumptions that require the Companys judgment. These estimates and assumptions include
a number of objective and subjective factors, including external market conditions, guideline public company information, the prices
at which the Company sold its common stock to third parties in arms length transactions, the rights and preferences of securities
senior to the Companys common stock at the time, and the likelihood of achieving a liquidity event such as an initial public offering
or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options at each
valuation date, as applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
fair value of each stock option grant is estimated using the Black-Scholes option-pricing model. The Company was a private company and
lacked company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on
the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics similar to
the Company. The expected term of the Companys stock options has been determined utilizing the simplified method
for awards that qualify as plain-vanilla options. The expected term of stock options granted to non-employees is equal
to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve
in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend
yield is zero, based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the
foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f110" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:EarningsPerShareDiluted id="f111" decimals="INF" contextRef="c" unitRef="usd1">-0.72</us-gaap:EarningsPerShareDiluted>
  <us-gaap:Depreciation id="f112" decimals="-3" contextRef="c21" unitRef="usd">277000.0</us-gaap:Depreciation>
  <us-gaap:PreferredStockSharesOutstanding id="f113" decimals="INF" contextRef="c39" unitRef="shares">5000000.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:SaleOfStockPricePerShare id="f114" decimals="INF" contextRef="c40" unitRef="usd1">6.0</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="f115" decimals="-3" contextRef="c25" unitRef="usd">285000.0</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="f116" decimals="INF" contextRef="c41" unitRef="usd1">6.0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f117" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <us-gaap:LiabilitiesNoncurrent id="f118" decimals="-3" contextRef="c3" unitRef="usd">9688000.0</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:ShareBasedCompensation id="f119" decimals="-3" contextRef="c" unitRef="usd">467000.0</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="f120" decimals="-3" contextRef="c" unitRef="usd">-1658000.0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <genelux.com:PaymentOfDeferredOfferingCosts id="f121" decimals="-3" contextRef="c" unitRef="usd">303000.0</genelux.com:PaymentOfDeferredOfferingCosts>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f122" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <us-gaap:IncreaseDecreaseInOperatingLeaseLiability id="f123" decimals="-3" contextRef="c" unitRef="usd">-265000.0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
  <us-gaap:NotesPayable id="f124" decimals="-3" contextRef="c24" unitRef="usd">65000.0</us-gaap:NotesPayable>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="f125" decimals="INF" contextRef="c9" unitRef="usd1">6.0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <genelux.com:RepricingCosts id="f126" decimals="-3" contextRef="c" unitRef="usd">2642000.0</genelux.com:RepricingCosts>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange id="f127" decimals="INF" contextRef="c42" unitRef="usd1">3.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f128" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees id="f129" decimals="-3" contextRef="c22" unitRef="usd">29892000.0</genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="f130" decimals="-3" contextRef="c37" unitRef="usd">15918000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="f131" decimals="INF" contextRef="c38" unitRef="usd1">10.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:StockholdersEquity id="f132" decimals="-3" contextRef="c17" unitRef="usd">-433000.0</us-gaap:StockholdersEquity>
  <us-gaap:IncreaseDecreaseInOperatingLeaseLiability id="f133" decimals="-3" contextRef="c21" unitRef="usd">-184000.0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
  <genelux.com:DescriptionOfWarrants id="f134" contextRef="c">Company issued the note holders stock warrants to purchase up to an aggregate total of
44,441 shares of its common stock with an exercise price per share equal to 90% of the IPO price, or $5.40 per share, based on the IPO
closing price</genelux.com:DescriptionOfWarrants>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="f135" decimals="INF" contextRef="c11" unitRef="usd1">9.67</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="f136" decimals="-3" contextRef="c43" unitRef="shares">71615000.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f137" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:OperatingIncomeLoss id="f138" decimals="-3" contextRef="c25" unitRef="usd">-2799000.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f139" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f140" decimals="INF" contextRef="c" unitRef="shares">5353316.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="f141" decimals="INF" contextRef="c42" unitRef="usd1">6.0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharesOutstanding id="f142" decimals="INF" contextRef="c44" unitRef="shares">22094889.0</us-gaap:SharesOutstanding>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="f143" decimals="INF" contextRef="c45" unitRef="pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:PreferredStockSharesAuthorized id="f144" decimals="INF" contextRef="c46" unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange id="f145" decimals="INF" contextRef="c47" unitRef="usd1">10.5</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f146" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <us-gaap:EarningsPerShareBasic id="f147" decimals="INF" contextRef="c" unitRef="usd1">-0.72</us-gaap:EarningsPerShareBasic>
  <genelux.com:ScheduleOfConvertibleNotesPayableToShareholdersTableTextBlock id="f148" contextRef="c">&lt;p id="xdx_89A_ecustom--ScheduleOfConvertibleNotesPayableToShareholdersTableTextBlock_zo0TQ9uG9fC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
notes payable to shareholders consisted of the following as of June 30, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_z7CnBoYmzlOa" style="display: none"&gt;SCHEDULE
OF CONVERTIBLE NOTES PAYABLE TO SHAREHOLDERS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230630_zubLt0ixcyBb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;June
    30,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zuv3m9yk67Z6" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
    31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zADCMmlY5Kx9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    notes payable - shareholders (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span id="xdx_F40_zp6jjVMA9Qqf" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;65&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;7,838&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zioXQAMyd8Rf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    note payable - shareholder (b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F4E_z5pySqSr3ufj" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1059"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zLuww6w1CMk5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    notes payable  shareholders (c)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F4F_z2ksBmH5VM9l" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;700&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_z5JZRhlEcYyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    notes payable - shareholders (d)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_F49_z7CyFZ1xnhSa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(d)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;5,369&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ConvertibleNotesPayable_iI_zH1muCF9Qno6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible notes payable - shareholders&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;65&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;15,407&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ConvertibleNotesPayableCurrent_iNI_pn3n3_di_zB5Ogawor7gd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Less:
    current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(65&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(15,407&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ConvertibleLongTermNotesPayable_iI_pn3n3_ziGxbUdoC7zc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    notes payable  shareholders  long - term portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1074"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F08_zcptrqkktFUa" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F13_zHJ2cNXcivM8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;During
    the years ended December 31, 2011 through 2016, the Company entered into convertible note payable agreements with individuals aggregating
    to a total amount of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20161231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_z6CYmUZyMQSg" title="Convertible notes payable"&gt;7,988&lt;/span&gt;. The notes initially accrued interest at &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20161231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zpEjixCeRAf1" title="Accrued interest percentage"&gt;8&lt;/span&gt;% per annum, are unsecured and are convertible into the Companys
    Series K preferred stock at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20161231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zc4xPjdvzuC" title="Conversion price per share"&gt;25.73&lt;/span&gt; per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    of December 31, 2022, the principal amount due on the notes aggregated to $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zeDAxY3fL9ok"&gt;7,838&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_z9pgPwLcLj53" title="Accrued and unpaid interest"&gt;2,890&lt;/span&gt;
    was owed on the notes. During the six months ended June 30, 2023, $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--RepaymentsOfDebt_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zjiRGy6AWW9g" title="Repayment of debt"&gt;60&lt;/span&gt; of principal and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--InterestExpenseDebt_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zITGMEv6uE9f" title="Payment on accrued and unpaid interest"&gt;36&lt;/span&gt; of accrued and unpaid interest were paid
    on the notes, and the notes accrued interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zwHRCaSUxSKk" title="Accrued interest"&gt;15&lt;/span&gt;. On January 30, 2023, the date of the closing of the IPO, total principal of
    $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zuArDuKlI5T9" title="Convertible notes payable"&gt;7,778&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zCLJHcNaVJu8" title="Accrued and unpaid interest"&gt;2,867&lt;/span&gt; was owed on the notes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Upon
    the closing of the IPO, all of the principal plus accrued and unpaid interest, except for $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--NotesPayable_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zh3zCrL0RDej" title="Notes payable"&gt;65&lt;/span&gt; of principal and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--NonconvertibleAccruedAndUnpaidInterest_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zkFD3kJubYfh" title="Nonconvertible accrued and unpaid interest"&gt;58&lt;/span&gt; of accrued and
    unpaid interest, automatically converted into &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230130__20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zIr0hHsZorf7" title="Debt conversion shares issued"&gt;1,554,814&lt;/span&gt; shares of the Companys common stock based on the conversion price
    of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zyl2mqqOgKN8" title="Conversion price"&gt;6.78&lt;/span&gt; per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    of June 30, 2023, total principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zYB7zKdgHlE5" title="Convertible notes payable"&gt;65&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zhYPWdFsOFRk" title="Accrued and unpaid interest"&gt;60&lt;/span&gt; was owed on the notes. The notes accrue interest
    at &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderOneMember_zs6bixIB5xPf" title="Accrued interest percentage"&gt;8&lt;/span&gt;% per annum, are unsecured and are past due and payable on demand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F01_z4Gum6JTe71k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zU5Go73PBnT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
    April 2016, the Company entered into a convertible note payable agreement with a shareholder in the amount of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20160430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zcFaEXPxTlM4" title="Convertible notes payable"&gt;2,661&lt;/span&gt;. The note accrued
    interest at &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20160430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zN9TQOnwxd17" title="Accrued interest percentage"&gt;11.51&lt;/span&gt;% per annum, was unsecured, had an initial maturity date of May 2018 and was convertible into the Companys
    common stock at the price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20160430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_z3LCRFqiKMZ3" title="Conversion price"&gt;6.78&lt;/span&gt; per share. Interest payments are due monthly. In May 2018, the note was amended to include a provision
    under which the loan will accrue $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--LoanProcessingFee_pn3n3_c20180501__20180531__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zzP1DpC3X0c9" title="Loan fees"&gt;10&lt;/span&gt; per month of loan fees through the date the loan is repaid or is converted into the Companys
    common stock. The loan fees can be converted into shares of the Companys common stock at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20180531__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zXvs67LlZ3Xl" title="Conversion price"&gt;6.78&lt;/span&gt; per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    of December 31, 2022, total principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zBnt9Vl9u9ti"&gt;1,500&lt;/span&gt; and total accrued and unpaid loan fees of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--DebtInstrumentFeeAmount_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zf1XKJE8wwca" title="Accrued and unpaid loan fees owed on notes"&gt;560&lt;/span&gt; was owed on the note. During the six
    months ended June 30, 2023, the note accrued loan fees of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--LoanProcessingFee_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zaItfU4rV2Sh" title="Accrued loan fees"&gt;10&lt;/span&gt;, and on January 30, 2023, the date of the closing of the IPO, total
    principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zItRqxS5Czzg"&gt;1,500&lt;/span&gt; and total accrued and unpaid loan fees of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentFeeAmount_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_z29H5eonEQLg" title="Accrued and unpaid loan fees owed on notes"&gt;570&lt;/span&gt; was owed on the notes. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Upon
    the closing of the IPO, all of the principal plus accrued and unpaid loan fees automatically converted into &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230130__20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_zuOatzeccjsf" title="Debt conversion shares issued"&gt;303,835&lt;/span&gt; shares of the
    Companys common stock based on the conversion price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderTwoMember_z7asHZqCWx3i" title="Conversion price"&gt;6.78&lt;/span&gt;. As of June 30, 2023, no principal, interest or loan fees was
    due on the notes. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F0A_zyECcDj7h2Wb" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_ziHjfgpDvJZi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
    April 2018, the Company entered into two convertible note payable agreements with a shareholder under which the Company borrowed
    an aggregate total of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20180430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zdWHrbBzFX8h" title="Convertible notes payable"&gt;700&lt;/span&gt;. The notes accrue interest at&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20180430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zrfV0TbCQy4" title="Accrued interest percentage"&gt; 5.0&lt;/span&gt;% per annum, are unsecured, and are convertible into the Companys
    common stock at the lesser of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20180430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zy2Z1HKX7kN7" title="Conversion price"&gt;12.00&lt;/span&gt; per share, or &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--InitialPublicOfferingClosingPricePercentage_iI_pid_dp_c20180430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zJxLefVAXA15" title="Initial public offering closing price"&gt;90&lt;/span&gt;% of the Companys IPO price, if it were to occur. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    of December 31, 2022, total principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_z9ovmBKxizL5" title="Principal amount owed on notes"&gt;700&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zqppqRcRuEId"&gt;164&lt;/span&gt; was owed on the notes. During the six
    months ended June 30, 2023, the notes accrued interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zhAmUOwlmcs9" title="Accrued interest"&gt;3&lt;/span&gt;, and on January 30, 2023, the date of the closing of the IPO, total
    principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_z6DC2RtTimZh"&gt;700&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zNmWduK5k354"&gt;167&lt;/span&gt; was owed on the notes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Upon
    the closing of the IPO, all of the principal plus accrued and unpaid interest automatically converted into &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230130__20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zCY8CmIXhQob" title="Debt conversion shares issued"&gt;160,563&lt;/span&gt; shares of the
    Companys common stock based on the conversion price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zoTT5lHg1h9e" title="Conversion price"&gt;5.40&lt;/span&gt;, which was &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--InitialPublicOfferingClosingPricePercentage_iI_pid_dp_c20180430__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderThreeMember_zUwnf10ISvp4" title="Initial public offering closing price"&gt;90&lt;/span&gt;% of the IPO closing price. As of June 30, 2023,
    no principal or interest was due on the notes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0D_z6LRLcKGnnNi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(d)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zpXhdBJRpVC" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
    the years ended December 31, 2019 through 2021, the Company entered into convertible note payable agreements with several shareholders under which the Company borrowed an aggregate amount of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zEdWuOv6Bqr" title="Convertible notes payable"&gt;5,369&lt;/span&gt;. The notes accrue
interest at&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zKGyoNthY867" title="Accrued interest percentage"&gt; 5.0&lt;/span&gt;% per annum, are unsecured, and are convertible into the Companys common stock at the price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zlwkfbhURW72" title="Conversion price"&gt;12.00&lt;/span&gt; per share,
    or &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_ecustom--InitialPublicOfferingClosingPricePercentage_iI_pid_dp_c20191231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_z1rbAwSAMqak"&gt;90&lt;/span&gt;% of the Companys IPO price, if it were to occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    of December 31, 2022, total principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zneBwt09seYa"&gt;5,369&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zoblmnSqgsq7" title="Accrued and unpaid interest"&gt;758&lt;/span&gt; was owed on the notes. During the six
    months ended June 30, 2023, the notes accrued interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zdCKFFJz8x0k" title="Accrued interest"&gt;22&lt;/span&gt;, and on January 30, 2023, the date of the closing of the IPO, total
    principal of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zyTxPomkYF7h" title="Principal amount owed on notes"&gt;5,369&lt;/span&gt; and total accrued and unpaid interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zEdlkDffphy7"&gt;780&lt;/span&gt; was owed on the notes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Upon
    the closing of the IPO, all of the principal plus accrued and unpaid interest automatically converted into &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230130__20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zRAh7bifUp66" title="Conversion of common stock"&gt;1,134,063&lt;/span&gt; shares of the
    Companys common stock based on the conversion price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_z0DIpY0Otpx9" title="Conversion price"&gt;5.40&lt;/span&gt;, which was &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_ecustom--InitialPublicOfferingClosingPricePercentage_iI_pid_dp_c20230130__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_z7XIic4G7ina" title="Initial public offering closing price"&gt;90&lt;/span&gt;% of the IPO closing price. As of June 30, 2023,
    no principal or interest was due on the notes. During the six months ended June 30, 2023, the Company issued the shareholders stock
    warrants to purchase up to &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_zfGZ0vrGn6re" title="Warrants to purchase shares"&gt;111,828&lt;/span&gt; shares of the Companys common stock at an exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableShareholderFourMember_z3zKuhbBnBI7" title="Warrants exercise price"&gt;10.50&lt;/span&gt;. All of the warrant
    shares were exercised during the six months ended June 30, 2023 (see Note 9).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</genelux.com:ScheduleOfConvertibleNotesPayableToShareholdersTableTextBlock>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction id="f149" decimals="-3" contextRef="c37" unitRef="usd">12632000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <dei:DocumentTransitionReport id="f150" contextRef="c">false</dei:DocumentTransitionReport>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="f151" decimals="INF" contextRef="c48" unitRef="shares">44441.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:StockOptionExercisePriceIncrease id="f152" decimals="INF" contextRef="c49" unitRef="usd1">6.0</us-gaap:StockOptionExercisePriceIncrease>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f153" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <genelux.com:NotePayableShareholdersTextBlock id="f154" contextRef="c">&lt;p id="xdx_80C_ecustom--NotePayableShareholdersTextBlock_zO7oRkITGnNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTE
6  &lt;span id="xdx_829_zHU1U3oXiGla"&gt;NOTES PAYABLE  SHAREHOLDERS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2022, the Company, in anticipation of closing its IPO, entered into note payable agreements with several
shareholders totaling $&lt;span id="xdx_907_eus-gaap--NotesPayable_iI_pn3n3_c20221231__us-gaap--TypeOfArrangementAxis__custom--NotePayableAgreementsMember_zpoWM6YCepM9" title="Note payable"&gt;1,100&lt;/span&gt;. The notes accrue interest at &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20221231__us-gaap--TypeOfArrangementAxis__custom--NotePayableAgreementsMember_z1un94X32Nv5" title="Notes accrued interest"&gt;12&lt;/span&gt;% per annum, are unsecured and are due at the earlier of June 15, 2023 or
the month after the closing of the IPO. As of December 31, 2022, the outstanding principal and accrued and unpaid interest balances on
the notes were $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20221231_zzJZe4GLbu3l" title="Outstanding principal amount"&gt;1,100&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--DebtInstrumentAccruedAndUnpaidInterest_pn3n3_c20220101__20221231_zRXEoS50xalg" title="Accrued and unpaid interest"&gt;5&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the six months ended June 30, 2023, the Company extended the due date on the notes until April 30, 2023. During the six months ended
June 30, 2023, the Company borrowed an additional $&lt;span id="xdx_905_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20230630_zbIowbg4LPa6" title="Borrowings"&gt;900&lt;/span&gt; from its shareholders, repaid $&lt;span id="xdx_905_eus-gaap--RepaymentsOfRelatedPartyDebt_pn3n3_c20230101__20230630_zTsGLgtVud7g" title="Repayment of debt"&gt;600&lt;/span&gt; of principal and $&lt;span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20230630_zYB09xyIdzsf" title="Accrued interest"&gt;11&lt;/span&gt; of accrued interest, and
$&lt;span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20230630_z8jKoSa511Pk" title="Borrowed principal"&gt;1,400&lt;/span&gt; of principal and $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pn3n3_c20230101__20230630_zO8rChpcaTY3" title="Debt accrued interest"&gt;63&lt;/span&gt; of accrued interest was converted into &lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20230630_zqyM1XEF61ki" title="Conversion of convertible shares"&gt;73,134&lt;/span&gt; shares of the Companys common stock with a fair value
of $&lt;span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20230101__20230630_zLc6i80J0Mxf" title="Fair value on conversion of convertible"&gt;1,865&lt;/span&gt;. The notes accrued interest of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20230101__20230630_z4AwRGg0wXB2" title="Notes accrued interest"&gt;69&lt;/span&gt; during the six-month period. As of June 30, 2023, there was no outstanding principal and
accrued and unpaid interest owed on the notes. Upon conversion of the notes payable, the Company incurred a debt extinguishment cost
of $&lt;span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_pn3n3_di_c20230101__20230630_zdsRkn5FXsZ6"&gt;402&lt;/span&gt;, as the conversion price was lower than the fair value of the shares on the conversion date. This amount was recorded as debt
extinguishment costs in the Statements of Operations during the three and six months ended June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
consideration for the notes issued in 2022, the &lt;span id="xdx_904_ecustom--DescriptionOfWarrants_c20230101__20230630_zJVTf8PT80ja" title="Description of warrants"&gt;Company issued the note holders stock warrants to purchase up to an aggregate total of
&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zheREMS2WiT4" title="Warrants issued"&gt;44,441&lt;/span&gt; shares of its common stock with an exercise price per share equal to 90% of the IPO price, or $5.40 per share, based on the IPO
closing price&lt;/span&gt; (see Note 9). The issuance of the warrants was contingent upon the closing of the IPO, and as such, were not formally granted
until the closing of the IPO in January 2023. The warrants expire in December 2025. The Company determined the warrants should be accounted
for as a liability on the date of issuance. The Company calculated the fair value of the warrants issued to the noteholders to be $&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230630__srt--TitleOfIndividualAxis__custom--NoteHoldersMember_zWTQnyINLIjg" title="Fair value of warrants"&gt;169&lt;/span&gt;
using a Black Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock_z7TM1DpNQYl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_z1w8Wi9HBII7" style="display: none"&gt;SCHEDULE
OF WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 84%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Exercise
    price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9QgVUl4i5s5" title="Exercise price"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Expected
    dividends&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0zOjqNfqyA4" title="Expected dividends"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1036"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJhvcSDrclkl" title="Expected volatility"&gt;96.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Risk
    free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmZdCYElRs2h" title="Risk free interest rate"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Life
    of the warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKvyrmThuTm9" title="Life of the warrants"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zGWC219Aj9ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company recognized a liability and recorded a debt discount at the date of issuance in 2022 in the amount of $&lt;span id="xdx_909_eus-gaap--DeferredFinanceCostsNet_iI_pn3n3_c20230630_zQRo7mAsdGD1" title="Debt discount of issuance amount"&gt;169&lt;/span&gt;. The Company recorded
the fair value of the warrants as warrant liabilities as of December 31, 2022. The notes discounts are being amortized over the
term of the notes and the unamortized portion is recognized as a reduction to the carrying amount of the notes (a valuation debt discount).
During the year ended December 31, 2022, the Company amortized $&lt;span id="xdx_905_ecustom--AmortizationOfDebtDiscount_pn3n3_c20220101__20221231_zCpTyjABFx8f" title="Amortized debt discount"&gt;61&lt;/span&gt; of debt discount, leaving an unamortized balance of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20221231_zJsxFehTyXah" title="Unamortized debt discount"&gt;108&lt;/span&gt; at December
31, 2022. During the six months ended June 30, 2023, the Company amortized $&lt;span id="xdx_905_ecustom--AmortizationOfDebtDiscount_pn3n3_c20230101__20230630_zkOjYwLojrp1" title="Amortized debt discount"&gt;108&lt;/span&gt; of debt discount, leaving no unamortized balance at June
30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

</genelux.com:NotePayableShareholdersTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f155" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <us-gaap:CommonStockSharesAuthorized id="f156" decimals="INF" contextRef="c16" unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice id="f157" decimals="INF" contextRef="c20" unitRef="usd1">7.64</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f158" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="f159" decimals="-3" contextRef="c3" unitRef="usd">2950000.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:FairValueAdjustmentOfWarrants id="f160" decimals="-3" contextRef="c50" unitRef="usd">169000.0</us-gaap:FairValueAdjustmentOfWarrants>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedExercisePriceRange id="f161" decimals="INF" contextRef="c51" unitRef="usd1">9.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedExercisePriceRange>
  <us-gaap:ProceedsFromWarrantExercises id="f162" decimals="-3" contextRef="c49" unitRef="usd">430000.0</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:NetIncomeLoss id="f163" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:EarningsPerShareDiluted id="f164" decimals="INF" contextRef="c21" unitRef="usd1">-0.73</us-gaap:EarningsPerShareDiluted>
  <us-gaap:ConvertibleNotesPayable id="f165" decimals="-3" contextRef="c52" unitRef="usd">7988000.0</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ConvertibleNotesPayable id="f166" decimals="-3" contextRef="c24" unitRef="usd">7778000.0</us-gaap:ConvertibleNotesPayable>
  <genelux.com:GainOnForgivenessOfPppLoanPayable id="f167" decimals="-3" contextRef="c21" unitRef="usd">-314000.0</genelux.com:GainOnForgivenessOfPppLoanPayable>
  <us-gaap:SharesOutstanding id="f168" decimals="INF" contextRef="c53" unitRef="shares">25855511.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f169" decimals="-3" contextRef="c54" unitRef="usd">-209412000.0</us-gaap:StockholdersEquity>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExercisePriceRange id="f170" decimals="INF" contextRef="c41" unitRef="usd1">3.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExercisePriceRange>
  <us-gaap:NetIncomeLoss id="f171" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="f172" decimals="INF" contextRef="c9" unitRef="shares">3897135.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:NetIncomeLoss id="f173" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="f174" decimals="INF" contextRef="c13" unitRef="usd1">6.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:NetIncomeLoss id="f175" decimals="-3" contextRef="c12" unitRef="usd">-16185000.0</us-gaap:NetIncomeLoss>
  <us-gaap:PropertyPlantAndEquipmentGross id="f176" decimals="-3" contextRef="c55" unitRef="usd">148000.0</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="f177" decimals="INF" contextRef="c52" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedExercisePriceRange id="f178" decimals="INF" contextRef="c56" unitRef="usd1">10.5</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedExercisePriceRange>
  <us-gaap:NetIncomeLoss id="f179" xsi:nil="true" contextRef="c22" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="f180" decimals="INF" contextRef="c13" unitRef="shares">113500.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:AmortizationOfDebtDiscountPremium id="f181" decimals="-3" contextRef="c" unitRef="usd">649000.0</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:Cash id="f182" decimals="0" contextRef="c13" unitRef="usd">27500.0</us-gaap:Cash>
  <us-gaap:PropertyPlantAndEquipmentGross id="f183" decimals="-3" contextRef="c57" unitRef="usd">557000.0</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:NetIncomeLoss id="f184" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f185" decimals="-3" contextRef="c" unitRef="usd">2642000.0</genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing>
  <dei:LocalPhoneNumber id="f186" contextRef="c">267-9889</dei:LocalPhoneNumber>
  <genelux.com:ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock id="f187" contextRef="c">&lt;p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock_z7TM1DpNQYl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_z1w8Wi9HBII7" style="display: none"&gt;SCHEDULE
OF WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 84%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Exercise
    price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9QgVUl4i5s5" title="Exercise price"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Expected
    dividends&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0zOjqNfqyA4" title="Expected dividends"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1036"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJhvcSDrclkl" title="Expected volatility"&gt;96.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Risk
    free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmZdCYElRs2h" title="Risk free interest rate"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Life
    of the warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKvyrmThuTm9" title="Life of the warrants"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</genelux.com:ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice id="f188" decimals="INF" contextRef="c3" unitRef="usd1">8.24</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="f189" decimals="-3" contextRef="c19" unitRef="usd">24000.0</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:PreferredStockSharesOutstanding id="f190" decimals="INF" contextRef="c58" unitRef="shares">4500000.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued id="f191" decimals="INF" contextRef="c32" unitRef="shares">2757442.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="f192" decimals="INF" contextRef="c59" unitRef="usd1">25.73</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <genelux.com:RepricingCosts id="f193" decimals="-3" contextRef="c60" unitRef="usd">2733000.0</genelux.com:RepricingCosts>
  <us-gaap:EarningsPerShareBasic id="f194" decimals="INF" contextRef="c21" unitRef="usd1">-0.73</us-gaap:EarningsPerShareBasic>
  <us-gaap:NotesPayable id="f195" decimals="-3" contextRef="c45" unitRef="usd">1100000.0</us-gaap:NotesPayable>
  <us-gaap:PreferredStockSharesAuthorized id="f196" decimals="INF" contextRef="c61" unitRef="shares">4000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="f197" contextRef="c">&lt;p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmJb7BqTROn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTE
3 - &lt;span id="xdx_829_zgZdLumvdqie"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zAGftTxZJUp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Property
and equipment consisted of the following at June 30, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zWhTfacaOAZk" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230630_zvXLWnRId01d" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;June
    30,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231_z5Zgh1ROBme" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
    31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z0PGR4DhLIkh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Furniture
    and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zAIPwdI9i50j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Laboratory
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2,762&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2,762&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQg00HEesaOj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Computer
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;127&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;127&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdsAndLeaseholdImprovementsMember_z4dXwnhGWfGd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;557&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;557&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zJBOY8xQUpo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;505&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zEicxJ0igt77" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;4,099&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;3,594&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zdiy4ECbgYf1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Less:
    accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(3,221&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(2,950&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_iI_zEqjDn6rp5Nc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Property
    and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;878&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;644&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zqyqSDRkDVdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Depreciation
expense for the six months ended June 30, 2023 and 2022 was $&lt;span id="xdx_905_eus-gaap--Depreciation_pn3n3_c20230101__20230630_zpsQE7NA6O3i" title="Depreciation expense"&gt;271&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--Depreciation_pn3n3_c20220101__20220630_zhvvdJaiQHq4" title="Depreciation expense"&gt;277&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f198" decimals="INF" contextRef="c39" unitRef="usd1">5000.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesOutstanding id="f199" decimals="INF" contextRef="c32" unitRef="shares">2757442.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="f200" decimals="INF" contextRef="c62" unitRef="usd1">6.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f201" xsi:nil="true" contextRef="c63" unitRef="usd"/>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice id="f202" decimals="INF" contextRef="c13" unitRef="usd1">7.64</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber id="f203" decimals="INF" contextRef="c20" unitRef="shares">932854.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f204" xsi:nil="true" contextRef="c64" unitRef="usd"/>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="f205" decimals="-3" contextRef="c" unitRef="usd">170000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f206" decimals="-3" contextRef="c65" unitRef="usd">429000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:ShareBasedCompensation id="f207" decimals="-3" contextRef="c21" unitRef="usd">669000.0</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="f208" decimals="-3" contextRef="c21" unitRef="usd">940000.0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <dei:EntityAddressCityOrTown id="f209" contextRef="c">Westlake Village</dei:EntityAddressCityOrTown>
  <us-gaap:InterestPayableCurrent id="f210" decimals="-3" contextRef="c3" unitRef="usd">1178000.0</us-gaap:InterestPayableCurrent>
  <us-gaap:NetIncomeLoss id="f211" decimals="-3" contextRef="c66" unitRef="usd">-6621000.0</us-gaap:NetIncomeLoss>
  <genelux.com:PaymentOfDeferredOfferingCosts id="f212" decimals="-3" contextRef="c21" unitRef="usd">564000.0</genelux.com:PaymentOfDeferredOfferingCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f213" xsi:nil="true" contextRef="c67" unitRef="usd"/>
  <us-gaap:NonoperatingIncomeExpense id="f214" decimals="-3" contextRef="c" unitRef="usd">-4328000.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f215" decimals="-3" contextRef="c22" unitRef="usd">627000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="f216" decimals="INF" contextRef="c34" unitRef="pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="f217" decimals="INF" contextRef="c62" unitRef="usd1">10.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f218" xsi:nil="true" contextRef="c68" unitRef="usd"/>
  <us-gaap:SharesOutstanding id="f219" decimals="INF" contextRef="c69" unitRef="shares">22094889.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f220" decimals="-3" contextRef="c70" unitRef="usd">154401000.0</us-gaap:StockholdersEquity>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="f221" decimals="INF" contextRef="c71" unitRef="shares">168507.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f222" xsi:nil="true" contextRef="c72" unitRef="usd"/>
  <us-gaap:OperatingIncomeLoss id="f223" decimals="-3" contextRef="c" unitRef="usd">-11857000.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="f224" decimals="-3" contextRef="c" unitRef="usd">21642000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest id="f225" decimals="-3" contextRef="c73" unitRef="usd">15000.0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice id="f226" decimals="INF" contextRef="c" unitRef="usd1">10.31</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice>
  <us-gaap:WarrantExercisePriceIncrease id="f227" decimals="INF" contextRef="c74" unitRef="usd1">10.5</us-gaap:WarrantExercisePriceIncrease>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f228" xsi:nil="true" contextRef="c63" unitRef="usd"/>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsVestedInPeriodTotalFairValueEnding id="f229" decimals="-3" contextRef="c" unitRef="usd">119000.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsVestedInPeriodTotalFairValueEnding>
  <us-gaap:OperatingLeaseLiabilityCurrent id="f230" decimals="-3" contextRef="c13" unitRef="usd">585000.0</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f231" xsi:nil="true" contextRef="c64" unitRef="usd"/>
  <genelux.com:RightofuseAsset id="f232" decimals="-3" contextRef="c" unitRef="usd">274000.0</genelux.com:RightofuseAsset>
  <dei:CityAreaCode id="f233" contextRef="c">(805)</dei:CityAreaCode>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f234" decimals="INF" contextRef="c71" unitRef="usd1">6.0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f235" xsi:nil="true" contextRef="c67" unitRef="usd"/>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f236" xsi:nil="true" contextRef="c75" unitRef="usd"/>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="f237" decimals="-3" contextRef="c" unitRef="usd">48000.0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="f238" decimals="INF" contextRef="c13" unitRef="shares">195752.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="f239" decimals="INF" contextRef="c76" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f240" xsi:nil="true" contextRef="c68" unitRef="usd"/>
  <us-gaap:GeneralAndAdministrativeExpense id="f241" decimals="-3" contextRef="c25" unitRef="usd">972000.0</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:CommonStockSharesAuthorized id="f242" decimals="INF" contextRef="c77" unitRef="shares">75000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f243" decimals="INF" contextRef="c78" unitRef="shares">127373.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f244" xsi:nil="true" contextRef="c72" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f245" decimals="-3" contextRef="c19" unitRef="usd">-5821000.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="f246" decimals="-3" contextRef="c53" unitRef="usd">26000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f247" decimals="-3" contextRef="c79" unitRef="usd">2000.0</us-gaap:StockholdersEquity>
  <us-gaap:ConvertibleNotesPayable id="f248" decimals="-3" contextRef="c1" unitRef="usd">5369000.0</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted id="f249" decimals="INF" contextRef="c" unitRef="shares">340972.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f250" xsi:nil="true" contextRef="c25" unitRef="usd"/>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="f251" decimals="-3" contextRef="c19" unitRef="usd">-402000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:NonoperatingIncomeExpense id="f252" decimals="-3" contextRef="c19" unitRef="usd">-426000.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f253" decimals="INF" contextRef="c80" unitRef="shares">4201019.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="f254" decimals="-3" contextRef="c13" unitRef="usd">111765000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:NetIncomeLoss id="f255" xsi:nil="true" contextRef="c63" unitRef="usd"/>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f256" decimals="INF" contextRef="c" unitRef="shares">22334311.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <dei:EntityRegistrantName id="f257" contextRef="c">GENELUX CORPORATION</dei:EntityRegistrantName>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="f258" contextRef="c">&lt;p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zAGftTxZJUp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Property
and equipment consisted of the following at June 30, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zWhTfacaOAZk" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230630_zvXLWnRId01d" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;June
    30,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231_z5Zgh1ROBme" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
    31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z0PGR4DhLIkh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Furniture
    and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zAIPwdI9i50j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Laboratory
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2,762&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2,762&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQg00HEesaOj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Computer
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;127&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;127&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdsAndLeaseholdImprovementsMember_z4dXwnhGWfGd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;557&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;557&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zJBOY8xQUpo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;505&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zEicxJ0igt77" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;4,099&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;3,594&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zdiy4ECbgYf1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Less:
    accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(3,221&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(2,950&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_iI_zEqjDn6rp5Nc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Property
    and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;878&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;644&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:NetIncomeLoss id="f259" xsi:nil="true" contextRef="c64" unitRef="usd"/>
  <us-gaap:AmortizationOfDebtDiscountPremium id="f260" decimals="-3" contextRef="c21" unitRef="usd">99000.0</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f261" decimals="INF" contextRef="c" unitRef="shares">22334311.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:PropertyPlantAndEquipmentGross id="f262" decimals="-3" contextRef="c81" unitRef="usd">557000.0</us-gaap:PropertyPlantAndEquipmentGross>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice id="f263" decimals="INF" contextRef="c80" unitRef="usd1">10.5</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
  <us-gaap:NetIncomeLoss id="f264" xsi:nil="true" contextRef="c67" unitRef="usd"/>
  <genelux.com:ExtensionOfRightofuseAssetAndOperatingLease id="f265" decimals="-3" contextRef="c" unitRef="usd">649000.0</genelux.com:ExtensionOfRightofuseAssetAndOperatingLease>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="f266" decimals="INF" contextRef="c13" unitRef="usd1">6.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f267" decimals="INF" contextRef="c82" unitRef="shares">2796400.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <genelux.com:AccruedInterestPayableDirectorAndShareholders id="f268" decimals="-3" contextRef="c13" unitRef="usd">60000.0</genelux.com:AccruedInterestPayableDirectorAndShareholders>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f269" decimals="-3" contextRef="c19" unitRef="usd">240000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="f270" decimals="INF" contextRef="c9" unitRef="usd1">6.0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:NetIncomeLoss id="f271" xsi:nil="true" contextRef="c75" unitRef="usd"/>
  <dei:EntityAddressAddressLine2 id="f272" contextRef="c">Suite 230</dei:EntityAddressAddressLine2>
  <us-gaap:LeaseAndRentalExpense id="f273" decimals="-3" contextRef="c21" unitRef="usd">18000.0</us-gaap:LeaseAndRentalExpense>
  <us-gaap:NetIncomeLoss id="f274" xsi:nil="true" contextRef="c68" unitRef="usd"/>
  <us-gaap:CommonStockValue id="f275" decimals="-3" contextRef="c3" unitRef="usd">9000.0</us-gaap:CommonStockValue>
  <us-gaap:PaymentsForRent id="f276" decimals="-3" contextRef="c83" unitRef="usd">10000.0</us-gaap:PaymentsForRent>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f277" decimals="INF" contextRef="c32" unitRef="usd1">2757.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:NonoperatingIncomeExpense id="f278" decimals="-3" contextRef="c25" unitRef="usd">-21000.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:InterestExpenseDebt id="f279" decimals="-3" contextRef="c73" unitRef="usd">36000.0</us-gaap:InterestExpenseDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f280" xsi:nil="true" contextRef="c84" unitRef="usd"/>
  <us-gaap:Liabilities id="f281" decimals="-3" contextRef="c13" unitRef="usd">9107000.0</us-gaap:Liabilities>
  <us-gaap:SharesOutstanding id="f282" decimals="INF" contextRef="c85" unitRef="shares">22094889.0</us-gaap:SharesOutstanding>
  <genelux.com:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNonvestedOptionsWeightedAverageExercisePrice id="f283" decimals="INF" contextRef="c13" unitRef="usd1">6.0</genelux.com:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNonvestedOptionsWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations id="f284" decimals="INF" contextRef="c" unitRef="shares">4762.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f285" xsi:nil="true" contextRef="c86" unitRef="usd"/>
  <us-gaap:PropertyPlantAndEquipmentGross id="f286" decimals="-3" contextRef="c87" unitRef="usd">2762000.0</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f287" xsi:nil="true" contextRef="c88" unitRef="usd"/>
  <us-gaap:NonoperatingIncomeExpense id="f288" decimals="-3" contextRef="c21" unitRef="usd">-358000.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingLeaseLiability id="f289" decimals="-3" contextRef="c89" unitRef="usd">656000.0</us-gaap:OperatingLeaseLiability>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f290" xsi:nil="true" contextRef="c90" unitRef="usd"/>
  <us-gaap:PreferredStockSharesIssued id="f291" decimals="INF" contextRef="c61" unitRef="shares">1866853.0</us-gaap:PreferredStockSharesIssued>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice id="f292" decimals="INF" contextRef="c20" unitRef="usd1">7.64</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
  <genelux.com:ConversionofNotesPayableShareholdersAndAccruedInterestShares id="f293" decimals="INF" contextRef="c91" unitRef="shares">73134.0</genelux.com:ConversionofNotesPayableShareholdersAndAccruedInterestShares>
  <us-gaap:StockholdersEquity id="f294" decimals="-3" contextRef="c69" unitRef="usd">22000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f295" decimals="-3" contextRef="c92" unitRef="usd">2000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f296" decimals="INF" contextRef="c5" unitRef="shares">1117079.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <genelux.com:AdditionalCommitmentsReceived id="f297" decimals="-3" contextRef="c13" unitRef="usd">27500000.0</genelux.com:AdditionalCommitmentsReceived>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f298" xsi:nil="true" contextRef="c66" unitRef="usd"/>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="f299" decimals="INF" contextRef="c93" unitRef="shares">105943.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:OperatingIncomeLoss id="f300" decimals="-3" contextRef="c21" unitRef="usd">-6263000.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="f301" decimals="-3" contextRef="c" unitRef="usd">26743000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <genelux.com:ConversionOfDividendsPayableToShareholdersEquity id="f302" decimals="-3" contextRef="c" unitRef="usd">3443000.0</genelux.com:ConversionOfDividendsPayableToShareholdersEquity>
  <us-gaap:PreferredStockSharesOutstanding id="f303" decimals="INF" contextRef="c61" unitRef="shares">1866853.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f304" xsi:nil="true" contextRef="c84" unitRef="usd"/>
  <us-gaap:LesseeOperatingLeaseDiscountRate id="f305" decimals="INF" contextRef="c89" unitRef="pure">0.04</us-gaap:LesseeOperatingLeaseDiscountRate>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="f306" decimals="INF" contextRef="c94" unitRef="shares">1665213.0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="f307" decimals="INF" contextRef="c" unitRef="shares">113500.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:PreferredStockSharesAuthorized id="f308" decimals="INF" contextRef="c95" unitRef="shares">3000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f309" xsi:nil="true" contextRef="c86" unitRef="usd"/>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayable id="f310" decimals="-3" contextRef="c12" unitRef="usd">-3443000.0</genelux.com:IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayable>
  <genelux.com:RightofuseAsset id="f311" decimals="-3" contextRef="c21" unitRef="usd">205000.0</genelux.com:RightofuseAsset>
  <genelux.com:AccruedInterestPayableDirectorAndShareholders id="f312" decimals="-3" contextRef="c3" unitRef="usd">3817000.0</genelux.com:AccruedInterestPayableDirectorAndShareholders>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="f313" decimals="-3" contextRef="c" unitRef="usd">167000.0</us-gaap:InterestExpenseDebtExcludingAmortization>
  <genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCostsShares id="f314" decimals="INF" contextRef="c5" unitRef="shares">2653000.0</genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCostsShares>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisePriceRange id="f315" decimals="INF" contextRef="c51" unitRef="usd1">5.4</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisePriceRange>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice id="f316" decimals="INF" contextRef="c13" unitRef="usd1">7.64</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f317" xsi:nil="true" contextRef="c88" unitRef="usd"/>
  <genelux.com:FairValueOfRestrictedStockUnits id="f318" decimals="-3" contextRef="c" unitRef="usd">627000.0</genelux.com:FairValueOfRestrictedStockUnits>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="f319" decimals="-3" contextRef="c" unitRef="usd">-168000.0</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:ProceedsFromIssuanceOfWarrants id="f320" decimals="-3" contextRef="c" unitRef="usd">1174000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f321" decimals="-3" contextRef="c7" unitRef="usd">-3571000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="f322" decimals="-3" contextRef="c13" unitRef="usd">1511000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f323" xsi:nil="true" contextRef="c35" unitRef="usd"/>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="f324" decimals="-3" contextRef="c21" unitRef="usd">514000.0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:SaleOfStockPricePerShare id="f325" decimals="INF" contextRef="c96" unitRef="usd1">20.0</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f326" xsi:nil="true" contextRef="c90" unitRef="usd"/>
  <us-gaap:Liabilities id="f327" decimals="-3" contextRef="c3" unitRef="usd">41314000.0</us-gaap:Liabilities>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue id="f328" decimals="INF" contextRef="c13" unitRef="usd1">6.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <dei:EntityAddressAddressLine1 id="f329" contextRef="c">2625 Townsgate Road</dei:EntityAddressAddressLine1>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f330" decimals="-3" contextRef="c" unitRef="usd">1865000.0</genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisePriceRange id="f331" decimals="INF" contextRef="c56" unitRef="usd1">10.5</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisePriceRange>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f332" xsi:nil="true" contextRef="c66" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f333" decimals="-3" contextRef="c25" unitRef="usd">-2820000.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquityReverseStockSplit id="f334" contextRef="c97">1-for-3 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:SharesOutstanding id="f335" decimals="INF" contextRef="c98" unitRef="shares">-433333.0</us-gaap:SharesOutstanding>
  <us-gaap:PropertyPlantAndEquipmentGross id="f336" decimals="-3" contextRef="c13" unitRef="usd">4099000.0</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="f337" decimals="INF" contextRef="c99" unitRef="usd1">9.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f338" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement id="f339" decimals="0" contextRef="c100" unitRef="usd">33300.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice id="f340" decimals="INF" contextRef="c101" unitRef="usd1">6.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:RepaymentsOfDebt id="f341" decimals="-3" contextRef="c73" unitRef="usd">60000.0</us-gaap:RepaymentsOfDebt>
  <us-gaap:ConvertibleNotesPayable id="f342" decimals="-3" contextRef="c102" unitRef="usd">2661000.0</us-gaap:ConvertibleNotesPayable>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredExercisePriceRange id="f343" decimals="INF" contextRef="c" unitRef="usd1">10.5</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredExercisePriceRange>
  <us-gaap:NetIncomeLoss id="f344" xsi:nil="true" contextRef="c84" unitRef="usd"/>
  <us-gaap:FairValueAdjustmentOfWarrants id="f345" decimals="-3" contextRef="c" unitRef="usd">3110000.0</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f346" decimals="-3" contextRef="c" unitRef="usd">627000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:NetIncomeLoss id="f347" xsi:nil="true" contextRef="c86" unitRef="usd"/>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent id="f348" decimals="-3" contextRef="c3" unitRef="usd">108000.0</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:ConvertibleNotesPayable id="f349" decimals="-3" contextRef="c103" unitRef="usd">1500000.0</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="f350" decimals="INF" contextRef="c99" unitRef="usd1">10.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:NetIncomeLoss id="f351" xsi:nil="true" contextRef="c88" unitRef="usd"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f352" decimals="-3" contextRef="c21" unitRef="usd">669000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <genelux.com:ExtensionOfRightofuseAssetAndOperatingLease id="f353" decimals="-3" contextRef="c21" unitRef="usd">686000.0</genelux.com:ExtensionOfRightofuseAssetAndOperatingLease>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="f354" decimals="INF" contextRef="c102" unitRef="pure">0.1151</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <genelux.com:CancellationOfBridgeLoanAndAccruedInterest id="f355" decimals="-3" contextRef="c96" unitRef="usd">1463000.0</genelux.com:CancellationOfBridgeLoanAndAccruedInterest>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="f356" decimals="INF" contextRef="c80" unitRef="usd1">6.09</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:NetIncomeLoss id="f357" xsi:nil="true" contextRef="c35" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f358" xsi:nil="true" contextRef="c90" unitRef="usd"/>
  <us-gaap:OperatingLeasePayments id="f359" decimals="-3" contextRef="c" unitRef="usd">265000.0</us-gaap:OperatingLeasePayments>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock id="f360" contextRef="c">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zXBRAG9Ys41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information concerning outstanding and exercisable options as of June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z5QSuUSQlKoe" style="display: none"&gt;SCHEDULE
OF OUTSTANDING AND EXERCISABLE OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Options Exercisable&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&lt;b&gt;Range of Exercise&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: left; font-weight: bold"&gt; Prices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zHRVZEWROPgd" title="Range of exercise prices, upper limit"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zn8s2CyH3O44" style="width: 10%; text-align: right" title="Options outstanding number of outstanding"&gt;4,092,887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zjbp16j5Laz6" title="Options outstanding average remaining contractual life"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zpzu9BPvAUx6" style="width: 10%; text-align: right" title="Options outstaning weighted average exercise price"&gt;6.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zKVEesO2p0B9" style="width: 10%; text-align: right" title="Options exercisable number of outstanding"&gt;3,897,135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zj3GXeNWYs0c" title="Options exercisable average remaining contractual life"&gt;4.81&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zPNBTy8lIjDl" style="width: 10%; text-align: right" title="Options exercisable weighted average exercise price"&gt;6.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zagom9u9FME8" title="Range of exercise prices, lower limit"&gt;9.00&lt;/span&gt; - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z1urwc3puxWh" title="Range of exercise prices, upper limit"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z3I6Eg1Z2PXd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options outstanding number of outstanding"&gt;108,132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z26xMMs4Vt28" title="Options outstanding average remaining contractual life"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zzwLkhHKiWy" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options outstaning weighted average exercise price"&gt;9.67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zK6wN7LeDsvl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options exercisable number of outstanding"&gt;108,132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z1vTcR8eWk0l" title="Options exercisable average remaining contractual life"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z3JyKn3ZqEtc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options exercisable weighted average exercise price"&gt;9.67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zeBZ4asJIyGj" title="Range of exercise prices, lower limit"&gt;6.00&lt;/span&gt;
- &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zm54RlQnrgrf" title="Range of exercise prices, upper limit"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zSmywBKw1Z92" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding number of outstanding"&gt;4,201,019&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zMVXldGWX131" title="Options outstanding average remaining contractual life"&gt;4.91&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z4O9qYO8iRui" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstaning weighted average exercise price"&gt;6.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zhQNu1sDxQo5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable number of outstanding"&gt;4,005,267&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_znmNvKFYwKhf" title="Options exercisable average remaining contractual life"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z5Ws6oDxMrRb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable weighted average exercise price"&gt;6.10&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="f361" decimals="INF" contextRef="c104" unitRef="shares">184703.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f362" decimals="-3" contextRef="c22" unitRef="usd">21640000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ConvertibleDebtNoncurrent id="f363" decimals="-3" contextRef="c105" unitRef="usd">9065000.0</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:StockholdersEquity id="f364" decimals="-3" contextRef="c85" unitRef="usd">22000.0</us-gaap:StockholdersEquity>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="f365" contextRef="c">&lt;p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zXXKWPkcBkIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTE
2  &lt;span id="xdx_821_zeZQKqltDMzc"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zAKIM8om7bei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_864_ztfcvuBj8cV7"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;The
preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities
at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are
used in the valuation of accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax
assets, among others. Actual results could differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zXoXyBQjJef1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_86A_zFe4YoWtsRX7"&gt;Income
(Loss) Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Basic
loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common
shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted
average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive
potential common shares had been issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;For
the six months ended June 30, 2023 and 2022, the basic and diluted shares outstanding were the same, as potentially dilutive shares were
considered anti-dilutive. The potentially dilutive securities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDtejWi6b2sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zt9z8ZgRTLsa" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20230630_zOSuiXUw7RNi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;June 30,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220101__20220630_z07BwLv81g32" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zDhctm3YUTji" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; color: Black; text-align: left"&gt;Convertible notes payable&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 12%; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 12%; color: Black; text-align: right"&gt;3,339,752&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockEquivalentOfSeriesAThroughKConvertiblePreferredStockMember_zEypPXWUm2Zh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Common stock equivalent of Series A through K convertible preferred stock&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;7,567,630&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zkOfXSU2nce7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;4,201,019&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;3,962,719&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zC2bdHDOF5Gb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Stock warrants&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;932,854&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;751,745&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z9X5zOuBNSHl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;113,500&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsIssuableUponConversionOfNotesPayableMember_zhYNOraAWZUh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Stock warrants, issuable in connection with convertible notes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;105,943&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;183,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zpM5QF5IeFz" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;5,353,316&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;15,805,698&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_zGy4AVKjlJf7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zcPMDEwUzNW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_86D_zOlJVLY372uk"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company records revenue under the guidance of Accounting Standards Codification (ASC) 606, &lt;i&gt;Revenue from Contracts with
Customers (Topic 606)&lt;/i&gt; which requires a company to recognize revenue to depict the transfer of goods or services to a customer at
an amount that reflects the consideration it expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company determines revenue recognition through the following steps:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Identification
    of the contract, or contracts, with a customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Identification
    of the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Determination
    of the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Allocation
    of the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Recognition
    of revenue when, or as, we satisfy a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Under
certain of the Companys licensing, supply and collaboration agreements, it is entitled to receive payment upon the achievement
of contingent milestone events or the performance of obligations. The Company recognizes revenue based on guidance in ASC 606. In evaluating
revenue recognition under a license agreement, the Company uses a two-step process for determining whether a promised good or service
(including a license of intellectual property) is distinct and, therefore, is a performance obligation: (1) consideration of the individual
good or service (i.e., whether the good or service is capable of being distinct); and (2) consideration of whether the good or service
is separately identifiable from other promises in the contract (i.e., whether the promise to transfer the good or service is distinct
in the context of the contract). Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue
on the Companys balance sheet. Amounts expected to be recognized as revenue in the next 12 months following the balance sheet
date are classified as current liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2022, the Company, under its Newsoara agreement, invoiced and collected $170 relating to supplying product
for Newsoara to use in their clinical trials. As the product did not ship during the year ended December 31, 2022, the Company recorded
the cash received as deferred revenue until the product was shipped. During the six months ended June 30, 2023, the Company shipped the
product to Newsoara and thus recognized the revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--DeferredOfferingCostsPolicyTextBlock_zz2OgEzxO30l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_866_zRPGzIQsfrs4"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity
issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs
are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned,
the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statement of Operations. As of December
31, 2022, the Company incurred $&lt;span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zevW9c76EsQc" title="Deferred offering costs"&gt;1,568&lt;/span&gt; of deferred offering costs related to the Companys IPO,
and during the six months ended June 30, 2023, the Company incurred an additional $&lt;span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20230630_z1BT5prYbSkg" title="Deferred offering costs"&gt;303&lt;/span&gt; of costs. During the six months ended June 30,
2023, a total of $&lt;span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAwt74bUw8y6" title="Deferred offering costs"&gt;1,871&lt;/span&gt; of deferred offering costs were recorded against the net proceeds received from the IPO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zG8MfqCEB3V" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_86A_zUctjO5yeHj6"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an
orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the
use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs,
of which the first two are considered observable and the last unobservable, to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Level
    1 &lt;/i&gt; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Level
    2 &lt;/i&gt; Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets
    or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable
    market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Level
    3 &lt;/i&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of
    the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
carrying amount of the Companys warrant liabilities of $&lt;span id="xdx_90F_ecustom--WarrantLiabilities_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSI3M2PU9Lwk" title="Warrant liabilities"&gt;169&lt;/span&gt; at December 31, 2022 was based on Level 3 measurements. The carrying
amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values due
to the short-term maturities of these instruments. The carrying amounts of the Companys convertible notes payable approximate
their fair values as the interest rates of the notes payable are based on prevailing market rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zy2Bbd9YIJXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_86F_zSkbarTNl9Qk"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company measures all stock options and other stock-based awards granted based on the fair value of the award on the date of the grant
and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the
respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized
for an award that is forfeited because of a failure to satisfy a service or performance condition is recognized in the period of the
forfeiture. Generally, the Company issues stock options with only service-based vesting conditions and records the expense for these
awards using the straight-line method over the requisite service period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipients
payroll costs are classified or in which the award recipients service payments are classified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company was a private company until the completion of its IPO on January 30, 2023. In 2022 and prior, the Company estimated the fair
value of common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified
Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. Each
valuation methodology includes estimates and assumptions that require the Companys judgment. These estimates and assumptions include
a number of objective and subjective factors, including external market conditions, guideline public company information, the prices
at which the Company sold its common stock to third parties in arms length transactions, the rights and preferences of securities
senior to the Companys common stock at the time, and the likelihood of achieving a liquidity event such as an initial public offering
or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options at each
valuation date, as applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
fair value of each stock option grant is estimated using the Black-Scholes option-pricing model. The Company was a private company and
lacked company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on
the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics similar to
the Company. The expected term of the Companys stock options has been determined utilizing the simplified method
for awards that qualify as plain-vanilla options. The expected term of stock options granted to non-employees is equal
to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve
in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend
yield is zero, based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the
foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZIFZoBm4cc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_868_zJZJRVm30Wt7"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
June 2016, the FASB issued ASU No. 2016-13, Credit LossesMeasurement of Credit Losses on Financial Instruments (ASC 326).
The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables.
The standard will replace todays incurred loss approach with an expected loss model, under which companies
will recognize allowances based on expected rather than incurred losses. Entities will apply the standards provisions as a cumulative-effect
adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is
effective for the Company beginning January 1, 2023. The adoption of ASU 2016-13 did not have a material impact on the Companys
financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), DebtModifications and Extinguishments (Subtopic 470-50),
CompensationStock Compensation (Topic 718), and Derivatives and HedgingContracts in Entitys Own Equity (Subtopic
815-40): Issuers Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. ASU
2021-04 provides clarification and reduces diversity in an issuers accounting for modifications or exchanges of freestanding equity-classified
written call options (such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of
a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant
immediately before modification or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions
and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications
unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning
after December 15, 2021. The adoption of ASU 2021-04 did not have a material impact on the Companys financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Companys
present or future consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_850_z0RdzDOCGc7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="f366" decimals="INF" contextRef="c102" unitRef="usd1">6.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:InvestmentOwnedAtCost id="f367" decimals="0" contextRef="c96" unitRef="usd">17500.0</us-gaap:InvestmentOwnedAtCost>
  <us-gaap:PreferredStockSharesIssued id="f368" decimals="INF" contextRef="c58" unitRef="shares">4500000.0</us-gaap:PreferredStockSharesIssued>
  <genelux.com:GainOnForgivenessOfPppLoanPayable id="f369" decimals="-3" contextRef="c25" unitRef="usd">-314000.0</genelux.com:GainOnForgivenessOfPppLoanPayable>
  <us-gaap:PropertyPlantAndEquipmentGross id="f370" decimals="-3" contextRef="c106" unitRef="usd">2762000.0</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ConvertibleNotesPayable id="f371" decimals="-3" contextRef="c13" unitRef="usd">65000.0</us-gaap:ConvertibleNotesPayable>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice id="f372" decimals="INF" contextRef="c" unitRef="usd1">7.4</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice>
  <us-gaap:IncreaseDecreaseInInterestPayableNet id="f373" decimals="-3" contextRef="c21" unitRef="usd">388000.0</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:OperatingLeasePayments id="f374" decimals="-3" contextRef="c21" unitRef="usd">184000.0</us-gaap:OperatingLeasePayments>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f375" decimals="INF" contextRef="c104" unitRef="usd1">6.0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:NetIncomeLoss id="f376" decimals="-3" contextRef="c7" unitRef="usd">-5207000.0</us-gaap:NetIncomeLoss>
  <us-gaap:PropertyPlantAndEquipmentGross id="f377" decimals="-3" contextRef="c107" unitRef="usd">505000.0</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:LoanProcessingFee id="f378" decimals="-3" contextRef="c108" unitRef="usd">10000.0</us-gaap:LoanProcessingFee>
  <us-gaap:PaymentsForProceedsFromInvestments id="f379" decimals="0" contextRef="c109" unitRef="usd">2500.0</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:SharesOutstanding id="f380" decimals="INF" contextRef="c110" unitRef="shares">9126726.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f381" decimals="-3" contextRef="c111" unitRef="usd">-189784000.0</us-gaap:StockholdersEquity>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice id="f382" decimals="INF" contextRef="c" unitRef="usd1">10.5</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice>
  <us-gaap:ProceedsFromNotesPayable id="f383" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f384" decimals="INF" contextRef="c61" unitRef="usd1">1867.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="f385" decimals="-3" contextRef="c21" unitRef="usd">-293000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:ConvertibleNotesPayable id="f386" decimals="-3" contextRef="c76" unitRef="usd">65000.0</us-gaap:ConvertibleNotesPayable>
  <us-gaap:AllocatedShareBasedCompensationExpense id="f387" decimals="-3" contextRef="c" unitRef="usd">467000.0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RepaymentsOfNotesPayable id="f388" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f389" decimals="INF" contextRef="c91" unitRef="shares">1117079.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:OperatingLeaseLiability id="f390" decimals="-3" contextRef="c13" unitRef="usd">1814000.0</us-gaap:OperatingLeaseLiability>
  <us-gaap:PreferredStockSharesAuthorized id="f391" decimals="INF" contextRef="c29" unitRef="shares">2500000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f392" decimals="INF" contextRef="c11" unitRef="shares">108132.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange id="f393" decimals="INF" contextRef="c38" unitRef="usd1">10.5</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange>
  <us-gaap:RepaymentsOfConvertibleDebt id="f394" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="f395" decimals="INF" contextRef="c112" unitRef="usd1">6.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:OtherInvestments id="f396" decimals="0" contextRef="c113" unitRef="usd">17500.0</us-gaap:OtherInvestments>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="f397" decimals="-3" contextRef="c21" unitRef="usd">573000.0</us-gaap:InterestExpenseDebtExcludingAmortization>
  <genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts id="f398" decimals="-3" contextRef="c5" unitRef="usd">3000.0</genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="f399" decimals="-3" contextRef="c114" unitRef="usd">2890000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="f400" decimals="INF" contextRef="c80" unitRef="shares">4005267.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ProceedsFromIssuanceOfWarrants id="f401" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="f402" decimals="-3" contextRef="c21" unitRef="usd">12000.0</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:SharesOutstanding id="f403" decimals="INF" contextRef="c115" unitRef="shares">22094889.0</us-gaap:SharesOutstanding>
  <genelux.com:ConversionOfConvertibleNotesPayableAccruedInterestAndLoanFeesToShareholdersEquity id="f404" decimals="-3" contextRef="c" unitRef="usd">29896000.0</genelux.com:ConversionOfConvertibleNotesPayableAccruedInterestAndLoanFeesToShareholdersEquity>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="f405" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:GeneralAndAdministrativeExpense id="f406" decimals="-3" contextRef="c" unitRef="usd">6239000.0</us-gaap:GeneralAndAdministrativeExpense>
  <genelux.com:DebtInstrumentAccruedAndUnpaidInterest id="f407" decimals="-3" contextRef="c7" unitRef="usd">5000.0</genelux.com:DebtInstrumentAccruedAndUnpaidInterest>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="f408" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="f409" decimals="-3" contextRef="c" unitRef="usd">-170000.0</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:PaymentsForProceedsFromInvestments id="f410" decimals="0" contextRef="c116" unitRef="usd">2500.0</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:PreferredStockSharesIssued id="f411" decimals="INF" contextRef="c95" unitRef="shares">3000000.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:IncomeTaxesPaidNet id="f412" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f413" decimals="-3" contextRef="c" unitRef="usd">-16185000.0</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f414" decimals="-3" contextRef="c19" unitRef="usd">429000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:StockholdersEquity id="f415" decimals="-3" contextRef="c98" unitRef="usd">-433000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f416" decimals="-3" contextRef="c117" unitRef="usd">-188378000.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeTaxesPaidNet id="f417" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:PreferredStockSharesOutstanding id="f418" decimals="INF" contextRef="c95" unitRef="shares">3000000.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="f419" decimals="-3" contextRef="c" unitRef="usd">37256000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="f420" decimals="-3" contextRef="c118" unitRef="usd">34274000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber id="f421" decimals="INF" contextRef="c13" unitRef="shares">932854.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
  <genelux.com:ReclassificationOfDeferredOfferingCostsToShareholdersEquity id="f422" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="f423" decimals="-3" contextRef="c13" unitRef="usd">27140000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:OtherInvestments id="f424" decimals="0" contextRef="c119" unitRef="usd">17500.0</us-gaap:OtherInvestments>
  <dei:EntityFileNumber id="f425" contextRef="c">001-41599</dei:EntityFileNumber>
  <us-gaap:DeferredRevenueCurrent id="f426" decimals="-3" contextRef="c3" unitRef="usd">170000.0</us-gaap:DeferredRevenueCurrent>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="f427" decimals="-3" contextRef="c" unitRef="usd">-402000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <genelux.com:ReclassificationOfWarrantLiabilitiesToShareholdersEquity id="f428" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="f429" decimals="INF" contextRef="c120" unitRef="shares">44441.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <genelux.com:ConversionOfConvertibleNotesPayableAccruedInterestAndLoanFeesToShareholdersEquity id="f430" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:PreferredStockSharesAuthorized id="f431" decimals="INF" contextRef="c121" unitRef="shares">10000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures id="f432" decimals="INF" contextRef="c" unitRef="shares">36.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
  <genelux.com:ConversionOfPreferredStockToCommonStock id="f433" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:UseOfEstimates id="f434" contextRef="c">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zAKIM8om7bei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_864_ztfcvuBj8cV7"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;The
preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities
at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are
used in the valuation of accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax
assets, among others. Actual results could differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="f435" decimals="INF" contextRef="c109" unitRef="shares">842079.0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <dei:DocumentType id="f436" contextRef="c">10-Q</dei:DocumentType>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="f437" decimals="-3" contextRef="c13" unitRef="usd">4484000.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:BasisOfAccounting id="f438" contextRef="c">&lt;p id="xdx_80B_eus-gaap--BasisOfAccounting_zoEaVxV62Ir1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTE
1  &lt;span id="xdx_828_zTynVWflWVg6"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Organization
and Operations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;Genelux
Corporation (Genelux or the Company), a Delaware Corporation, incorporated on September 4, 2001, is a biomedical
company located in Westlake Village, California. The Company is engaged in the research and development of diagnostic and therapeutic
solutions for cancer for which there is no effective treatment today. The Company is focused on the development of therapeutic approaches
for cancer that are designed to generate a personalized multi-prong attack to overwhelm a tumors sophisticated defense mechanisms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Basis
of Presentation of Unaudited Financial Information&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally
accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation
S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have
been included. Operating results for the six months ended June 30, 2023 are not necessarily indicative of the results that may be expected
for the year ending December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Liquidity
and Capital Resources&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets
and the settlement of liabilities and commitments in the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2022, the Company incurred a net loss of $&lt;span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20220101__20221231_z8QwbfEBqq0h" title="Net income (loss)"&gt;5,207&lt;/span&gt; and used cash in operations of $&lt;span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20220101__20221231_z6i8NqfilYU2" title="Cash used in operations"&gt;3,571&lt;/span&gt; and had a shareholders
deficit of $&lt;span id="xdx_902_eus-gaap--StockholdersEquity_iNI_pn3n3_di_c20221231_z21c1mkP9cal" title="Shareholders' deficit"&gt;35,783&lt;/span&gt; as of December 31, 2022. As reflected in the accompanying condensed financial statements, during the six months ended
June 30, 2023, the Company incurred a net loss of $&lt;span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20230101__20230630_zvOQBMfAWYD" title="Net income (loss)"&gt;16,185&lt;/span&gt; and used cash in operations of $&lt;span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20230101__20230630_zOzx7m8e0tWf" title="Cash used in operations"&gt;10,008&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the six months ended June 30, 2023, the Company closed its initial public offering (IPO) and the two Private Placements (see
Note 9) and received $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvsx1cRFCOne" title="Proceeds from initial public offerings"&gt;34,274&lt;/span&gt; of net proceeds from these offerings. At June 30, 2023, the Company had cash on hand in the amount of $&lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230630_ztzpme5mXeD2" title="Cash"&gt;27,140&lt;/span&gt;.
The Company also received commitments through the Private Placements in which the Company will receive an additional $&lt;span id="xdx_90B_ecustom--AdditionalCommitmentsReceived_iI_pn3n3_c20230630_zfn9TmMx9fG5" title="Additional commitments received"&gt;27,500&lt;/span&gt; subsequent
to June 2023, but before the end of 2023. Due to the funds received through these offerings, and the conversion of preferred stock and
convertible notes payable upon the closing of the IPO, the Company had shareholders equity of $&lt;span id="xdx_902_eus-gaap--StockholdersEquity_iI_pn3n3_c20230630_zi1SKCulpex9" title="Shareholders' deficit"&gt;22,256&lt;/span&gt; at June 30, 2023. The Company
now expects its cash on hand at June 30, 2023, together with the $&lt;span id="xdx_904_eus-gaap--Cash_iI_c20230630_z2Kl3Lj2KaEf" title="Cash"&gt;27,500&lt;/span&gt; of future commitments from the Private Placements, will last
for at least the next 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and
raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due.
Since inception, the Company has funded its operations primarily through equity and debt financings, and licensing income, and it expects
to continue to rely on these sources of capital in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;No
assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to
the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the
case of debt financing, or cause substantial dilution for our stockholders, in case of equity financing, or grant unfavorable terms in
licensing future licensing agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Reverse
Stock Split&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
August 2022, the Company effected a &lt;span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20220801__20220831_zNIKNJJuYUig" title="Reverse stock split"&gt;1-for-3 reverse stock split&lt;/span&gt; of its common stock. The par value and the authorized shares of the common
stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the conversion prices
of the convertible preferred stock to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion.
The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse stock split for all
periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccounting>
  <genelux.com:ConversionOfDividendsPayableToShareholdersEquity id="f439" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f440" decimals="INF" contextRef="c21" unitRef="shares">9111039.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f441" decimals="-3" contextRef="c65" unitRef="usd">1865000.0</genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f442" decimals="INF" contextRef="c120" unitRef="usd1">5.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="f443" decimals="INF" contextRef="c24" unitRef="usd1">6.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f444" decimals="INF" contextRef="c13" unitRef="shares">932854.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterestToShareholdersEquity id="f445" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:SharesOutstanding id="f446" decimals="INF" contextRef="c122" unitRef="shares">9113393.0</us-gaap:SharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f447" decimals="INF" contextRef="c21" unitRef="shares">9111039.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f448" xsi:nil="true" contextRef="c123" unitRef="shares"/>
  <us-gaap:AdditionalPaidInCapital id="f449" decimals="-3" contextRef="c3" unitRef="usd">154401000.0</us-gaap:AdditionalPaidInCapital>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="f450" decimals="0" contextRef="c100" unitRef="usd">16842.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ConvertibleNotesPayable id="f451" decimals="-3" contextRef="c3" unitRef="usd">15407000.0</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="f452" decimals="INF" contextRef="c124" unitRef="shares">113500.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange id="f453" decimals="INF" contextRef="c41" unitRef="usd1">3.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f454" xsi:nil="true" contextRef="c125" unitRef="shares"/>
  <us-gaap:ShortTermBorrowings id="f455" decimals="-3" contextRef="c13" unitRef="usd">900000.0</us-gaap:ShortTermBorrowings>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f456" xsi:nil="true" contextRef="c126" unitRef="shares"/>
  <us-gaap:CommonStockValue id="f457" decimals="-3" contextRef="c13" unitRef="usd">26000.0</us-gaap:CommonStockValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f458" decimals="-3" contextRef="c25" unitRef="usd">297000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockholdersEquity id="f459" decimals="-3" contextRef="c110" unitRef="usd">9000.0</us-gaap:StockholdersEquity>
  <us-gaap:PropertyPlantAndEquipmentGross id="f460" xsi:nil="true" contextRef="c127" unitRef="usd"/>
  <genelux.com:NetProceedsFromIssuanceOfCommonStock id="f461" decimals="0" contextRef="c100" unitRef="usd">16342.0</genelux.com:NetProceedsFromIssuanceOfCommonStock>
  <us-gaap:PreferredStockSharesAuthorized id="f462" decimals="INF" contextRef="c58" unitRef="shares">4500000.0</us-gaap:PreferredStockSharesAuthorized>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue id="f463" decimals="-3" contextRef="c124" unitRef="usd">746000.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="f464" xsi:nil="true" contextRef="c34" unitRef="pure"/>
  <us-gaap:EarningsPerShareBasic id="f465" decimals="INF" contextRef="c19" unitRef="usd1">-0.23</us-gaap:EarningsPerShareBasic>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f466" decimals="-3" contextRef="c91" unitRef="usd">2000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:RepaymentsOfRelatedPartyDebt id="f467" decimals="-3" contextRef="c" unitRef="usd">600000.0</us-gaap:RepaymentsOfRelatedPartyDebt>
  <us-gaap:ConvertibleNotesPayable id="f468" xsi:nil="true" contextRef="c128" unitRef="usd"/>
  <us-gaap:EarningsPerShareDiluted id="f469" decimals="INF" contextRef="c19" unitRef="usd1">-0.23</us-gaap:EarningsPerShareDiluted>
  <us-gaap:PropertyPlantAndEquipmentGross id="f470" decimals="-3" contextRef="c3" unitRef="usd">3594000.0</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="f471" decimals="-3" contextRef="c76" unitRef="usd">60000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:ConvertibleNotesPayable id="f472" xsi:nil="true" contextRef="c129" unitRef="usd"/>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="f473" decimals="-3" contextRef="c3" unitRef="usd">6775000.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity id="f474" decimals="-3" contextRef="c115" unitRef="usd">22000.0</us-gaap:StockholdersEquity>
  <us-gaap:PropertyPlantAndEquipmentGross id="f475" decimals="-3" contextRef="c130" unitRef="usd">127000.0</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="f476" decimals="INF" contextRef="c131" unitRef="usd1">6.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ConvertibleNotesPayable id="f477" xsi:nil="true" contextRef="c132" unitRef="usd"/>
  <dei:EntityTaxIdentificationNumber id="f478" contextRef="c">77-0583529</dei:EntityTaxIdentificationNumber>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="f479" decimals="-3" contextRef="c13" unitRef="usd">11000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="f480" decimals="INF" contextRef="c11" unitRef="usd1">9.67</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedExercisePriceRange id="f481" decimals="INF" contextRef="c" unitRef="usd1">9.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedExercisePriceRange>
  <us-gaap:RepaymentsOfShortTermDebt id="f482" decimals="0" contextRef="c" unitRef="usd">283.0</us-gaap:RepaymentsOfShortTermDebt>
  <us-gaap:ConvertibleLongTermNotesPayable id="f483" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <us-gaap:InterestPaidNet id="f484" decimals="-3" contextRef="c" unitRef="usd">50000.0</us-gaap:InterestPaidNet>
  <us-gaap:PreferredStockSharesIssued id="f485" decimals="INF" contextRef="c29" unitRef="shares">1281600.0</us-gaap:PreferredStockSharesIssued>
  <genelux.com:WarrantLiabilitiesCurrent id="f486" decimals="-3" contextRef="c3" unitRef="usd">169000.0</genelux.com:WarrantLiabilitiesCurrent>
  <us-gaap:PreferredStockSharesAuthorized id="f487" decimals="INF" contextRef="c77" unitRef="shares">29927994.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="f488" decimals="INF" contextRef="c121" unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="f489" decimals="INF" contextRef="c80" unitRef="usd1">6.1</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ConvertibleLongTermNotesPayable id="f490" xsi:nil="true" contextRef="c3" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f491" decimals="-3" contextRef="c21" unitRef="usd">-6621000.0</us-gaap:NetIncomeLoss>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="f492" decimals="INF" contextRef="c133" unitRef="shares">111828.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:StockholdersEquity id="f493" decimals="-3" contextRef="c134" unitRef="usd">232073000.0</us-gaap:StockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f494" decimals="INF" contextRef="c95" unitRef="usd1">3000.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesOutstanding id="f495" decimals="INF" contextRef="c29" unitRef="shares">1281600.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized id="f496" decimals="INF" contextRef="c3" unitRef="shares">29927994.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ConvertibleDebtNoncurrent id="f497" xsi:nil="true" contextRef="c135" unitRef="usd"/>
  <us-gaap:ConvertibleNotesPayable id="f498" decimals="-3" contextRef="c114" unitRef="usd">7838000.0</us-gaap:ConvertibleNotesPayable>
  <genelux.com:ScheduleOfOutstandingAndExercisableWarrantsTableTextBlock id="f499" contextRef="c">&lt;p id="xdx_89E_ecustom--ScheduleOfOutstandingAndExercisableWarrantsTableTextBlock_zdns4zXq6EUf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information concerning outstanding and exercisable warrants as of June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_z3qy5DTLmuUl" style="display: none"&gt;SCHEDULE
OF OUTSTANDING AND EXERCISABLE WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Range of Exercise&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Number&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Prices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zqBtFU3J5xnk" title="Range of exercise prices, upper limit"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zeJZKCRVaxQ5" style="width: 11%; text-align: right" title="Warrants Outstanding number of outstanding"&gt;133,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z1aFkVofJfS6" title="Warrants outstanding average remaining contractual life"&gt;3.67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zNzKr1qFiVTd" style="width: 11%; text-align: right" title="Warrants outstaning weighted average exercise price"&gt;3.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zOuiBZgwvTpl" style="width: 10%; text-align: right" title="Warrants exercisable number of outstanding"&gt;133,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z09mguBmFl85" title="Warrants exercisable average remaining contractual life"&gt;3.67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zsOwXCXGCxS1" style="width: 10%; text-align: right" title="Warrants exercisable weighted average exercise price"&gt;3.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantExercisePriceDecrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z21glvwUc5E" title="Range of exercise prices, lower limit"&gt;3.01&lt;/span&gt;  &lt;span id="xdx_903_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zeZgEUUs6aN1" title="Range of exercise prices, upper limit"&gt;10.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zIOCxGFqfEG3" style="text-align: right" title="Warrants Outstanding number of outstanding"&gt;637,643&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zqti9RRpek4c" title="Warrants outstanding average remaining contractual life"&gt;3.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zykpvV8YtPmk" style="text-align: right" title="Warrants outstaning weighted average exercise price"&gt;7.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zT99KXhP5SYh" style="text-align: right" title="Warrants exercisable number of outstanding"&gt;637,643&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zyXphZtvhFNc" title="Warrants exercisable average remaining contractual life"&gt;3.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zdR9yI7FUzgh" style="text-align: right" title="Warrants exercisable weighted average exercise price"&gt;7.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z1i1RuejUnVg" title="Range of exercise prices, upper limit"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z3Jw8G9EQnTh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding number of outstanding"&gt;161,878&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z3mXsCTU9lS9" title="Warrants outstanding average remaining contractual life"&gt;2.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zjS8MtwMoAPj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstaning weighted average exercise price"&gt;10.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zXXYsesWFQCl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercisable number of outstanding"&gt;161,878&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zJ2Gq99MahLd" title="Warrants exercisable average remaining contractual life"&gt;2.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zszizi9qg0I8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercisable weighted average exercise price"&gt;10.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantExercisePriceDecrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zXcF95QUdQr7" title="Range of exercise prices, lower limit"&gt;3.00&lt;/span&gt;  &lt;span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zJtQT93zBSq8" title="Range of exercise prices, upper limit"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zjyc9KpeZMac" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding number of outstanding"&gt;932,854&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zG8SZmcJcTja" title="Warrants outstanding average remaining contractual life"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zQ0Pq9lHttqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstaning weighted average exercise price"&gt;7.64&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zoLNzshKm4Tl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable number of outstanding"&gt;932,854&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zZeVpzgjgsVf" title="Warrants exercisable average remaining contractual life"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zqX4FWyugasf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable weighted average exercise price"&gt;7.64&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</genelux.com:ScheduleOfOutstandingAndExercisableWarrantsTableTextBlock>
  <dei:DocumentQuarterlyReport id="f500" contextRef="c">true</dei:DocumentQuarterlyReport>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="f501" decimals="-3" contextRef="c21" unitRef="usd">-694000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterestToShareholdersEquity id="f502" decimals="-3" contextRef="c" unitRef="usd">1463000.0</genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterestToShareholdersEquity>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="f503" decimals="0" contextRef="c" unitRef="usd">1400.0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="f504" decimals="INF" contextRef="c136" unitRef="shares">1554814.0</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent id="f505" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <us-gaap:StockIssuedDuringPeriodSharesOther id="f506" decimals="INF" contextRef="c64" unitRef="shares">3333.0</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="f507" decimals="-3" contextRef="c137" unitRef="usd">4202000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f508" decimals="-3" contextRef="c65" unitRef="usd">240000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="f509" decimals="-3" contextRef="c13" unitRef="usd">3221000.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:IncreaseDecreaseInInterestPayableNet id="f510" decimals="-3" contextRef="c" unitRef="usd">44000.0</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:DeferredFinanceCostsNet id="f511" decimals="-3" contextRef="c13" unitRef="usd">169000.0</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f512" decimals="INF" contextRef="c133" unitRef="usd1">10.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="f513" decimals="-3" contextRef="c3" unitRef="usd">2000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OperatingLeaseRightOfUseAsset id="f514" decimals="-3" contextRef="c137" unitRef="usd">1335000.0</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:DebtInstrumentFeeAmount id="f515" decimals="-3" contextRef="c103" unitRef="usd">560000.0</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="f516" decimals="INF" contextRef="c138" unitRef="shares">900000.0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f517" decimals="-3" contextRef="c19" unitRef="usd">36000.0</genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="f518" decimals="-3" contextRef="c13" unitRef="usd">2684000.0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f519" decimals="-3" contextRef="c3" unitRef="usd">-189784000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:FairValueAdjustmentOfWarrants id="f520" decimals="-3" contextRef="c34" unitRef="usd">3110000.0</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants id="f521" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f522" decimals="-3" contextRef="c122" unitRef="usd">9000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f523" decimals="-3" contextRef="c137" unitRef="usd">-39063000.0</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="f524" decimals="-3" contextRef="c13" unitRef="usd">7878000.0</us-gaap:LiabilitiesCurrent>
  <us-gaap:LoanProcessingFee id="f525" decimals="-3" contextRef="c139" unitRef="usd">10000.0</us-gaap:LoanProcessingFee>
  <us-gaap:SaleOfStockPricePerShare id="f526" decimals="INF" contextRef="c140" unitRef="usd1">20.0</us-gaap:SaleOfStockPricePerShare>
  <genelux.com:CostOfStockOptionRepricing id="f527" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="f528" decimals="-3" contextRef="c3" unitRef="usd">2852000.0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f529" decimals="INF" contextRef="c132" unitRef="usd1">10.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedInPeriodTotalFairValueEnding id="f530" decimals="-3" contextRef="c" unitRef="usd">119000.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedInPeriodTotalFairValueEnding>
  <us-gaap:ConvertibleNotesPayableCurrent id="f531" decimals="-3" contextRef="c3" unitRef="usd">15407000.0</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f532" decimals="INF" contextRef="c141" unitRef="shares">7567630.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="f533" decimals="INF" contextRef="c13" unitRef="shares">111828.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:StockholdersEquity id="f534" decimals="-3" contextRef="c142" unitRef="usd">24000.0</us-gaap:StockholdersEquity>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="f535" contextRef="c">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zmDHTFicztLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the Companys stock option activities for the six months ended June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zVBDe7tdKSf8" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Price Range&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Option Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230630_zg2Ua5WQw9j2" style="width: 14%; text-align: right" title="Number of options shares, beginning"&gt;4,201,019&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zYca9pBnZvO3" title="Exercise price range, beginning"&gt;6.00&lt;/span&gt; - &lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zva9OGosWjnc" title="Exercise price range, beginning"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630_zNwQgxzZuBqi" style="width: 14%; text-align: right" title="Weighted average exercise price, beginning"&gt;6.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230630_zYE3KPBrXrf3" style="text-align: right" title="Number of options shares, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1434"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630_zNZMnwpEFAI3" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1436"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20230630_zLv8P26xhkC2" style="text-align: right" title="Number of options shares, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1438"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630_zIIyjFGbKeQe" style="text-align: right" title="Weighted average exercise price, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1440"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20230630_zTmqbAcC6gXd" style="text-align: right" title="Number of options shares, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1442"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630_zg24uYCREUfi" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1444"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20230630_z2SwmxfCqWz2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options shares, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1446"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630_zQWvtwgzbjPe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1448"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230630_zbfdZy9lEF6b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options shares, ending"&gt;4,201,019&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zcugCTJ4SaJ7" title="Exercise price range, ending"&gt;6.00&lt;/span&gt;
- &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zJzxGdzneUm1" title="Exercise price range, ending"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630_zF7aXBIW24qc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending"&gt;6.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Vested and exercisable, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20230101__20230630_zElnzo4WerXg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options shares, vested and exercisable"&gt;4,005,267&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zlEferJh6Kh2" title="Exercise price range, vested and exercisable ending"&gt;6.00&lt;/span&gt;
- &lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zXIPZtBlHkpi" title="Exercise price range, vested and exercisable ending"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20230630_z1Xe3OSxleE8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and exercisable ending"&gt;6.10&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Unvested, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20230630_zthLQzwHX9ng" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options shares, unvested, ending"&gt;195,752&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNonvestedOptionsWeightedAverageExercisePrice_iE_pid_c20230101__20230630_zWjDOy9IR7ch" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise price range, unvested ending"&gt;6.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230630_zFAdYoRk17Pb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, unvested ending"&gt;6.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="f536" decimals="INF" contextRef="c2" unitRef="shares">-22094889.0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:EarningsPerSharePolicyTextBlock id="f537" contextRef="c">&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zXoXyBQjJef1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_86A_zFe4YoWtsRX7"&gt;Income
(Loss) Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Basic
loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common
shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted
average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive
potential common shares had been issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;For
the six months ended June 30, 2023 and 2022, the basic and diluted shares outstanding were the same, as potentially dilutive shares were
considered anti-dilutive. The potentially dilutive securities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDtejWi6b2sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zt9z8ZgRTLsa" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20230630_zOSuiXUw7RNi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;June 30,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220101__20220630_z07BwLv81g32" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zDhctm3YUTji" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; color: Black; text-align: left"&gt;Convertible notes payable&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 12%; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 12%; color: Black; text-align: right"&gt;3,339,752&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockEquivalentOfSeriesAThroughKConvertiblePreferredStockMember_zEypPXWUm2Zh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Common stock equivalent of Series A through K convertible preferred stock&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;7,567,630&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zkOfXSU2nce7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;4,201,019&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;3,962,719&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zC2bdHDOF5Gb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Stock warrants&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;932,854&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;751,745&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z9X5zOuBNSHl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;113,500&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsIssuableUponConversionOfNotesPayableMember_zhYNOraAWZUh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Stock warrants, issuable in connection with convertible notes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;105,943&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;183,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zpM5QF5IeFz" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;5,353,316&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;15,805,698&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_zGy4AVKjlJf7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ConvertibleNotesPayable id="f538" decimals="-3" contextRef="c143" unitRef="usd">1500000.0</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement id="f539" decimals="0" contextRef="c144" unitRef="usd">18000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice id="f540" decimals="INF" contextRef="c9" unitRef="usd1">3.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice id="f541" decimals="INF" contextRef="c11" unitRef="usd1">7.85</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
  <dei:EntityCommonStockSharesOutstanding id="f542" decimals="INF" contextRef="c145" unitRef="shares">26182892.0</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="f543" decimals="-3" contextRef="c13" unitRef="usd">1543000.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromWarrantExercises id="f544" decimals="-3" contextRef="c" unitRef="usd">1174000.0</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="f545" decimals="-3" contextRef="c18" unitRef="usd">164000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f546" decimals="-3" contextRef="c65" unitRef="usd">1174000.0</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:DebtInstrumentFeeAmount id="f547" decimals="-3" contextRef="c143" unitRef="usd">570000.0</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:InvestmentOwnedAtCost id="f548" decimals="0" contextRef="c140" unitRef="usd">12500.0</us-gaap:InvestmentOwnedAtCost>
  <us-gaap:SharesOutstanding id="f549" decimals="INF" contextRef="c146" unitRef="shares">9110060.0</us-gaap:SharesOutstanding>
  <genelux.com:ReclassificationOfDeferredOfferingCostsToShareholdersEquity id="f550" decimals="-3" contextRef="c" unitRef="usd">1871000.0</genelux.com:ReclassificationOfDeferredOfferingCostsToShareholdersEquity>
  <us-gaap:StockholdersEquity id="f551" decimals="-3" contextRef="c44" unitRef="usd">22000.0</us-gaap:StockholdersEquity>
  <us-gaap:LesseeOperatingLeasesTextBlock id="f552" contextRef="c">&lt;p id="xdx_80F_eus-gaap--LesseeOperatingLeasesTextBlock_zN5dBofCITZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTE
5  &lt;span id="xdx_82D_zdohRM6Qmrt"&gt;LEASE LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;i&gt;Operating
Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company accounts for leases in accordance with ASC 842, which requires a lessee to record a right-of-use asset and a corresponding lease
liability at the inception of the lease initially measured at the present value of the lease payments. In July 2018, the Company entered
into a long-term non-cancellable lease agreement for its manufacturing facility that requires aggregate average monthly payments of $&lt;span id="xdx_908_eus-gaap--PaymentsForRent_pn3n3_c20180701__20180731_zp5eRWfk7q51" title="Aggregate average monthly payments"&gt;10&lt;/span&gt;
beginning October 2018. The lease terminates in September 2023, with a Company&lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseOptionToExtend_pn3n3_c20180701__20180731_zCvx3IBxV1te" title="Option to extend lease"&gt; option to extend for an additional five years&lt;/span&gt;. The Company
classified the lease as an operating lease and determined that the value of the right of use asset and lease liability at the adoption
date was $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20180731__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_z8l4RyVnTTZ" title="Operating lease right of use asset"&gt;518&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20180731__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zI8bOFKfrhva" title="Operating lease liability"&gt;519&lt;/span&gt;, respectively, using a discount rate of &lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_c20180731_zxzyRm3Ykfg1" title="Operating lease discount rate"&gt;4.00&lt;/span&gt;%. Effective April 2022, the Company extended the lease for the additional
five-year period, with no changes to any of the other terms of the lease, and has &lt;span id="xdx_906_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20220401__20220430_zKjOhhlhaYef" title="Option to extend lease"&gt;the option to extend the lease for an additional five
years&lt;/span&gt;. Prior to the extension, the remaining lease liability amounted to $&lt;span id="xdx_902_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20180731_zx70q3zhAyU8" title="Operating lease liability"&gt;174&lt;/span&gt;. On the date of the extension, the Company determined that
the value of the new right of use asset and lease liability was $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20220430_zJ8GSuYNh7Ab" title="Operating lease right of use asset"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20220430_zV5XljRHo2ki" title="Operating lease liability"&gt;860&lt;/span&gt;&lt;/span&gt;, respectively, using a discount rate of&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_c20220430_zqVmgt36Yj8j" title="Operating lease discount rate"&gt; 4.00&lt;/span&gt;%. As such, the Company
recorded an increase in lease liability of $&lt;span id="xdx_900_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_pn3n3_c20220401__20220430_zL862RYHXj9i" title="Increase in lease liability"&gt;686&lt;/span&gt; as a result of the lease extension.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
December 2020, the Company entered into a long-term non-cancellable lease agreement for a laboratory facility that requires aggregate
average monthly payments of $&lt;span id="xdx_90C_eus-gaap--PaymentsForRent_pn3n3_c20201201__20201231_zKgYM50DABc6" title="Monthly lease payments"&gt;18&lt;/span&gt; beginning January 2021. The lease terminates in February 2023. The Company classified the lease as an
operating lease and determined that the value of the right of use asset and lease liability at the adoption date was $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zxTdImHMvnie" title="Operating lease liability"&gt;439&lt;/span&gt;, respectively,
using a discount rate of &lt;span id="xdx_906_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_c20201231_zRSM1M3z1xP5" title="Operating lease discount rate"&gt;4.00&lt;/span&gt;%. Effective February 2023, the Company &lt;span id="xdx_90A_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20230201__20230228_ziF0LwZDLmil" title="Option to extend lease"&gt;extended the lease through December 2024, with no changes to any
of the other terms of the lease&lt;/span&gt;. The average monthly rent payment on the extended lease is approximately $&lt;span id="xdx_909_eus-gaap--PaymentsForRent_pn3n3_c20230201__20230228_zZnOl4UZClFg" title="Aggregate average monthly payments"&gt;30&lt;/span&gt; per month. Prior to the
extension, the remaining lease liability amounted to $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231_zJTLiu1ldgM8" title="Operating lease liability"&gt;12&lt;/span&gt;. On the date of the extension, the Company determined that the value of the
new right of use asset and lease liability was $&lt;span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20230228_zqoMNuLBwnk4" title="Operating lease right of use asset"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20230228_zKe8gOctH6Ig" title="Operating lease liability"&gt;649&lt;/span&gt;&lt;/span&gt;, respectively, using a discount rate of &lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_c20230228_zMM4INlLaIt" title="Operating lease discount rate"&gt;5.5&lt;/span&gt;%. As such, the Company recorded an increase
in lease liability of $&lt;span id="xdx_906_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_pn3n3_c20230201__20230228_zjQyGUXeIend" title="Increase in lease liability"&gt;637&lt;/span&gt; as a result of the lease extension.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
July 2021, the Company entered into a long-term non-cancellable lease agreement for its new corporate headquarters that requires aggregate
average monthly payments of $&lt;span id="xdx_909_eus-gaap--PaymentsForRent_pn3n3_c20210701__20210731_zjNSVuQMEBJj" title="Aggregate average monthly payments"&gt;10&lt;/span&gt; beginning August 2021. The lease terminates in July 2027. The Company classified the lease as an operating
lease and determined that the value of the right of use asset and lease liability at the adoption date was $&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20210731_zO8uxnhWFa36" title="Operating lease liability"&gt;656&lt;/span&gt;, respectively, using
a discount rate of &lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_c20210731_zuNmrg5W71zh" title="Operating lease discount rate"&gt;4.00&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the six months ended June 30, 2023 and 2022, the Company made combined aggregate payments of $&lt;span id="xdx_901_eus-gaap--OperatingLeasePayments_pn3n3_c20230101__20230630_zJUDgHBzATi5" title="Payment for operating lease"&gt;265&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--OperatingLeasePayments_pn3n3_c20220101__20220630_zd7nHlZrLIo1" title="Payment for operating lease"&gt;184&lt;/span&gt;, respectively, towards the
lease liabilities. As of June 30, 2023 and December 31, 2022, the combined lease liability amounted to $&lt;span id="xdx_90F_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20230630_zupCOdUQAPke" title="Operating lease liability"&gt;1,814&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20221231_z5U48e0O6YJl" title="Operating lease liability"&gt;1,430&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;ASC
842 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated
over the lease term, generally on a straight-line basis. During the six months ended June 30, 2023 and 2022, the Company reflected combined
amortization of the right of use assets of $&lt;span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_pn3n3_c20230101__20230630_zs8otfOnVKf7" title="Amortization of right of use assets"&gt;274&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_pn3n3_c20220101__20220630_zzYrcdfhxIbf" title="Amortization of right of use assets"&gt;205&lt;/span&gt;, respectively, related to the leases, resulting in a combined net asset balance
of $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20230630_z0eHgDo2SySk" title="Operating lease right of use asset"&gt;1,710&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20220630_zEHsUXoPVsLl" title="Operating lease right of use asset"&gt;1,335&lt;/span&gt; as of June 30, 2023 and December 31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;i&gt;Other
Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
November 2019, the Company entered into a short-term lease agreement for one of its office facilities, which was subsequently
extended until December 2022 and is currently on a month-to-month basis. Rent expense was $&lt;span id="xdx_901_eus-gaap--LeaseAndRentalExpense_pn3n3_c20230101__20230630_zxHYz9Okq4ff" title="Rent expense"&gt;&lt;span id="xdx_906_eus-gaap--LeaseAndRentalExpense_pn3n3_c20220101__20220630_zgH3YX108aQh" title="Rent expense"&gt;18&lt;/span&gt;&lt;/span&gt;
during the six months ended June 30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest id="f553" decimals="-3" contextRef="c147" unitRef="usd">3000.0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f554" decimals="INF" contextRef="c148" unitRef="usd1">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <genelux.com:FairValueOfRestrictedStockUnits id="f555" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:GeneralAndAdministrativeExpense id="f556" decimals="-3" contextRef="c19" unitRef="usd">2452000.0</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:InterestPaidNet id="f557" decimals="-3" contextRef="c21" unitRef="usd">185000.0</us-gaap:InterestPaidNet>
  <us-gaap:ConvertibleNotesPayable id="f558" decimals="-3" contextRef="c105" unitRef="usd">9065000.0</us-gaap:ConvertibleNotesPayable>
  <dei:EntityCurrentReportingStatus id="f559" contextRef="c">Yes</dei:EntityCurrentReportingStatus>
  <us-gaap:LiabilitiesCurrent id="f560" decimals="-3" contextRef="c3" unitRef="usd">31626000.0</us-gaap:LiabilitiesCurrent>
  <us-gaap:EarningsPerShareBasic id="f561" decimals="INF" contextRef="c25" unitRef="usd1">0.31</us-gaap:EarningsPerShareBasic>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="f562" decimals="INF" contextRef="c149" unitRef="shares">275000.0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f563" decimals="INF" contextRef="c150" unitRef="usd1">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:StockholdersEquity id="f564" decimals="-3" contextRef="c151" unitRef="usd">2000.0</us-gaap:StockholdersEquity>
  <us-gaap:EarningsPerShareDiluted id="f565" decimals="INF" contextRef="c25" unitRef="usd1">0.31</us-gaap:EarningsPerShareDiluted>
  <us-gaap:ConvertibleNotesPayable id="f566" decimals="-3" contextRef="c152" unitRef="usd">700000.0</us-gaap:ConvertibleNotesPayable>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f567" decimals="INF" contextRef="c58" unitRef="usd1">4500.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:StockholdersEquity id="f568" decimals="-3" contextRef="c13" unitRef="usd">22256000.0</us-gaap:StockholdersEquity>
  <us-gaap:ResearchAndDevelopmentExpense id="f569" decimals="-3" contextRef="c19" unitRef="usd">2943000.0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="f570" decimals="-3" contextRef="c105" unitRef="usd">1178000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="f571" decimals="0" contextRef="c149" unitRef="usd">5500.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber id="f572" decimals="INF" contextRef="c9" unitRef="shares">133333.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
  <dei:EntityCentralIndexKey id="f573" contextRef="c">0001231457</dei:EntityCentralIndexKey>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="f574" decimals="-3" contextRef="c3" unitRef="usd">1495000.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <dei:AmendmentFlag id="f575" contextRef="c">false</dei:AmendmentFlag>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="f576" decimals="-3" contextRef="c152" unitRef="usd">167000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:PreferredStockSharesIssued id="f577" decimals="INF" contextRef="c3" unitRef="shares">22094889.0</us-gaap:PreferredStockSharesIssued>
  <dei:CurrentFiscalYearEndDate id="f578" contextRef="c">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:PreferredStockSharesAuthorized id="f579" decimals="INF" contextRef="c148" unitRef="shares">10000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f580" decimals="INF" contextRef="c153" unitRef="shares">4201019.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest id="f581" decimals="-3" contextRef="c154" unitRef="usd">45000.0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <dei:DocumentFiscalPeriodFocus id="f582" contextRef="c">Q2</dei:DocumentFiscalPeriodFocus>
  <us-gaap:AdditionalPaidInCapital id="f583" decimals="-3" contextRef="c13" unitRef="usd">232073000.0</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="f584" decimals="-3" contextRef="c" unitRef="usd">3110000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:PreferredStockSharesOutstanding id="f585" decimals="INF" contextRef="c3" unitRef="shares">22094889.0</us-gaap:PreferredStockSharesOutstanding>
  <genelux.com:NetProceedsFromIssuanceOfCommonStock id="f586" decimals="0" contextRef="c149" unitRef="usd">5300.0</genelux.com:NetProceedsFromIssuanceOfCommonStock>
  <us-gaap:PreferredStockSharesAuthorized id="f587" decimals="INF" contextRef="c150" unitRef="shares">10000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="f588" decimals="INF" contextRef="c155" unitRef="shares">1591994.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="f589" decimals="INF" contextRef="c156" unitRef="shares">16666.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:DeferredCosts id="f590" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <us-gaap:SharesOutstanding id="f591" decimals="INF" contextRef="c157" unitRef="shares">-433333.0</us-gaap:SharesOutstanding>
  <us-gaap:ConvertibleDebtTableTextBlock id="f592" contextRef="c">&lt;p id="xdx_890_eus-gaap--ConvertibleDebtTableTextBlock_z6rKLQAgnzth" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
notes payable consisted of the following as of June 30, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zBMwWvyANH2c" style="display: none"&gt;SCHEDULE
OF CONVERTIBLE NOTES PAYABLE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230630_zHFc0hIiItMj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;June
    30,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_z4inYs74iYKd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
    31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ConvertibleDebtNoncurrent_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zA7KDR1ROMle" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    note payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;9,065&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iNI_pn3n3_di_zhIuBJgo18gg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Less:
    debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1189"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(541&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ConvertibleDebtNoncurrent_iI_pn3n3_zPLoEcvFJuZ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    notes payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1192"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;8,524&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:InterestPayableCurrent id="f593" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <us-gaap:PropertyPlantAndEquipmentNet id="f594" decimals="-3" contextRef="c13" unitRef="usd">878000.0</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="f595" contextRef="c">&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZIFZoBm4cc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_868_zJZJRVm30Wt7"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
June 2016, the FASB issued ASU No. 2016-13, Credit LossesMeasurement of Credit Losses on Financial Instruments (ASC 326).
The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables.
The standard will replace todays incurred loss approach with an expected loss model, under which companies
will recognize allowances based on expected rather than incurred losses. Entities will apply the standards provisions as a cumulative-effect
adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is
effective for the Company beginning January 1, 2023. The adoption of ASU 2016-13 did not have a material impact on the Companys
financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), DebtModifications and Extinguishments (Subtopic 470-50),
CompensationStock Compensation (Topic 718), and Derivatives and HedgingContracts in Entitys Own Equity (Subtopic
815-40): Issuers Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. ASU
2021-04 provides clarification and reduces diversity in an issuers accounting for modifications or exchanges of freestanding equity-classified
written call options (such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of
a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant
immediately before modification or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions
and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications
unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning
after December 15, 2021. The adoption of ASU 2021-04 did not have a material impact on the Companys financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Companys
present or future consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ConvertibleNotesPayable id="f596" decimals="-3" contextRef="c158" unitRef="usd">9065000.0</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="f597" decimals="INF" contextRef="c" unitRef="usd1">6.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f598" decimals="-3" contextRef="c" unitRef="usd">21642000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="f599" decimals="INF" contextRef="c132" unitRef="shares">111828.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:DeferredRevenueCurrent id="f600" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f601" decimals="-3" contextRef="c75" unitRef="usd">297000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f602" decimals="INF" contextRef="c159" unitRef="usd1">953.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f603" decimals="INF" contextRef="c156" unitRef="usd1">9.0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <genelux.com:WarrantLiabilitiesCurrent id="f604" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <us-gaap:SharesOutstanding id="f605" decimals="INF" contextRef="c160" unitRef="shares">-433333.0</us-gaap:SharesOutstanding>
  <dei:EntityInteractiveDataCurrent id="f606" contextRef="c">Yes</dei:EntityInteractiveDataCurrent>
  <us-gaap:OtherNotesPayableCurrent id="f607" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f608" decimals="-3" contextRef="c3" unitRef="usd">-35783000.0</us-gaap:StockholdersEquity>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="f609" decimals="-3" contextRef="c158" unitRef="usd">1223000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued id="f610" decimals="-3" contextRef="c22" unitRef="usd">169000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:ConvertibleDebtNoncurrent id="f611" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f612" decimals="INF" contextRef="c161" unitRef="shares">11666.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f613" decimals="-3" contextRef="c" unitRef="usd">-10008000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PreferredStockValue id="f614" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts id="f615" decimals="-3" contextRef="c22" unitRef="usd">12629000.0</genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="f616" xsi:nil="true" contextRef="c19" unitRef="usd"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f617" decimals="INF" contextRef="c162" unitRef="shares">3962719.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:StockholdersEquity id="f618" decimals="-3" contextRef="c146" unitRef="usd">9000.0</us-gaap:StockholdersEquity>
  <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense id="f619" decimals="-3" contextRef="c21" unitRef="usd">205000.0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="f620" xsi:nil="true" contextRef="c25" unitRef="usd"/>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="f621" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayableShares id="f622" decimals="INF" contextRef="c5" unitRef="shares">272101.0</genelux.com:IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayableShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f623" decimals="INF" contextRef="c80" unitRef="shares">161878.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:DeferredCosts id="f624" decimals="-3" contextRef="c3" unitRef="usd">1568000.0</us-gaap:DeferredCosts>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="f625" decimals="INF" contextRef="c5" unitRef="shares">8355610.0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:AmortizationOfDebtDiscountPremium id="f626" xsi:nil="true" contextRef="c19" unitRef="usd"/>
  <us-gaap:PreferredStockSharesIssued id="f627" decimals="INF" contextRef="c150" unitRef="shares">22094889.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:SharesOutstanding id="f628" decimals="INF" contextRef="c163" unitRef="shares">9110060.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f629" decimals="-3" contextRef="c164" unitRef="usd">-184577000.0</us-gaap:StockholdersEquity>
  <us-gaap:PreferredStockSharesOutstanding id="f630" decimals="INF" contextRef="c46" unitRef="shares">536000.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:OtherNonoperatingExpense id="f631" xsi:nil="true" contextRef="c19" unitRef="usd"/>
  <us-gaap:PreferredStockSharesOutstanding id="f632" decimals="INF" contextRef="c150" unitRef="shares">22094889.0</us-gaap:PreferredStockSharesOutstanding>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f633" decimals="-3" contextRef="c65" unitRef="usd">36000.0</genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing>
  <us-gaap:OtherNonoperatingExpense id="f634" xsi:nil="true" contextRef="c25" unitRef="usd"/>
  <us-gaap:ResearchAndDevelopmentExpense id="f635" decimals="-3" contextRef="c25" unitRef="usd">1827000.0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="f636" contextRef="c">&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDtejWi6b2sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zt9z8ZgRTLsa" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20230630_zOSuiXUw7RNi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;June 30,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220101__20220630_z07BwLv81g32" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zDhctm3YUTji" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; color: Black; text-align: left"&gt;Convertible notes payable&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 12%; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 12%; color: Black; text-align: right"&gt;3,339,752&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockEquivalentOfSeriesAThroughKConvertiblePreferredStockMember_zEypPXWUm2Zh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Common stock equivalent of Series A through K convertible preferred stock&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;7,567,630&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zkOfXSU2nce7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;4,201,019&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;3,962,719&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zC2bdHDOF5Gb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Stock warrants&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;932,854&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;751,745&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z9X5zOuBNSHl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;113,500&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsIssuableUponConversionOfNotesPayableMember_zhYNOraAWZUh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Stock warrants, issuable in connection with convertible notes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;105,943&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;183,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zpM5QF5IeFz" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;5,353,316&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;15,805,698&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:OtherNonoperatingExpense id="f637" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="f638" decimals="INF" contextRef="c165" unitRef="shares">303835.0</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <genelux.com:InitialPublicOfferingClosingPricePercentage id="f639" decimals="INF" contextRef="c15" unitRef="pure">0.9</genelux.com:InitialPublicOfferingClosingPricePercentage>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="f640" xsi:nil="true" contextRef="c25" unitRef="usd"/>
  <us-gaap:SharesIssued id="f641" decimals="INF" contextRef="c166" unitRef="shares">1117079.0</us-gaap:SharesIssued>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="f642" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:OperatingLeaseRightOfUseAsset id="f643" decimals="-3" contextRef="c13" unitRef="usd">1710000.0</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:DebtInstrumentUnamortizedDiscount id="f644" decimals="-3" contextRef="c105" unitRef="usd">541000.0</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f645" decimals="INF" contextRef="c3" unitRef="usd1">22095.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <genelux.com:GainOnForgivenessOfPppLoanPayable id="f646" xsi:nil="true" contextRef="c19" unitRef="usd"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f647" decimals="-3" contextRef="c" unitRef="usd">467000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="f648" decimals="INF" contextRef="c143" unitRef="usd1">6.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice id="f649" decimals="INF" contextRef="c9" unitRef="usd1">3.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue id="f650" decimals="-3" contextRef="c13" unitRef="usd">16917000.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
  <us-gaap:PreferredStockSharesIssued id="f651" decimals="INF" contextRef="c46" unitRef="shares">536000.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f652" decimals="INF" contextRef="c3" unitRef="usd1">6.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <genelux.com:GainOnForgivenessOfPppLoanPayable id="f653" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <us-gaap:TreasuryStockValue id="f654" decimals="-3" contextRef="c3" unitRef="usd">433000.0</us-gaap:TreasuryStockValue>
  <us-gaap:StockholdersEquity id="f655" decimals="-3" contextRef="c157" unitRef="usd">-433000.0</us-gaap:StockholdersEquity>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement id="f656" decimals="0" contextRef="c167" unitRef="usd">22342.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="f657" decimals="-3" contextRef="c22" unitRef="usd">14000.0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:PreferredStockSharesAuthorized id="f658" decimals="INF" contextRef="c168" unitRef="shares">608000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:StockholdersEquity id="f659" xsi:nil="true" contextRef="c169" unitRef="usd"/>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f660" decimals="-3" contextRef="c19" unitRef="usd">1865000.0</genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest>
  <us-gaap:AmortizationOfDebtDiscountPremium id="f661" decimals="-3" contextRef="c154" unitRef="usd">541000.0</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:SharesOutstanding id="f662" xsi:nil="true" contextRef="c169" unitRef="shares"/>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="f663" decimals="-3" contextRef="c" unitRef="usd">505000.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense id="f664" decimals="-3" contextRef="c" unitRef="usd">274000.0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="f665" decimals="INF" contextRef="c170" unitRef="shares">6166666.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f666" xsi:nil="true" contextRef="c171" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f667" decimals="-3" contextRef="c160" unitRef="usd">-433000.0</us-gaap:StockholdersEquity>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f668" decimals="INF" contextRef="c172" unitRef="shares">932854.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <genelux.com:NetProceedsFromIssuanceOfPrivatePlacement id="f669" decimals="0" contextRef="c167" unitRef="usd">21642.0</genelux.com:NetProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="f670" decimals="INF" contextRef="c173" unitRef="shares">160563.0</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:PreferredStockSharesIssued id="f671" decimals="INF" contextRef="c155" unitRef="shares">1591994.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f672" xsi:nil="true" contextRef="c91" unitRef="usd"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f673" xsi:nil="true" contextRef="c174" unitRef="usd"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f674" decimals="-3" contextRef="c65" unitRef="usd">21640000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesOther id="f675" decimals="INF" contextRef="c91" unitRef="shares">111828.0</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:PreferredStockSharesOutstanding id="f676" decimals="INF" contextRef="c155" unitRef="shares">1591994.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:OtherAssetsNoncurrent id="f677" decimals="-3" contextRef="c13" unitRef="usd">92000.0</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f678" decimals="-3" contextRef="c21" unitRef="usd">417000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f679" xsi:nil="true" contextRef="c175" unitRef="usd"/>
  <genelux.com:ConversionofNotesPayableShareholdersAndAccruedInterestShares id="f680" decimals="INF" contextRef="c5" unitRef="shares">73134.0</genelux.com:ConversionofNotesPayableShareholdersAndAccruedInterestShares>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="f681" decimals="INF" contextRef="c152" unitRef="usd1">5.4</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f682" xsi:nil="true" contextRef="c176" unitRef="usd"/>
  <us-gaap:SharesOutstanding id="f683" decimals="INF" contextRef="c177" unitRef="shares">-433333.0</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f684" xsi:nil="true" contextRef="c171" unitRef="usd"/>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="f685" decimals="-3" contextRef="c13" unitRef="usd">2000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f686" xsi:nil="true" contextRef="c174" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f687" decimals="-3" contextRef="c72" unitRef="usd">-2820000.0</us-gaap:NetIncomeLoss>
  <us-gaap:RepaymentsOfNotesPayable id="f688" decimals="-3" contextRef="c" unitRef="usd">660000.0</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:PaymentsForRent id="f689" decimals="-3" contextRef="c178" unitRef="usd">10000.0</us-gaap:PaymentsForRent>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f690" xsi:nil="true" contextRef="c175" unitRef="usd"/>
  <us-gaap:WarrantExercisePriceDecrease id="f691" decimals="INF" contextRef="c99" unitRef="usd1">3.01</us-gaap:WarrantExercisePriceDecrease>
  <us-gaap:StockholdersEquity id="f692" decimals="-3" contextRef="c163" unitRef="usd">9000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f693" decimals="-3" contextRef="c179" unitRef="usd">-33111000.0</us-gaap:StockholdersEquity>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="f694" decimals="INF" contextRef="c47" unitRef="usd1">10.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f695" xsi:nil="true" contextRef="c176" unitRef="usd"/>
  <us-gaap:PreferredStockValue id="f696" decimals="-3" contextRef="c3" unitRef="usd">22000.0</us-gaap:PreferredStockValue>
  <genelux.com:ConvertibleNotesPayablePastDueCurrent id="f697" decimals="-3" contextRef="c3" unitRef="usd">105000.0</genelux.com:ConvertibleNotesPayablePastDueCurrent>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f698" xsi:nil="true" contextRef="c171" unitRef="usd"/>
  <us-gaap:ResearchAndDevelopmentExpense id="f699" decimals="-3" contextRef="c" unitRef="usd">5788000.0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f700" decimals="INF" contextRef="c180" unitRef="shares">751745.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="f701" decimals="INF" contextRef="c15" unitRef="usd1">5.4</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="f702" decimals="INF" contextRef="c181" unitRef="shares">979619.0</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:LesseeOperatingLeaseOptionToExtend id="f703" contextRef="c178">option to extend for an additional five years</us-gaap:LesseeOperatingLeaseOptionToExtend>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f704" xsi:nil="true" contextRef="c91" unitRef="usd"/>
  <us-gaap:WarrantExercisePriceIncrease id="f705" decimals="INF" contextRef="c99" unitRef="usd1">10.49</us-gaap:WarrantExercisePriceIncrease>
  <us-gaap:PreferredStockSharesOutstanding id="f706" decimals="INF" contextRef="c182" unitRef="shares">22094889.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod id="f707" decimals="INF" contextRef="c183" unitRef="shares">2059073.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f708" xsi:nil="true" contextRef="c174" unitRef="usd"/>
  <us-gaap:OtherAssetsNoncurrent id="f709" decimals="-3" contextRef="c3" unitRef="usd">92000.0</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="f710" contextRef="c">&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zcPMDEwUzNW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_86D_zOlJVLY372uk"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company records revenue under the guidance of Accounting Standards Codification (ASC) 606, &lt;i&gt;Revenue from Contracts with
Customers (Topic 606)&lt;/i&gt; which requires a company to recognize revenue to depict the transfer of goods or services to a customer at
an amount that reflects the consideration it expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company determines revenue recognition through the following steps:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Identification
    of the contract, or contracts, with a customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Identification
    of the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Determination
    of the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Allocation
    of the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Recognition
    of revenue when, or as, we satisfy a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Under
certain of the Companys licensing, supply and collaboration agreements, it is entitled to receive payment upon the achievement
of contingent milestone events or the performance of obligations. The Company recognizes revenue based on guidance in ASC 606. In evaluating
revenue recognition under a license agreement, the Company uses a two-step process for determining whether a promised good or service
(including a license of intellectual property) is distinct and, therefore, is a performance obligation: (1) consideration of the individual
good or service (i.e., whether the good or service is capable of being distinct); and (2) consideration of whether the good or service
is separately identifiable from other promises in the contract (i.e., whether the promise to transfer the good or service is distinct
in the context of the contract). Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue
on the Companys balance sheet. Amounts expected to be recognized as revenue in the next 12 months following the balance sheet
date are classified as current liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2022, the Company, under its Newsoara agreement, invoiced and collected $170 relating to supplying product
for Newsoara to use in their clinical trials. As the product did not ship during the year ended December 31, 2022, the Company recorded
the cash received as deferred revenue until the product was shipped. During the six months ended June 30, 2023, the Company shipped the
product to Newsoara and thus recognized the revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f711" xsi:nil="true" contextRef="c175" unitRef="usd"/>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="f712" decimals="INF" contextRef="c158" unitRef="usd1">10.5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:AssetsCurrent id="f713" decimals="-3" contextRef="c3" unitRef="usd">1892000.0</us-gaap:AssetsCurrent>
  <us-gaap:OperatingLeaseRightOfUseAsset id="f714" decimals="-3" contextRef="c184" unitRef="usd">518000.0</us-gaap:OperatingLeaseRightOfUseAsset>
  <genelux.com:ConversionOfNotesPayableshareholdersAndAccruedInterest id="f715" xsi:nil="true" contextRef="c176" unitRef="usd"/>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f716" decimals="INF" contextRef="c46" unitRef="usd1">536.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="f717" decimals="INF" contextRef="c185" unitRef="shares">8355610.0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="f718" decimals="INF" contextRef="c186" unitRef="shares">3774260.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f719" xsi:nil="true" contextRef="c171" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f720" decimals="-3" contextRef="c187" unitRef="usd">152535000.0</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f721" xsi:nil="true" contextRef="c91" unitRef="usd"/>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f722" decimals="-3" contextRef="c22" unitRef="usd">1174000.0</us-gaap:StockIssuedDuringPeriodValueOther>
  <genelux.com:DeferredOfferingCostsPolicyTextBlock id="f723" contextRef="c">&lt;p id="xdx_84F_ecustom--DeferredOfferingCostsPolicyTextBlock_zz2OgEzxO30l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_866_zRPGzIQsfrs4"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity
issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs
are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned,
the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statement of Operations. As of December
31, 2022, the Company incurred $&lt;span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zevW9c76EsQc" title="Deferred offering costs"&gt;1,568&lt;/span&gt; of deferred offering costs related to the Companys IPO,
and during the six months ended June 30, 2023, the Company incurred an additional $&lt;span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20230630_z1BT5prYbSkg" title="Deferred offering costs"&gt;303&lt;/span&gt; of costs. During the six months ended June 30,
2023, a total of $&lt;span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAwt74bUw8y6" title="Deferred offering costs"&gt;1,871&lt;/span&gt; of deferred offering costs were recorded against the net proceeds received from the IPO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</genelux.com:DeferredOfferingCostsPolicyTextBlock>
  <us-gaap:OperatingLeaseLiability id="f724" decimals="-3" contextRef="c184" unitRef="usd">519000.0</us-gaap:OperatingLeaseLiability>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f725" xsi:nil="true" contextRef="c174" unitRef="usd"/>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="f726" decimals="-3" contextRef="c21" unitRef="usd">16000.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ConversionOfStockSharesConverted1 id="f727" decimals="INF" contextRef="c185" unitRef="shares">991172.0</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod id="f728" decimals="INF" contextRef="c188" unitRef="shares">5833333.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f729" xsi:nil="true" contextRef="c175" unitRef="usd"/>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f730" decimals="-3" contextRef="c13" unitRef="usd">31363000.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:StockholdersEquity id="f731" decimals="-3" contextRef="c189" unitRef="usd">206689000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="f732" contextRef="c">&lt;p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z9NPQjDmXmhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTE
9 - &lt;span id="xdx_828_zhzBjeu1Sau3"&gt;SHAREHOLDERS EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Preferred
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zUkW0fyE3d36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of December 31, 2022, authorized shares and shares issued and outstanding of the Companys preferred stock by series were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zFpt5plyTD0g" style="display: none"&gt;SCHEDULE
OF PREFERRED STOCK&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_zV7zVashGqyd" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Authorized&lt;br/&gt;
    Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Issued
    and&lt;br/&gt; Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_zCP6GKgOjLm4" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Par&lt;br/&gt;
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zi7dTZrzp1r6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;4,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;4,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;4,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z38guahuwWxi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;608,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_902_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;608,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;608&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zTi7LY6LBCHf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    C Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z9NrMmrADQi3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    D Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;3,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zzrQkVqFXMMe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    E Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1,591,994&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;1,591,994&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1,592&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zoGdwBZKt1e1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    F Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;953,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;953,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;953&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_ziGpmvSmErc5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    H Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;536,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;536&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_410_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_zsiWtUbst7yi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    I Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2,775,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_zlXraVuTkeM3" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_zX8XstcooqZj" title="Preferred stock, shares outstanding"&gt;2,757,442&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2,757&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zJLFpGCmCqnd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    J Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zezTQ4jvVEn" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zm55HhRKQjw8" title="Preferred stock, shares outstanding"&gt;1,281,600&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1,282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_415_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zb22jjhSjmE3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    K Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;4,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zz2GbydDgkU5" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zARWiGkqkYC7" title="Preferred stock, shares outstanding"&gt;1,866,853&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1,867&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20221231_z4UEeX7AVWWa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;29,927,994&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231_zcBV7QcrO6Dc" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231_z4A8aS6h9Ml9" title="Preferred stock, shares outstanding"&gt;22,094,889&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;22,095&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zTlkEp3uFdO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the closing of the Companys IPO on January 30, 2023, all of the Companys &lt;span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20230130__us-gaap--StatementClassOfStockAxis__custom--SeriesAThroughKPreferredStockMember_zF7dKXUSzXJ4" title="Preferred stock, shares outstanding"&gt;22,094,889&lt;/span&gt; outstanding shares of Series A through
Series K preferred stock automatically converted into &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230130__20230130_zXUAJbx3F0El" title="Conversion of common stock"&gt;8,355,610&lt;/span&gt; shares of common stock, of which &lt;span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230130__20230130_zb3zZrt9Uas2" title="Conversion price adjustment"&gt;991,172&lt;/span&gt; shares were attributable to
conversion price adjustments based on a weighted-average anti-dilution formula.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of January 30, 2023, earned but undeclared and unpaid Series H dividends were $&lt;span id="xdx_900_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_pn3n3_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zSoz8aJdH4X2" title="Undeclared and unpaid shares earned"&gt;3,443&lt;/span&gt;. Upon the closing of the IPO, the unpaid dividends
were automatically converted into &lt;span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zJgYq1IJbfJf" title="Conversion price adjustment"&gt;272,101&lt;/span&gt; shares of the Companys common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2023, the Companys Certificate of
Incorporation with the state of Delaware was amended to change the number of authorized preferred shares from &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20230131__srt--RangeAxis__srt--MinimumMember_znEHwPMPQs4a" title="Preferred stock, shares authorized"&gt;29,927,994&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20230131__srt--RangeAxis__srt--MaximumMember_za2br7SqWZgc" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt;.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Authorized
Shares&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Companys Certificate of Incorporation authorizes the Company to issue up to &lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230331_zPOawDgcMOT8" title="Common stock, shares authorized"&gt;200,000,000&lt;/span&gt; of its common shares. Holders of shares
of common stock have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends as may
be declared by the Board out of funds legally available therefore and share pro rata in any distributions to shareholders upon liquidation.
Shareholders have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully paid and non-assessable.
As of June 30, 2023 and December 31, 2022, there were &lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230630_zWiebkSUSrLe" title="Common stock, shares outstanding"&gt;25,855,511&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zQTvnNWJotBl" title="Common stock, shares outstanding"&gt;9,126,726&lt;/span&gt; shares of common stock issued and outstanding, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2023, the Companys Certificate
of Incorporation with the state of Delaware was amended to change the number of authorized common shares from &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20230131__srt--RangeAxis__srt--MinimumMember_zNha0tBm4a6" title="Common stock, shares authorized"&gt;75,000,000&lt;/span&gt; to &lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20230131__srt--RangeAxis__srt--MaximumMember_zfOR4oByWTk2" title="Common stock, shares authorized"&gt;200,000,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock Issued for Cash Upon Closing of the Companys IPO&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 30, 2023, the Company completed its underwritten IPO of its common stock, in which the
Company issued and sold &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230130__20230130__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z4vbR5l55CTa" title="Common stock issued and sold"&gt;2,500,000&lt;/span&gt; shares of its common stock at a public offering price of $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230130__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpGoK5aFnzz8" title="Sale of stock per share"&gt;6.00&lt;/span&gt; per share. In February 2023, the Company
sold an additional &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230201__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zOLLCklDi4sj" title="Common stock issued and sold"&gt;153,000&lt;/span&gt; shares of common stock at $&lt;span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z1C8qIDklvEb" title="Sale of stock per share"&gt;6.00&lt;/span&gt; per share pursuant to the underwriters partial exercise of their option
to purchase additional shares of common stock. The total gross proceeds of the IPO were $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20230201__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zq180dMrSv5k" title="Gross proceeds of the IPO"&gt;15,918&lt;/span&gt; and the Company raised $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20230201__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z67POy0IN5Ce" title="Proceeds after deducting underwriting discounts and commissions and offering expenses payable"&gt;12,632&lt;/span&gt; in net
proceeds after deducting underwriting discounts and commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock Issued for Cash Upon Closing of the Companys Private Placements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 12, 2023, the Company entered into a securities purchase agreement (the PIPE 1 SPA) with certain investors (the
PIPE 1 Purchasers), pursuant to which the Company agreed to sell and issue &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230512__20230512__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zG5VsHuvPckh" title="Sale of stock, shares"&gt;1,665,213&lt;/span&gt;
shares of its common stock in a private placement transaction (the First Private Placement). The purchase price per
share of common stock was $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20230512__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--MayTwelveTwoThousandTwentyThreeMember_zNtoOJUjc6Oi" title="Sale of share price"&gt;20.00&lt;/span&gt;
per share. The initial closing of the First Private Placement occurred in May 2023 (the PIPE 1 Initial Closing)
subject to customary closing conditions. The total gross proceeds to the Company at the PIPE 1 Initial Closing from the First
Private Placement are expected to be approximately $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230511__20230512__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--MayTwelveTwoThousandTwentyThreeMember_zfIxHnyYznW2" title="Proceeds from issuance of private placement"&gt;33,300&lt;/span&gt;,
including $&lt;span id="xdx_903_ecustom--CancellationOfBridgeLoanAndAccruedInterest_iI_pn3n3_c20230512__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--MayTwelveTwoThousandTwentyThreeMember_z6m6nqZclYHi" title="Cancellation of bridge loan and accrued interest"&gt;1,463&lt;/span&gt;
from the cancellation of certain of the Companys bridge loans and accrued interest (see Note 6). Two of the PIPE 1 Purchasers
will, and are contractually obligated to, fund up to $&lt;span id="xdx_90F_eus-gaap--InvestmentOwnedAtCost_iI_c20230512__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--MayTwelveTwoThousandTwentyThreeMember_zWIaNivTTQ67" title="Contractual obligation"&gt;17,500&lt;/span&gt;
of such PIPE 1 Purchasers investment amounts following the PIPE 1 Initial Closing but no later than November 15, 2023. During
the six months ended June 30, 2023, the Company received $&lt;span id="xdx_901_eus-gaap--PaymentsForProceedsFromInvestments_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--MayTwelveTwoThousandTwentyThreeMember_zbJ2kaYXh1a5" title="Received amount on investment"&gt;2,500&lt;/span&gt;
of the committed amount of $&lt;span id="xdx_90C_eus-gaap--OtherInvestments_iI_c20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--MayTwelveTwoThousandTwentyThreeMember_ztwk5IYPq5Hl" title="Committed amount"&gt;17,500&lt;/span&gt;,
and subsequent to June 30, 2023, the Company received another $&lt;span id="xdx_903_eus-gaap--PaymentsForProceedsFromInvestments_c20230701__20230811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--MayTwelveTwoThousandTwentyThreeMember_zMA9uISkLsn6" title="Received amount on investment"&gt;2,500&lt;/span&gt;
of the committed $&lt;span id="xdx_903_eus-gaap--OtherInvestments_iI_c20230811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--MayTwelveTwoThousandTwentyThreeMember_z10bFIjCb1O8" title="Committed amount"&gt;17,500&lt;/span&gt;
(see Note 11). As of June 30, 2023, the Company sold &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--MayTwelveTwoThousandTwentyThreeMember_zqSOSIVG1q34" title="Sale of stock, shares"&gt;842,079&lt;/span&gt;
shares of its common stock under the PIPE 1 SPA resulting in gross and net proceeds to the Company of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230511__20230512__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--MayTwelveTwoThousandTwentyThreeMember_zC8d2BgG1mQ9" title="Gross proceeds from common stock"&gt;16,842&lt;/span&gt;
and $&lt;span id="xdx_90E_ecustom--NetProceedsFromIssuanceOfCommonStock_c20230511__20230512__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--MayTwelveTwoThousandTwentyThreeMember_zvEkv08Mmyr4" title="Net proceeds from common stock"&gt;16,342&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 9, 2023, the Company entered into another securities purchase agreement (the PIPE 2 SPA, and, together with the
PIPE 1 SPA, the Purchase Agreements) with certain investors (the PIPE 2 Purchasers), pursuant to which
the Company agreed to sell and issue &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230609__20230609__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--JuneNineTwoThousandTwentyThreeMember_z9AVgiLefbn7" title="Sale of stock, shares"&gt;900,000&lt;/span&gt;
shares of the Companys common stock in a private placement transaction (the Second Private Placement, and,
together with the First Private Placement, the Private Placements). The purchase price per share of Common Stock was
$&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20230609__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--JuneNineTwoThousandTwentyThreeMember_zGB7fyOdcMc5" title="Sale of share price"&gt;20.00&lt;/span&gt;
per share. The initial closing of this Second Private Placement occurred in June 2023 (the PIPE 2 Initial Closing),
subject to customary closing conditions. The total gross proceeds to the Company from the Second Private Placement are expected to
be approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230608__20230609__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--JuneNineTwoThousandTwentyThreeMember_zTBBuussDPdg" title="Proceeds from issuance of private placement"&gt;18,000&lt;/span&gt;.
One of the PIPE 2 Purchasers will, and is contractually obligated to, fund up to $&lt;span id="xdx_903_eus-gaap--InvestmentOwnedAtCost_iI_c20230609__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--JuneNineTwoThousandTwentyThreeMember_zxmbfa3MAkc2" title="Contractual obligation"&gt;12,500&lt;/span&gt;
of such PIPE 2 Purchasers investment amounts following the PIPE 2 Initial Closing, but no later than November 15, 2023. As of
June 30, 2023, the Company sold &lt;span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--JuneNineTwoThousandTwentyThreeMember_zEJYyHyhGQd5" title="Sale of stock, shares"&gt;275,000&lt;/span&gt;
shares of its common stock under the PIPE 2 SPA resulting in gross and net proceeds to the Company of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--JuneNineTwoThousandTwentyThreeMember_zTaYhbgRgBB1" title="Gross proceeds from common stock"&gt;5,500&lt;/span&gt;
and $&lt;span id="xdx_906_ecustom--NetProceedsFromIssuanceOfCommonStock_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__custom--JuneNineTwoThousandTwentyThreeMember_zbr5yaKHVike" title="Net proceeds from common stock"&gt;5,300&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, the Company sold &lt;span id="xdx_90E_eus-gaap--SharesIssued_iI_c20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zk8YNoz4l7Xh"&gt;1,117,079&lt;/span&gt;
shares of its common stock under the Purchase Agreements resulting in the total gross and net proceeds to the Company from the First Private Placement and the Second Private Placement of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z3KvNMH8icEc" title="Gross proceeds from common stock"&gt;22,342&lt;/span&gt;
and $&lt;span id="xdx_905_ecustom--NetProceedsFromIssuanceOfPrivatePlacement_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNDspo657Nng" title="Net proceeds from common stock"&gt;21,642&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Grant
of Restricted Stock Units&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zznEwT3Ptap3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes restricted common stock activity during the six months ended June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zfvfp0C2jdY8" style="display: none"&gt;SCHEDULE
OF RESTRICTED COMMON STOCK ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average Grant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Restricted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Date Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-vested, December 31, 2022&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20230630_zVkf9ShzNSOj" style="text-align: right" title="Number of restricted shares, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1372"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedInPeriodTotalFairValueBeginning_c20230101__20230630_zbUd2vxVZTe5" style="text-align: right" title="Fair value, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1374"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230630_zL8EHy78SVUf" style="text-align: right" title="Weighted average grant date fair value, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1376"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20230630_z8GVoYfilPKl" style="width: 12%; text-align: right" title="Number of restricted shares, granted"&gt;113,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_pn3n3_c20230101__20230630_zXSgUHalW7mb" style="width: 12%; text-align: right" title="Fair value, granted"&gt;746&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230630_z81yBBgm0Iv6" style="width: 12%; text-align: right" title="Weighted average grant date fair value, granted"&gt;6.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vested&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20230101__20230630_znMZZwWAhfOl" style="text-align: right" title="Number of restricted shares, vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1384"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_iN_pn3n3_di_c20230101__20230630_zATDjgzosQk5" style="text-align: right" title="Fair value, vested"&gt;(627&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230630_z18z4Ajhmh04" style="text-align: right" title="Weighted average grant date fair value, vested"&gt;6.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20230101__20230630_zVeeYKOc7oRf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of restricted shares, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1390"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodTotalFairValue_c20230101__20230630_zZKxotFe3p1a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1392"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20230630_zfsHBbVIYd14" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1394"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Non-vested, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20230630_zfW0Ex57WAQh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of restricted shares, ending"&gt;113,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsVestedInPeriodTotalFairValueEnding_pn3n3_c20230101__20230630_zpHmllLbG52c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value, ending"&gt;119&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230630_zcr4lMNCRFwe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, ending"&gt;6.57&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A7_zNI7440pzNe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 17, 2023, the Companys Board of Directors approved the issuance of a combined total of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230216__20230217__srt--TitleOfIndividualAxis__srt--DirectorMember_zQAuEreMrP24" title="Issuance of restricted shares"&gt;113,500&lt;/span&gt; restricted shares of the
Companys common stock to certain of its officers, directors and consultants. The fair value of the shares on the date of grant
was $&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_pn3n3_c20230216__20230217__srt--TitleOfIndividualAxis__srt--DirectorMember_zVW6SwIsINO5" title="Fair value granted"&gt;746&lt;/span&gt;. All of the shares vested on July 25, 2023, but the shares will be issued to the RSU holders in August 2023. As such, no common
shares were issued during the six months ended June 30, 2023. The RSU shares were granted under the Companys 2022 Equity Incentive
Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023, the Company recorded $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn3n3_c20230101__20230630_zcqJ8sG72WQ6" title="Stock compensation"&gt;627&lt;/span&gt; of stock compensation for the fair value vesting of restricted common stock
and as of June 30, 2023, unamortized compensation of $&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedInPeriodTotalFairValueEnding_pn3n3_c20230101__20230630_zrg9cCRx0JO3" title="Unamortized compensation"&gt;119&lt;/span&gt; remained that will be amortized over the remaining vesting period, through
July 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Options&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2009, the Companys Board of Directors approved the adoption of the 2009 Equity Incentive Plan (the 2009 Plan).
The 2009 Plan was initiated to encourage and enable employees, directors and consultants of the Company to acquire and retain a proprietary
interest in the Company by ownership of its common stock. A total of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20090831__us-gaap--PlanNameAxis__custom--TwoThousandNineEquityIncentivePlanMember_z9gIOWUCOO2j" title="Common stock shares authorized"&gt;6,166,666&lt;/span&gt; of the authorized shares of the Companys common
stock may be subject to, or issued pursuant to, the terms of the plan. As of June 30, 2023 and December 31, 2022, no shares were available
for grant under the 2009 plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2018, the Companys Board of Directors approved the adoption of the 2019 Equity Incentive Plan (the 2019 Plan).
The 2019 Plan was initiated to encourage and enable employees, directors and consultants of the Company to acquire and retain a proprietary
interest in the Company by ownership of its common stock. The 2019 Plan allows for the following types of awards: (i) Incentive Stock
Options; (ii) Nonstatutory Stock Options; (iii) Stock Appreciation Rights; (iv) Restricted Stock Awards; (v) Restricted Stock Unit Awards;
(vi) Other Stock Awards. The maximum number of shares of our common stock that may be issued under our 2019 Plan is &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20180901__20180930__us-gaap--PlanNameAxis__custom--TwoThousandNineteenEquityIncentivePlanMember_zM3IErE28UT8" title="Common stock shares issued"&gt;2,059,073&lt;/span&gt; shares.
Outstanding stock awards granted under the 2009 Plan that (i) expire or terminate for any reason prior to exercise or settlement; (ii)
are forfeited because of failure to meet a contingency or condition required to vest such shares or otherwise return to us; or (iii)
are required or withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase
price or exercise price of a stock award can be added to the authorized shares as Returning Shares, not to exceed &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20180930__20180930__us-gaap--PlanNameAxis__custom--TwoThousandNineEquityIncentivePlanMember_z72zXw3p4Fri" title="Additional shares authorized"&gt;3,774,260&lt;/span&gt; shares. The
maximum number of shares of our common stock under our 2019 Plan that may be issued is &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20180901__20180930__us-gaap--PlanNameAxis__custom--TwoThousandNineteenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_znphjjtGn0Bc" title="Shares of common stock issued"&gt;5,833,333&lt;/span&gt; shares. As of June 30, 2023, a total
of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20230630__us-gaap--PlanNameAxis__custom--TwoThousandNineteenEquityIncentivePlanMember_z1ynG8SnwRn9" title="Shares available for grant"&gt;1,632,314&lt;/span&gt; shares were available for grant under the 2019 plan, and a total of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20230630__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoPlanMember_zaDQJl6ABapg" title="Shares available for grant"&gt;2,686,500&lt;/span&gt; were available for grant under the 2022 plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Option
exercise prices are set forth in the Grant Notice, without commission or other charge, provided however, that the price per share of
the shares subject to the option shall not be less than the greater of &lt;span id="xdx_902_ecustom--FairMarketValueOfSharesPercentageDescription_dp_c20230101__20230630_zJmQ7NF7IQod" title="Fair market value of shares percentage, description"&gt;(i) 100% of the fair market value of a share of stock on the grant
date, or (ii) 110% of the fair market value of a share of stock on the grant date in the case of a Participant then owning more than
10% of the total combined voting power of all classes of stock of the Company or any subsidiary corporation of the Company
or any parent corporation of the Company.&lt;/span&gt; Options to employees, directors and consultants generally vest and become exercisable
over a period not exceeding four years. Options typically expire ten years after date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Companys policy is to recognize compensation cost for awards with only service conditions on a straight- line basis over the requisite
service period for the entire award. Additionally, the Companys policy is to issue new shares of common stock to satisfy stock
option exercises. The Company applied fair value accounting for all share-based payments awards. The fair value of each option granted
is estimated on the date of grant using the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zmDHTFicztLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the Companys stock option activities for the six months ended June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zVBDe7tdKSf8" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Price Range&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Option Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230630_zg2Ua5WQw9j2" style="width: 14%; text-align: right" title="Number of options shares, beginning"&gt;4,201,019&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zYca9pBnZvO3" title="Exercise price range, beginning"&gt;6.00&lt;/span&gt; - &lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zva9OGosWjnc" title="Exercise price range, beginning"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630_zNwQgxzZuBqi" style="width: 14%; text-align: right" title="Weighted average exercise price, beginning"&gt;6.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230630_zYE3KPBrXrf3" style="text-align: right" title="Number of options shares, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1434"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630_zNZMnwpEFAI3" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1436"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20230630_zLv8P26xhkC2" style="text-align: right" title="Number of options shares, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1438"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630_zIIyjFGbKeQe" style="text-align: right" title="Weighted average exercise price, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1440"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20230630_zTmqbAcC6gXd" style="text-align: right" title="Number of options shares, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1442"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630_zg24uYCREUfi" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1444"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20230630_z2SwmxfCqWz2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options shares, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1446"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630_zQWvtwgzbjPe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1448"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230630_zbfdZy9lEF6b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options shares, ending"&gt;4,201,019&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zcugCTJ4SaJ7" title="Exercise price range, ending"&gt;6.00&lt;/span&gt;
- &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zJzxGdzneUm1" title="Exercise price range, ending"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630_zF7aXBIW24qc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending"&gt;6.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Vested and exercisable, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20230101__20230630_zElnzo4WerXg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options shares, vested and exercisable"&gt;4,005,267&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zlEferJh6Kh2" title="Exercise price range, vested and exercisable ending"&gt;6.00&lt;/span&gt;
- &lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zXIPZtBlHkpi" title="Exercise price range, vested and exercisable ending"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20230630_z1Xe3OSxleE8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and exercisable ending"&gt;6.10&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Unvested, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20230630_zthLQzwHX9ng" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options shares, unvested, ending"&gt;195,752&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNonvestedOptionsWeightedAverageExercisePrice_iE_pid_c20230101__20230630_zWjDOy9IR7ch" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise price range, unvested ending"&gt;6.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230630_zFAdYoRk17Pb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, unvested ending"&gt;6.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zZbNhrCqCdE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zXBRAG9Ys41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information concerning outstanding and exercisable options as of June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z5QSuUSQlKoe" style="display: none"&gt;SCHEDULE
OF OUTSTANDING AND EXERCISABLE OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Options Exercisable&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&lt;b&gt;Range of Exercise&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: left; font-weight: bold"&gt; Prices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zHRVZEWROPgd" title="Range of exercise prices, upper limit"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zn8s2CyH3O44" style="width: 10%; text-align: right" title="Options outstanding number of outstanding"&gt;4,092,887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zjbp16j5Laz6" title="Options outstanding average remaining contractual life"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zpzu9BPvAUx6" style="width: 10%; text-align: right" title="Options outstaning weighted average exercise price"&gt;6.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zKVEesO2p0B9" style="width: 10%; text-align: right" title="Options exercisable number of outstanding"&gt;3,897,135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zj3GXeNWYs0c" title="Options exercisable average remaining contractual life"&gt;4.81&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zPNBTy8lIjDl" style="width: 10%; text-align: right" title="Options exercisable weighted average exercise price"&gt;6.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zagom9u9FME8" title="Range of exercise prices, lower limit"&gt;9.00&lt;/span&gt; - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z1urwc3puxWh" title="Range of exercise prices, upper limit"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z3I6Eg1Z2PXd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options outstanding number of outstanding"&gt;108,132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z26xMMs4Vt28" title="Options outstanding average remaining contractual life"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zzwLkhHKiWy" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options outstaning weighted average exercise price"&gt;9.67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zK6wN7LeDsvl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options exercisable number of outstanding"&gt;108,132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z1vTcR8eWk0l" title="Options exercisable average remaining contractual life"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z3JyKn3ZqEtc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options exercisable weighted average exercise price"&gt;9.67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zeBZ4asJIyGj" title="Range of exercise prices, lower limit"&gt;6.00&lt;/span&gt;
- &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zm54RlQnrgrf" title="Range of exercise prices, upper limit"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zSmywBKw1Z92" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding number of outstanding"&gt;4,201,019&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zMVXldGWX131" title="Options outstanding average remaining contractual life"&gt;4.91&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z4O9qYO8iRui" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstaning weighted average exercise price"&gt;6.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zhQNu1sDxQo5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable number of outstanding"&gt;4,005,267&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_znmNvKFYwKhf" title="Options exercisable average remaining contractual life"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z5Ws6oDxMrRb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable weighted average exercise price"&gt;6.10&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zMPwPnmtHDe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2022, the Companys board of directors approved a stock option repricing whereby the exercise prices of previously granted
and unexercised options held by certain employees, directors and key advisers with exercise prices between $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zrOfyExtlrmk" title="Range of exercise prices, lower limit"&gt;9.00&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zCvXB6D6OWG3" title="Range of exercise prices, upper limit"&gt;10.50&lt;/span&gt; per share,
would be adjusted (the Stock Option Repricing) to equal the initial offering price, contingent and effective upon the completion
of the Companys IPO. In connection with the closing of the IPO, the Stock Option Repricing was completed and the options to purchase
&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zHsUpa7PKcY5" title="Options outstanding number of outstanding"&gt;4,092,887&lt;/span&gt; shares of the Companys common stock, with exercise prices previously between $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z9DVosrZtQi6" title="Range of exercise prices, lower limit"&gt;9.00&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zf5H8rnnFYhc" title="Range of exercise prices, upper limit"&gt;10.50&lt;/span&gt;, were repriced to the
initial offering price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zvdCenW0aMMb" title="Range of exercise prices, upper limit"&gt;6.00&lt;/span&gt; per share, of which a total of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndDirectorsMember_zz8Ce786s4k5" title="Options outstanding number of outstanding"&gt;2,796,400&lt;/span&gt; shares of Common Stock are held by executive officers and directors.
The total cost of the repricing was $&lt;span id="xdx_90D_ecustom--RepricingCosts_pn3n3_c20220901__20220930_zyVoHLaI5mpg" title="Repricing costs"&gt;2,733&lt;/span&gt;, of which $&lt;span id="xdx_906_ecustom--RepricingCosts_pn3n3_c20230101__20230630_zuMn5jtk1D36" title="Repricing costs"&gt;2,642&lt;/span&gt; was recorded during the six months ended June 30, 2023, with the remainder
of the cost being recorded over the future vesting periods of the options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023, the Company recorded $&lt;span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20230630_z7SOYdjI46k3" title="Share compensation"&gt;467&lt;/span&gt; of stock compensation for the value of all options vesting during the period.
As of June 30, 2023, unvested compensation of $&lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20230630_zuE0yy1DSiOj" title="Unvested compensation"&gt;1,511&lt;/span&gt; remained that will be amortized over the remaining vesting period, through September
2025. The aggregate intrinsic value for option shares outstanding at June 30, 2023 was $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20230630_zWgr5f3APk67" title="Aggregate intrinsic value outstanding"&gt;111,765&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the time of the issuances of stock options, the Company believed the Companys estimates of the fair value for financial reporting
purposes of the Companys common stock were reasonable and consistent with the Companys understanding of how similarly situated
companies in the industry were valued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zPytCGMLiLAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the Companys warrants activities for the six months ended June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zbONsK35yyej" style="display: none"&gt;SCHEDULE
OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Price Range&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrant Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230630_zjGDIUlEHMxd" style="width: 14%; text-align: right" title="Number of warrant shares, beginning"&gt;725,174&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange_iS_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zm3amvkQTmvi" title="Exercise price range range per share, beginning"&gt;3.00&lt;/span&gt;
- &lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange_iS_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zGyQr17D1iC4" title="Exercise price range range per share, beginning"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630_zdLfrDgxu4m2" style="width: 14%; text-align: right" title="Weighted average exercise price, beginning"&gt;8.24&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230630_zCgZhlWhm1lc" style="text-align: right" title="Number of warrant shares, granted"&gt;340,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisePriceRange_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zY8qZn09C4J" title="Exercise price range range per share, granted"&gt;5.40&lt;/span&gt; - &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisePriceRange_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zwe4JC6Z3zub" title="Exercise price range range per share, granted"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_pid_c20230101__20230630_zz3aXMgehR97" style="text-align: right" title="Weighted average exercise price, granted"&gt;7.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20230101__20230630_zYrd8Eeb8tzh" style="text-align: right" title="Number of warrant shares, cancelled"&gt;(36&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedExercisePriceRange_pid_c20230101__20230630_zdW8RgPK6ZP" title="Exercise price range range per share, cancelled"&gt;9.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice_pid_c20230101__20230630_zzFzMbSZqek4" style="text-align: right" title="Weighted average exercise price, cancelled"&gt;9.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20230630_zSidSuTdSLg4" style="text-align: right" title="Number of warrant shares, exercised"&gt;(128,494&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedExercisePriceRange_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zmZoAjyWU0N6" title="Exercise price range range per share, exercised"&gt;9.00&lt;/span&gt;  &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedExercisePriceRange_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zqQhT7xxQXze" title="Exercise price range range per share, exercised"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_pid_c20230101__20230630_zAf2cpDMnjc3" style="text-align: right" title="Weighted average exercise price, exercised"&gt;10.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20230630_zKVATZOoYsUb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrant shares, expired"&gt;(4,762&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredExercisePriceRange_pid_c20230101__20230630_zrbfnzm763h2" title="Exercise price range range per share, expired"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice_pid_c20230101__20230630_zGRjqmeMnCK7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;10.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230630_zqxR8PP6pPSf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrant shares, ending"&gt;932,854&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zWqFfB0Tg5Sc" title="Exercise price range range per share, ending"&gt;3.00&lt;/span&gt; - &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisePriceRange_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zNc1heACnARf" title="Exercise price range range per share, ending"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630_zVnYYK4cqjVb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, ending"&gt;7.64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested and exercisable, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20230101__20230630_zEXsfSrK7ik6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrant shares, exercisable"&gt;932,854&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExercisePriceRange_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zMpG9Gisejdd" title="Exercise price range range per share, exercisable"&gt;3.00&lt;/span&gt; - &lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExercisePriceRange_iE_pid_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zsxj90JfAx4a" title="Exercise price range range per share, exercisable"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20230630_ztTj4ud69AAl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercisable"&gt;7.64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zqbc9ZraIUC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfOutstandingAndExercisableWarrantsTableTextBlock_zdns4zXq6EUf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information concerning outstanding and exercisable warrants as of June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_z3qy5DTLmuUl" style="display: none"&gt;SCHEDULE
OF OUTSTANDING AND EXERCISABLE WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Range of Exercise&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Number&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Prices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zqBtFU3J5xnk" title="Range of exercise prices, upper limit"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zeJZKCRVaxQ5" style="width: 11%; text-align: right" title="Warrants Outstanding number of outstanding"&gt;133,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z1aFkVofJfS6" title="Warrants outstanding average remaining contractual life"&gt;3.67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zNzKr1qFiVTd" style="width: 11%; text-align: right" title="Warrants outstaning weighted average exercise price"&gt;3.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zOuiBZgwvTpl" style="width: 10%; text-align: right" title="Warrants exercisable number of outstanding"&gt;133,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_z09mguBmFl85" title="Warrants exercisable average remaining contractual life"&gt;3.67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zsOwXCXGCxS1" style="width: 10%; text-align: right" title="Warrants exercisable weighted average exercise price"&gt;3.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantExercisePriceDecrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z21glvwUc5E" title="Range of exercise prices, lower limit"&gt;3.01&lt;/span&gt;  &lt;span id="xdx_903_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zeZgEUUs6aN1" title="Range of exercise prices, upper limit"&gt;10.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zIOCxGFqfEG3" style="text-align: right" title="Warrants Outstanding number of outstanding"&gt;637,643&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zqti9RRpek4c" title="Warrants outstanding average remaining contractual life"&gt;3.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zykpvV8YtPmk" style="text-align: right" title="Warrants outstaning weighted average exercise price"&gt;7.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zT99KXhP5SYh" style="text-align: right" title="Warrants exercisable number of outstanding"&gt;637,643&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zyXphZtvhFNc" title="Warrants exercisable average remaining contractual life"&gt;3.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zdR9yI7FUzgh" style="text-align: right" title="Warrants exercisable weighted average exercise price"&gt;7.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z1i1RuejUnVg" title="Range of exercise prices, upper limit"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z3Jw8G9EQnTh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding number of outstanding"&gt;161,878&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z3mXsCTU9lS9" title="Warrants outstanding average remaining contractual life"&gt;2.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zjS8MtwMoAPj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstaning weighted average exercise price"&gt;10.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zXXYsesWFQCl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercisable number of outstanding"&gt;161,878&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zJ2Gq99MahLd" title="Warrants exercisable average remaining contractual life"&gt;2.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zszizi9qg0I8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercisable weighted average exercise price"&gt;10.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantExercisePriceDecrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zXcF95QUdQr7" title="Range of exercise prices, lower limit"&gt;3.00&lt;/span&gt;  &lt;span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zJtQT93zBSq8" title="Range of exercise prices, upper limit"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zjyc9KpeZMac" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding number of outstanding"&gt;932,854&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zG8SZmcJcTja" title="Warrants outstanding average remaining contractual life"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zQ0Pq9lHttqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstaning weighted average exercise price"&gt;7.64&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zoLNzshKm4Tl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable number of outstanding"&gt;932,854&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zZeVpzgjgsVf" title="Warrants exercisable average remaining contractual life"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zqX4FWyugasf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable weighted average exercise price"&gt;7.64&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AA_zA4ti7bex6Kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the closing of the IPO and the overallotment exercises, the Company agreed to issue to the underwriters, warrants entitling them to purchase
up to &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zxMxYTSq23l3" title="Warrants to purchase shares"&gt;184,703&lt;/span&gt; shares of the Companys common stock. The warrants have an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zEVEp1sykJTd" title="Exercise price"&gt;6.00&lt;/span&gt; per share and expire on the fifth
anniversary of the closing date of the IPO, or January 2028.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023, the Company granted warrants to certain of its lenders to purchase up to &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--LenderMember_zFSlwUblP34f" title="Warrants to purchase shares"&gt;44,441&lt;/span&gt; shares of the Companys
common stock (see Note 6). The warrants have an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--LenderMember_zLluYZkiZnp5" title="Exercise price"&gt;5.40&lt;/span&gt; per share and expire three years from the date of the grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023, the Company granted warrants to certain of its lenders to purchase up to &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630__srt--TitleOfIndividualAxis__custom--LenderMember_zwkt6Lg8GPs8" title="Warrants to purchase shares"&gt;111,828&lt;/span&gt; shares of the Companys
common stock. The warrants have an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__srt--TitleOfIndividualAxis__custom--LenderMember_zBE2yx5aJ2x3" title="Exercise price"&gt;10.50&lt;/span&gt; per share and expire in April 2023. The Company calculated the aggregate
fair value of the warrants on the date of grant to be $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYSJD3dzOOzl" title="Fair value of warrants"&gt;3,110&lt;/span&gt; using a Black-Scholes pricing model. As all of the debt converted during
the six months ended June 30, 2023, the value of the warrants was recorded as a financing cost during the same period. During the six
months ended June 30, 2023, the &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630_zxFXJLVmUfY5" title="Warrants to purchase shares"&gt;111,828&lt;/span&gt; shares were exercised for proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230101__20230630_zTeZUBvKU3Z9" title="Proceeds from warrant exercises"&gt;1,174&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023, a warrant holder completed a cashless exercise of a warrant to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zD4PKwKu13z5" title="Exercise of warrants shares"&gt;16,666 &lt;/span&gt;
shares of common stock at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zaeCeI3ernVl" title="Exercise price"&gt;9.00 &lt;/span&gt;per
share . Pursuant to this exercise, the warrant holder received &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zMkjQ3KIxJK" title="Common stock issued"&gt;11,666&lt;/span&gt;
shares of the Companys common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate intrinsic value for warrant shares outstanding at June 30, 2023 was $&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iI_pn3n3_c20230630_zJ5htPpRjoTl" title="Aggregate intrinsic value of warrants"&gt;16,917&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue id="f733" decimals="-3" contextRef="c" unitRef="usd">746000.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition id="f734" xsi:nil="true" contextRef="c176" unitRef="usd"/>
  <us-gaap:LesseeOperatingLeaseDiscountRate id="f735" decimals="INF" contextRef="c190" unitRef="pure">0.04</us-gaap:LesseeOperatingLeaseDiscountRate>
  <us-gaap:PreferredStockSharesIssued id="f736" decimals="INF" contextRef="c168" unitRef="shares">608000.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f737" decimals="INF" contextRef="c155" unitRef="usd1">1592.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f738" xsi:nil="true" contextRef="c171" unitRef="usd"/>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f739" decimals="INF" contextRef="c13" unitRef="usd1">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f740" decimals="INF" contextRef="c11" unitRef="shares">637643.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="f741" decimals="INF" contextRef="c191" unitRef="shares">1632314.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f742" xsi:nil="true" contextRef="c91" unitRef="usd"/>
  <us-gaap:PreferredStockSharesOutstanding id="f743" decimals="INF" contextRef="c168" unitRef="shares">608000.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f744" decimals="INF" contextRef="c3" unitRef="usd1">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="f745" decimals="INF" contextRef="c192" unitRef="shares">1134063.0</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f746" xsi:nil="true" contextRef="c174" unitRef="usd"/>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayable id="f747" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <genelux.com:ConvertibleNotesPayablePastDueCurrent id="f748" decimals="-3" contextRef="c13" unitRef="usd">65000.0</genelux.com:ConvertibleNotesPayablePastDueCurrent>
  <us-gaap:StockholdersEquity id="f749" decimals="-3" contextRef="c177" unitRef="usd">-433000.0</us-gaap:StockholdersEquity>
  <us-gaap:LesseeOperatingLeaseOptionToExtend id="f750" contextRef="c193">the option to extend the lease for an additional five
years</us-gaap:LesseeOperatingLeaseOptionToExtend>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f751" xsi:nil="true" contextRef="c175" unitRef="usd"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f752" decimals="INF" contextRef="c194" unitRef="shares">113500.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="f753" decimals="INF" contextRef="c195" unitRef="shares">2686500.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f754" xsi:nil="true" contextRef="c176" unitRef="usd"/>
  <dei:EntitySmallBusiness id="f755" contextRef="c">true</dei:EntitySmallBusiness>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="f756" decimals="-3" contextRef="c5" unitRef="usd">8000.0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f757" xsi:nil="true" contextRef="c171" unitRef="usd"/>
  <us-gaap:AssetsNoncurrent id="f758" decimals="-3" contextRef="c13" unitRef="usd">2680000.0</us-gaap:AssetsNoncurrent>
  <us-gaap:SharesOutstanding id="f759" decimals="INF" contextRef="c196" unitRef="shares">-433333.0</us-gaap:SharesOutstanding>
  <us-gaap:OperatingLeaseLiability id="f760" decimals="-3" contextRef="c190" unitRef="usd">174000.0</us-gaap:OperatingLeaseLiability>
  <us-gaap:LegalMattersAndContingenciesTextBlock id="f761" contextRef="c">&lt;p id="xdx_80E_eus-gaap--LegalMattersAndContingenciesTextBlock_zVrIoIb4xjyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 - &lt;span id="xdx_822_z4L3oRVASomf"&gt;LEGAL MATTERS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are currently involved in one pending litigation. Although the results of the pending legal proceeding in which we currently are involved
cannot be predicted with certainty, we do not believe that there is a reasonable possibility that the final outcome of this matter will
have a material adverse effect on our business or financial results. Regardless of the final outcome, however, litigation can have an
adverse impact on us because of defense and settlement costs, diversion of management resources, harm to our reputation and brand, and
other factors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; In the future,
we may be involved in additional actual and/or threatened legal proceedings, claims, investigations and government inquiries arising
in the ordinary course of our business, including legal proceedings, claims, investigations and government inquiries involving intellectual
property, data privacy and data protection, privacy and other torts, illegal or objectionable content, consumer protection, securities,
employment, contractual rights, civil rights infringement, false or misleading advertising, or other legal claims relating to our business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LegalMattersAndContingenciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f762" xsi:nil="true" contextRef="c91" unitRef="usd"/>
  <us-gaap:CommonStockSharesAuthorized id="f763" decimals="INF" contextRef="c13" unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:WarrantExercisePriceIncrease id="f764" decimals="INF" contextRef="c62" unitRef="usd1">10.5</us-gaap:WarrantExercisePriceIncrease>
  <us-gaap:ConvertibleNotesPayable id="f765" decimals="-3" contextRef="c197" unitRef="usd">9065000.0</us-gaap:ConvertibleNotesPayable>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f766" xsi:nil="true" contextRef="c174" unitRef="usd"/>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="f767" decimals="-3" contextRef="c13" unitRef="usd">1229000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f768" decimals="-3" contextRef="c3" unitRef="usd">5531000.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ResearchAndDevelopmentExpense id="f769" decimals="-3" contextRef="c21" unitRef="usd">4196000.0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f770" decimals="-3" contextRef="c5" unitRef="usd">2000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:CommonStockSharesAuthorized id="f771" decimals="INF" contextRef="c3" unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f772" xsi:nil="true" contextRef="c175" unitRef="usd"/>
  <us-gaap:ConvertibleNotesPayable id="f773" decimals="-3" contextRef="c198" unitRef="usd">5369000.0</us-gaap:ConvertibleNotesPayable>
  <dei:Security12bTitle id="f774" contextRef="c">Common     Stock, par value $0.001 per share</dei:Security12bTitle>
  <us-gaap:OperatingExpenses id="f775" decimals="-3" contextRef="c19" unitRef="usd">5395000.0</us-gaap:OperatingExpenses>
  <us-gaap:DividendsPayableCurrentAndNoncurrent id="f776" decimals="-3" contextRef="c199" unitRef="usd">3443000.0</us-gaap:DividendsPayableCurrentAndNoncurrent>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f777" xsi:nil="true" contextRef="c176" unitRef="usd"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="f778" decimals="-3" contextRef="c22" unitRef="usd">3110000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="f779" decimals="INF" contextRef="c197" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:NetIncomeLoss id="f780" xsi:nil="true" contextRef="c171" unitRef="usd"/>
  <us-gaap:ConvertibleNotesPayableCurrent id="f781" decimals="-3" contextRef="c13" unitRef="usd">65000.0</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:OperatingLeaseRightOfUseAsset id="f782" decimals="-3" contextRef="c200" unitRef="usd">860000.0</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="f783" decimals="INF" contextRef="c198" unitRef="pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:NetIncomeLoss id="f784" xsi:nil="true" contextRef="c91" unitRef="usd"/>
  <us-gaap:ConversionOfStockSharesConverted1 id="f785" decimals="INF" contextRef="c201" unitRef="shares">272101.0</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:NetIncomeLoss id="f786" xsi:nil="true" contextRef="c174" unitRef="usd"/>
  <us-gaap:CommonStockSharesIssued id="f787" decimals="INF" contextRef="c13" unitRef="shares">25855511.0</us-gaap:CommonStockSharesIssued>
  <us-gaap:StockholdersEquity id="f788" decimals="-3" contextRef="c202" unitRef="usd">2000.0</us-gaap:StockholdersEquity>
  <us-gaap:OperatingLeaseLiability id="f789" decimals="-3" contextRef="c200" unitRef="usd">860000.0</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseRightOfUseAsset id="f790" decimals="-3" contextRef="c3" unitRef="usd">1335000.0</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="f791" decimals="INF" contextRef="c197" unitRef="usd1">10.5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:NetIncomeLoss id="f792" xsi:nil="true" contextRef="c65" unitRef="usd"/>
  <us-gaap:CommonStockSharesOutstanding id="f793" decimals="INF" contextRef="c13" unitRef="shares">25855511.0</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="f794" decimals="INF" contextRef="c198" unitRef="usd1">12.0</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:NetIncomeLoss id="f795" xsi:nil="true" contextRef="c175" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f796" decimals="INF" contextRef="c13" unitRef="shares">4201019.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:AssetsNoncurrent id="f797" decimals="-3" contextRef="c3" unitRef="usd">3639000.0</us-gaap:AssetsNoncurrent>
  <us-gaap:LesseeOperatingLeaseDiscountRate id="f798" decimals="INF" contextRef="c200" unitRef="pure">0.04</us-gaap:LesseeOperatingLeaseDiscountRate>
  <genelux.com:FairMarketValueOfSharesPercentageDescription id="f799" contextRef="c">(i) 100% of the fair market value of a share of stock on the grant
date, or (ii) 110% of the fair market value of a share of stock on the grant date in the case of a Participant then owning more than
10% of the total combined voting power of all classes of stock of the Company or any subsidiary corporation of the Company
or any parent corporation of the Company.</genelux.com:FairMarketValueOfSharesPercentageDescription>
  <us-gaap:StockholdersEquity id="f800" xsi:nil="true" contextRef="c203" unitRef="usd"/>
  <us-gaap:TreasuryStockValue id="f801" decimals="-3" contextRef="c13" unitRef="usd">433000.0</us-gaap:TreasuryStockValue>
  <us-gaap:StockholdersEquity id="f802" decimals="-3" contextRef="c204" unitRef="usd">2000.0</us-gaap:StockholdersEquity>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="f803" decimals="-3" contextRef="c3" unitRef="usd">397000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:DeferredOfferingCosts id="f804" decimals="-3" contextRef="c205" unitRef="usd">1568000.0</us-gaap:DeferredOfferingCosts>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="f805" decimals="INF" contextRef="c197" unitRef="shares">146641.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:SharesOutstanding id="f806" xsi:nil="true" contextRef="c203" unitRef="shares"/>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="f807" decimals="-3" contextRef="c3" unitRef="usd">1164000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f808" decimals="INF" contextRef="c19" unitRef="shares">25068334.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock id="f809" contextRef="c">&lt;p id="xdx_89B_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zznEwT3Ptap3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table summarizes restricted common stock activity during the six months ended June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zfvfp0C2jdY8" style="display: none"&gt;SCHEDULE
OF RESTRICTED COMMON STOCK ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average Grant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Restricted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Date Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-vested, December 31, 2022&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20230630_zVkf9ShzNSOj" style="text-align: right" title="Number of restricted shares, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1372"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedInPeriodTotalFairValueBeginning_c20230101__20230630_zbUd2vxVZTe5" style="text-align: right" title="Fair value, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1374"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230630_zL8EHy78SVUf" style="text-align: right" title="Weighted average grant date fair value, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1376"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20230630_z8GVoYfilPKl" style="width: 12%; text-align: right" title="Number of restricted shares, granted"&gt;113,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_pn3n3_c20230101__20230630_zXSgUHalW7mb" style="width: 12%; text-align: right" title="Fair value, granted"&gt;746&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230630_z81yBBgm0Iv6" style="width: 12%; text-align: right" title="Weighted average grant date fair value, granted"&gt;6.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vested&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20230101__20230630_znMZZwWAhfOl" style="text-align: right" title="Number of restricted shares, vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1384"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_iN_pn3n3_di_c20230101__20230630_zATDjgzosQk5" style="text-align: right" title="Fair value, vested"&gt;(627&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230630_z18z4Ajhmh04" style="text-align: right" title="Weighted average grant date fair value, vested"&gt;6.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20230101__20230630_zVeeYKOc7oRf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of restricted shares, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1390"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodTotalFairValue_c20230101__20230630_zZKxotFe3p1a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1392"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20230630_zfsHBbVIYd14" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1394"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Non-vested, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20230630_zfW0Ex57WAQh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of restricted shares, ending"&gt;113,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsVestedInPeriodTotalFairValueEnding_pn3n3_c20230101__20230630_zpHmllLbG52c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value, ending"&gt;119&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230630_zcr4lMNCRFwe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, ending"&gt;6.57&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
  <genelux.com:InitialPublicOfferingClosingPricePercentage id="f810" decimals="INF" contextRef="c206" unitRef="pure">0.9</genelux.com:InitialPublicOfferingClosingPricePercentage>
  <us-gaap:DebtDisclosureTextBlock id="f811" contextRef="c">&lt;p id="xdx_805_eus-gaap--DebtDisclosureTextBlock_zLGhv83ro5v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTE
8  &lt;span id="xdx_82B_z58KIJ0AThee"&gt;CONVERTIBLE NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ConvertibleDebtTableTextBlock_z6rKLQAgnzth" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
notes payable consisted of the following as of June 30, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zBMwWvyANH2c" style="display: none"&gt;SCHEDULE
OF CONVERTIBLE NOTES PAYABLE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230630_zHFc0hIiItMj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;June
    30,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_z4inYs74iYKd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
    31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ConvertibleDebtNoncurrent_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zA7KDR1ROMle" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    note payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;9,065&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iNI_pn3n3_di_zhIuBJgo18gg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Less:
    debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1189"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(541&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ConvertibleDebtNoncurrent_iI_pn3n3_zPLoEcvFJuZ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Convertible
    notes payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1192"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;8,524&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zleytc66eywb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the years ended December 31, 2020 and 2021, the Company entered into convertible note payable agreements with an investing group under
which the Company borrowed an aggregate amount of $&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePayableAgreementsMember_z7nwxhDr5Vi5" title="Convertible notes payable"&gt;9,065&lt;/span&gt;. The notes accrue interest at &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePayableAgreementsMember_zSNtgP0iS5Tc" title="Accrued interest percentage"&gt;6.0&lt;/span&gt;% per annum, are unsecured, and are convertible
into the Companys common stock at the price of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePayableAgreementsMember_zLWwL3eIvWWa" title="Conversion price"&gt;10.50&lt;/span&gt; per share. In consideration for the notes, the Company issued the noteholder
stock warrants to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePayableAgreementsMember_zyqBMoDIhMt" title="Warrants to purchase shares"&gt;146,641&lt;/span&gt; shares of its common stock with an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePayableAgreementsMember_zsvehcTP7jjf" title="Warrants exercise price"&gt;10.50&lt;/span&gt; per share. The warrants expire in
September 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of December 31, 2022, the Company owed $&lt;span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z2V7wxmiiQYe" title="Principal amount owed on notes"&gt;9,065&lt;/span&gt; of principal on the notes and $&lt;span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zvghFpunhdti" title="Accrued and unpaid interest"&gt;1,178&lt;/span&gt; of accrued and unpaid interest. During the six months
ended June 30, 2023, the notes accrued interest of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zpOuzi84JPKb" title="Accrued interest"&gt;45&lt;/span&gt;, and on January 30, 2023, the date of the closing of the IPO, total principal
of $&lt;span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zsZtITpiTGFk"&gt;9,065&lt;/span&gt; and total accrued and unpaid interest of $&lt;span id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20230130__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zRsHGbrUreX2"&gt;1,223&lt;/span&gt; was owed on the notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company calculated the relative fair value of the warrants issued to the noteholder and recognized a debt discount at the date of issuance.
The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying
amount of the note (a valuation debt discount). As of December 31, 2022, the notes had an unamortized debt discount balance of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zvjjNk6NFngl" title="Unamortized debt discount"&gt;541&lt;/span&gt;.
During the six months ended June 30, 2023, the Company amortized $&lt;span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z6wJ4n5ndt94" title="Amortized debt discount"&gt;541&lt;/span&gt; of debt discount, leaving no unamortized balance at June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Upon
the closing of the IPO, all of the principal plus accrued and unpaid interest automatically converted into &lt;span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230130__20230130__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zXuq4rDS1wq9" title="Debt conversion shares issued"&gt;979,619&lt;/span&gt; shares of the Companys
common stock based on the conversion price of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230130__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zzSBJUEnq1Rg" title="Conversion price"&gt;10.50&lt;/span&gt; per share. As of June 30, 2023, no principal or interest was due on the notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f812" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:ConvertibleNotesPayable id="f813" decimals="-3" contextRef="c207" unitRef="usd">700000.0</us-gaap:ConvertibleNotesPayable>
  <dei:EntityEmergingGrowthCompany id="f814" contextRef="c">true</dei:EntityEmergingGrowthCompany>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f815" decimals="INF" contextRef="c19" unitRef="shares">25068334.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:IncreaseDecreaseInOperatingLeaseLiability id="f816" decimals="-3" contextRef="c193" unitRef="usd">686000.0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f817" decimals="INF" contextRef="c168" unitRef="usd1">608.0</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f818" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <us-gaap:CommonStockSharesIssued id="f819" decimals="INF" contextRef="c3" unitRef="shares">9126726.0</us-gaap:CommonStockSharesIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued id="f820" decimals="-3" contextRef="c" unitRef="usd">169000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:DeferredOfferingCosts id="f821" decimals="-3" contextRef="c13" unitRef="usd">303000.0</us-gaap:DeferredOfferingCosts>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f822" decimals="INF" contextRef="c197" unitRef="usd1">10.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f823" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <dei:TradingSymbol id="f824" contextRef="c">GNLX</dei:TradingSymbol>
  <us-gaap:CommonStockSharesOutstanding id="f825" decimals="INF" contextRef="c3" unitRef="shares">9126726.0</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="f826" decimals="-3" contextRef="c208" unitRef="usd">152238000.0</us-gaap:StockholdersEquity>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="f827" decimals="-3" contextRef="c179" unitRef="usd">4495000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="f828" decimals="INF" contextRef="c207" unitRef="pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f829" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue id="f830" decimals="-3" contextRef="c" unitRef="usd">627000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice id="f831" decimals="INF" contextRef="c11" unitRef="usd1">7.85</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f832" decimals="INF" contextRef="c209" unitRef="usd1">10.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts id="f833" decimals="-3" contextRef="c" unitRef="usd">12632000.0</genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="f834" decimals="-3" contextRef="c" unitRef="usd">-505000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f835" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:WarrantExercisePriceIncrease id="f836" decimals="INF" contextRef="c131" unitRef="usd1">3.0</us-gaap:WarrantExercisePriceIncrease>
  <us-gaap:DeferredOfferingCosts id="f837" decimals="-3" contextRef="c210" unitRef="usd">1871000.0</us-gaap:DeferredOfferingCosts>
  <genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts id="f838" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f839" decimals="-3" contextRef="c196" unitRef="usd">-433000.0</us-gaap:StockholdersEquity>
  <genelux.com:AccruedCompensationTextBlock id="f840" contextRef="c">&lt;p id="xdx_80E_ecustom--AccruedCompensationTextBlock_zBd1OyRGaTml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTE
4  &lt;span id="xdx_822_zxnmTTngZFp9"&gt;ACCRUED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of June 30, 2023 and December 31, 2022, the Company had accrued compensation owed to the Companys Chief Executive Officer,
another employee and two former employees that had accrued over a several year period. During the six months ended June 30, 2023,
the Company repaid $&lt;span id="xdx_90D_eus-gaap--RepaymentsOfShortTermDebt_c20230101__20230630_zaaMBDjIgzq9" title="Accured repaid"&gt;283&lt;/span&gt;
of the amounts that were accrued over the several year period. As of June 30, 2023 and December 31, 2022, a total of $&lt;span id="xdx_903_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_c20230630_znlgvEi1pR4b" title="Accrued compensation"&gt;2,684&lt;/span&gt;
and $&lt;span id="xdx_90F_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_c20221231_zOXOQxBUpCpf" title="Accrued compensation"&gt;2,852&lt;/span&gt;,
respectively, was owed to employees for these past due balances and for current accrued payroll and other compensation related
benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</genelux.com:AccruedCompensationTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="f841" decimals="INF" contextRef="c207" unitRef="usd1">12.0</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:PreferredStockSharesAuthorized id="f842" decimals="INF" contextRef="c159" unitRef="shares">953000.0</us-gaap:PreferredStockSharesAuthorized>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber id="f843" decimals="INF" contextRef="c80" unitRef="shares">161878.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
  <genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts id="f844" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts id="f845" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing id="f846" decimals="-3" contextRef="c22" unitRef="usd">2642000.0</genelux.com:AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionRepricing>
  <us-gaap:StockIssuedDuringPeriodSharesOther id="f847" decimals="INF" contextRef="c5" unitRef="shares">123494.0</us-gaap:StockIssuedDuringPeriodSharesOther>
  <genelux.com:IssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts id="f848" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent id="f849" decimals="-3" contextRef="c3" unitRef="usd">541000.0</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f850" decimals="INF" contextRef="c211" unitRef="shares">3339752.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ScheduleOfStockholdersEquityTableTextBlock id="f851" contextRef="c">&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zUkW0fyE3d36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of December 31, 2022, authorized shares and shares issued and outstanding of the Companys preferred stock by series were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zFpt5plyTD0g" style="display: none"&gt;SCHEDULE
OF PREFERRED STOCK&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_zV7zVashGqyd" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Authorized&lt;br/&gt;
    Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Issued
    and&lt;br/&gt; Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_zCP6GKgOjLm4" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Par&lt;br/&gt;
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zi7dTZrzp1r6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;4,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;4,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;4,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z38guahuwWxi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;608,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_902_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;608,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;608&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zTi7LY6LBCHf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    C Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z9NrMmrADQi3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    D Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;3,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zzrQkVqFXMMe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    E Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1,591,994&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;1,591,994&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1,592&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zoGdwBZKt1e1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    F Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;953,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;953,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;953&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_ziGpmvSmErc5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    H Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesIssued_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_pdd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_pdd" title="Preferred stock, shares outstanding"&gt;536,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;536&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_410_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_zsiWtUbst7yi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    I Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2,775,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_zlXraVuTkeM3" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_zX8XstcooqZj" title="Preferred stock, shares outstanding"&gt;2,757,442&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2,757&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zJLFpGCmCqnd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    J Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zezTQ4jvVEn" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zm55HhRKQjw8" title="Preferred stock, shares outstanding"&gt;1,281,600&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1,282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_415_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zb22jjhSjmE3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
    K Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;4,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zz2GbydDgkU5" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zARWiGkqkYC7" title="Preferred stock, shares outstanding"&gt;1,866,853&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1,867&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20221231_z4UEeX7AVWWa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;29,927,994&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231_zcBV7QcrO6Dc" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231_z4A8aS6h9Ml9" title="Preferred stock, shares outstanding"&gt;22,094,889&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;22,095&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="f852" decimals="INF" contextRef="c41" unitRef="usd1">6.0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:OperatingExpenses id="f853" decimals="-3" contextRef="c25" unitRef="usd">2799000.0</us-gaap:OperatingExpenses>
  <genelux.com:InitialPublicOfferingClosingPricePercentage id="f854" decimals="INF" contextRef="c207" unitRef="pure">0.9</genelux.com:InitialPublicOfferingClosingPricePercentage>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f855" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="f856" decimals="-3" contextRef="c22" unitRef="usd">467000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f857" decimals="INF" contextRef="c212" unitRef="shares">105943.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f858" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFeesShares id="f859" decimals="INF" contextRef="c5" unitRef="shares">4134367.0</genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFeesShares>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f860" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <us-gaap:PropertyPlantAndEquipmentNet id="f861" decimals="-3" contextRef="c3" unitRef="usd">644000.0</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 id="f862" decimals="INF" contextRef="c38" unitRef="usd1">10.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice id="f863" decimals="INF" contextRef="c80" unitRef="usd1">10.5</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
  <dei:EntityExTransitionPeriod id="f864" contextRef="c">false</dei:EntityExTransitionPeriod>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f865" decimals="-3" contextRef="c13" unitRef="usd">27140000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="f866" contextRef="c">&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zG8MfqCEB3V" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_86A_zUctjO5yeHj6"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an
orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the
use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs,
of which the first two are considered observable and the last unobservable, to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Level
    1 &lt;/i&gt; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Level
    2 &lt;/i&gt; Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets
    or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable
    market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Level
    3 &lt;/i&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of
    the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
carrying amount of the Companys warrant liabilities of $&lt;span id="xdx_90F_ecustom--WarrantLiabilities_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSI3M2PU9Lwk" title="Warrant liabilities"&gt;169&lt;/span&gt; at December 31, 2022 was based on Level 3 measurements. The carrying
amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values due
to the short-term maturities of these instruments. The carrying amounts of the Companys convertible notes payable approximate
their fair values as the interest rates of the notes payable are based on prevailing market rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:PaymentsForRent id="f867" decimals="-3" contextRef="c213" unitRef="usd">18000.0</us-gaap:PaymentsForRent>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f868" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f869" decimals="-3" contextRef="c214" unitRef="usd">-191198000.0</us-gaap:StockholdersEquity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="f870" decimals="INF" contextRef="c" unitRef="usd1">6.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber id="f871" decimals="INF" contextRef="c11" unitRef="shares">637643.0</genelux.com:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="f872" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f873" decimals="-3" contextRef="c176" unitRef="usd">-5821000.0</us-gaap:NetIncomeLoss>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f874" decimals="INF" contextRef="c21" unitRef="shares">15805698.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f875" decimals="INF" contextRef="c9" unitRef="shares">133333.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="f876" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <us-gaap:AssetsCurrent id="f877" decimals="-3" contextRef="c13" unitRef="usd">28683000.0</us-gaap:AssetsCurrent>
  <us-gaap:OperatingLeaseLiability id="f878" decimals="-3" contextRef="c215" unitRef="usd">439000.0</us-gaap:OperatingLeaseLiability>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f879" decimals="INF" contextRef="c216" unitRef="usd1">9.0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="f880" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:SharesOutstanding id="f881" decimals="INF" contextRef="c142" unitRef="shares">24553470.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f882" decimals="-3" contextRef="c217" unitRef="usd">-203591000.0</us-gaap:StockholdersEquity>
  <us-gaap:PreferredStockSharesOutstanding id="f883" decimals="INF" contextRef="c159" unitRef="shares">953000.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="f884" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <us-gaap:StockIssuedDuringPeriodSharesOther id="f885" decimals="INF" contextRef="c86" unitRef="shares">3333.0</us-gaap:StockIssuedDuringPeriodSharesOther>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees id="f886" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:ProceedsFromNotesPayable id="f887" decimals="-3" contextRef="c" unitRef="usd">900000.0</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:LesseeOperatingLeaseDiscountRate id="f888" decimals="INF" contextRef="c4" unitRef="pure">0.04</us-gaap:LesseeOperatingLeaseDiscountRate>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees id="f889" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f890" decimals="INF" contextRef="c218" unitRef="shares">183852.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <genelux.com:WarrantLiabilities id="f891" decimals="-3" contextRef="c219" unitRef="usd">169000.0</genelux.com:WarrantLiabilities>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees id="f892" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f893" decimals="-3" contextRef="c13" unitRef="usd">-209412000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f894" decimals="-3" contextRef="c19" unitRef="usd">21642000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueOther id="f895" decimals="-3" contextRef="c19" unitRef="usd">1174000.0</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:SubsequentEventsTextBlock id="f896" contextRef="c">&lt;p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zuLFOETWyJl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 - &lt;span id="xdx_82A_z6yF2sRO1Fal"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to June 30, 2023, the Company received $&lt;span id="xdx_90A_eus-gaap--PaymentsForProceedsFromInvestments_c20230701__20230811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zG9crDm6ytQg" title="Proceeds from private placement"&gt;2,500&lt;/span&gt; through its Private Placements (see Note 9).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to June 30, 2023, two option holders exercised &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn3n3_c20230811__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--TwoOptionHoldersMember_zLcCo3cIGeW5" title="Share-based payment arrangement, option, exercise price range, shares exercisable"&gt;71,615&lt;/span&gt; option shares at an exercise price of $&lt;span id="xdx_907_eus-gaap--StockOptionExercisePriceIncrease_pid_c20230701__20230811__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--TwoOptionHoldersMember_zL2Va1JLO5Wb" title="Stock option, exercise price, increase"&gt;6.00&lt;/span&gt; per share for proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230701__20230811__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--TwoOptionHoldersMember_znPNRDuB1cLc" title="Proceeds from warrant exercises"&gt;430&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to June 30, 2023, several warrant holders completed a cashless exercise of warrants to purchase &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--WarrantHolderMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zw2ab1ekBRjg" title="Exercise of warrants shares"&gt;168,507&lt;/span&gt;
shares of common stock at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--WarrantHolderMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6fs8dBeHeR4" title="Exercise price"&gt;6.00&lt;/span&gt;
per share. Pursuant to these exercises, the warrant holders received &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--WarrantHolderMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWuT3OSvG3Tb" title="Common stock issued"&gt;127,373 &lt;/span&gt;shares
of the Companys common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to June 30, 2023, the Company issued warrants to purchase shares of common stock to two stockholders in connection with their
converted convertible notes payable. The total warrant shares issued were &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpTMrMFjOnp8" title="Exercise of warrants shares"&gt;105,943&lt;/span&gt;
shares with exercise prices of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zgA0wP23xtEl" title="Exercise price"&gt;9.00&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zOM9PV0QceH4" title="Exercise price"&gt;10.50&lt;/span&gt;
per share.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees id="f897" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f898" decimals="INF" contextRef="c13" unitRef="usd1">6.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f899" decimals="-3" contextRef="c3" unitRef="usd">397000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="f900" decimals="-3" contextRef="c21" unitRef="usd">-16000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:LesseeOperatingLeaseOptionToExtend id="f901" contextRef="c27">extended the lease through December 2024, with no changes to any
of the other terms of the lease</us-gaap:LesseeOperatingLeaseOptionToExtend>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayable id="f902" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="f903" decimals="-3" contextRef="c2" unitRef="usd">-22000.0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:PreferredStockSharesIssued id="f904" decimals="INF" contextRef="c159" unitRef="shares">953000.0</us-gaap:PreferredStockSharesIssued>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayable id="f905" xsi:nil="true" contextRef="c5" unitRef="usd"/>
  <us-gaap:GeneralAndAdministrativeExpense id="f906" decimals="-3" contextRef="c21" unitRef="usd">2067000.0</us-gaap:GeneralAndAdministrativeExpense>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayable id="f907" decimals="-3" contextRef="c22" unitRef="usd">3443000.0</genelux.com:IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayable>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f908" decimals="INF" contextRef="c3" unitRef="shares">4201019.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:WarrantExercisePriceDecrease id="f909" decimals="INF" contextRef="c74" unitRef="usd1">3.0</us-gaap:WarrantExercisePriceDecrease>
  <dei:EntityShellCompany id="f910" contextRef="c">false</dei:EntityShellCompany>
  <us-gaap:StockholdersEquity id="f911" decimals="-3" contextRef="c220" unitRef="usd">151866000.0</us-gaap:StockholdersEquity>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayable id="f912" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <us-gaap:OperatingLeaseLiability id="f913" decimals="-3" contextRef="c3" unitRef="usd">1430000.0</us-gaap:OperatingLeaseLiability>
  <us-gaap:OtherNotesPayableCurrent id="f914" decimals="-3" contextRef="c3" unitRef="usd">992000.0</us-gaap:OtherNotesPayableCurrent>
  <us-gaap:PaymentsForRent id="f915" decimals="-3" contextRef="c27" unitRef="usd">30000.0</us-gaap:PaymentsForRent>
  <us-gaap:PreferredStockSharesAuthorized id="f916" decimals="INF" contextRef="c39" unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
  <genelux.com:IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayable id="f917" xsi:nil="true" contextRef="c10" unitRef="usd"/>
  <us-gaap:RepaymentsOfConvertibleDebt id="f918" decimals="-3" contextRef="c21" unitRef="usd">130000.0</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:ConvertibleDebtNoncurrent id="f919" decimals="-3" contextRef="c3" unitRef="usd">8524000.0</us-gaap:ConvertibleDebtNoncurrent>
</xbrli:xbrl>
